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Obesity is a global health issue with nations struggling to deal with its treatment and economic 
impacts. Modified peptide hormones have already been shown to be effective at improving the 
treatment of other chronic conditions such as lymphoma or anaemia. However, peptide 
hormones, especially those targeted in treating obesity, are known to suffer from short drug 
lifetimes and thus requiring frequent administration. For the drug to take effect over a longer 
period requires a gel matrix-based drug carrier or a modification to the peptide itself. This thesis 
looks at how to use peptide modifications to potentially improve the delivery methods and 
efficacy of drugs used to control satiety levels. 
A novel lipopeptide, based on Peptide Tyrosine-Tyrosine (PYY3-36), was characterised by 
using circular dichroism spectroscopy (CD), small angle X-ray scattering, critical aggregation 
concentration experiments, and cryo-TEM. Studies were completed to investigate the 
secondary structures and the self-assembly processes over a range of physiological pHs and 
temperatures. While native PYY3-36 failed to form gels, PYY lipopeptides formed into gels 
with elongated fibre-like structures with a secondary structural change from α-helical to β-
sheet. Gels formed from natural peptides and water offer the potential for a highly 
biocompatible gel with a slow release profile. 
Using the same analytical techniques, the thesis goes on to investigate co-aggregation of 
PYY3-36 with β-cyclodextrin to establish if this common low-cost drug carrier can be used as 
an alternative delivery method. The results showed that β-cyclodextrin did show aggregation 
around the twisted sheet structure of the self-assembled PYY3-36 but did not show co-assembly 
or encapsulation, rendering it ineffective as a delivery mechanism. 
Lipidated PYY3-36 was mixed with lipopolysaccharide (LPS), providing some insight into how 
lipidated PYY3-36 could interact with amphiphilic molecules such as bacteria endotoxins. The 
results show that LPS do co-assemble with lipidated PYY3-36, however, unexpectedly the 
lipidated PYY3-36 elongated fibre structure remains largely unchanged following the co-
assembly. The implications of this observation warrant further analysis. 
Ultimately, the findings of this thesis could be applied to the development of drug formulations 
for other conditions, such as lymphoma or anaemia, which would benefit from the lipidation 
of large peptides that enable slow release mechanisms. Additionally, the results within this 
thesis add knowledge to the fundamental research of self-assembly and clarifies the effects of 
lipidation on larger peptides that allow gelation to occur. 
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1.1 Research Motivation 
Obesity is a global health issue, caused by the over accumulation of fat within the human body 
that leads to negative health and economic outcomes. Obesity has been linked to an increased 
risk of cardiovascular disease, diabetes, cancer, and strokes.1 Nonetheless, the percentage of 
the global population that is considered obese is still increasing. In the UK, for example, the 
percentage of the population that is obese has almost doubled from 15% to 29%, from 1993 to 
2016.2 USA and Mexico follow the same trend, 30% to 42% from 1999 to 2018, and 18% to 
29% from 1995 to 2016, respectively.3-4 With this chronic medical condition becoming more 
prevalent, various scientific, private, and governmental organisations have taken a keen interest 
in finding solutions to reduce this trend. The approaches taken towards the different solutions 
to the problem of obesity are varied, from understanding the method of fat storage through to 
the development of novel weight loss treatments. All of this work is being undertaken to reduce 
the long-term financial burden that an overly obese population places upon its national 
healthcare systems. 
For these reasons, there has been a large increase in research and development activities within 
the pharmaceutical sector for the development of anti-obesity or “weight-loss” drugs. Given 
the large numbers of the population that are obese in many developed and developing countries, 
a successful remedy could have far reaching societal impacts and deliver lucrative drug sales 
and development incomes for any company that can treat obesity successfully. There are only 
four approved drugs available in the USA: Orlistat (Alli, Xenical), Phentermine and 
Topiramate (Qsymia), Bupropion and Naltrexone (Contrave), and finally Liraglutide (Saxenda, 
Victoza). Only Orlistat (Alli, Xenical) is approved for use in the UK. All these drugs do state 
that their effects can vary from person to person, and close monitoring is needed for anyone 
taking them. 
The most common causes for obesity in children and adults worldwide are overeating and 
physical inactivity, which leads to a calorie surplus that the body stores in the form of 
subcutaneous fat.1, 5 In 1980 a peptide hormone was discovered which controls the body’s 
satiety levels through the creation of a feeling of being full and not hungry.6 This peptide 
hormone is called Peptide Tyrosine-Tyrosine (PYY3-36) and is formed a from small units 





interacting with a receptor in the brain (neuroreceptor Y1-5), which in turn causes the feeling 
of being full.  
However, peptide hormones, especially those targeted in treating obesity, are known to suffer 
from short drug lifetimes (typically between 4 to 6 hours), as they are removed through the 
biological processes of the body. This short drug lifetime therefore leads to frequent 
administration, making it less practical for the patient. For the drug to take effect over a longer 
period requires a gel matrix-based drug carrier or a superior modification of the peptide 
structure. This thesis looks at how to use peptide modifications to potentially improve the 
delivery methods and efficacy of peptide drugs used to control satiety levels. 
 
1.2 Peptides 
Peptides are a group of biological polymers formed from amino acid monomers joined by 
covalent amide bonds. Amide bonds are formed between the carboxyl group (-COOH) and the 
amino group (-NH2) of another corresponding amino acid. There are 20 different amino acids, 
but each contains the same backbone HOOC-C(R)H-NH2, as seen in Figure 1. These amino 
acids vary by the R group constituent. Of the 20 amino acids found in organisms, 9 are classed 
as essential with the further 11 being non-essential. They are classed this way because of the 
necessity for the human body to obtain them. The common proteinogenic amino acids cannot 
be synthesised by the human body, so they need to be consumed. These are Histidine (H), 
Methionine (M), Threonine (T), Lysine (K), Tryptophan (W), Phenylalanine (F), Isoleucine 
(I), Leucine (L) and Valine (V). The non-essential amino acids are produced by the body, so 
do not need to be ingested. These include Alanine (A), Arginine (R), Asparagine (N), Aspartic 
Acid (D), Cysteine (C), Glutamic Acid (E), Glutamine (Q), Glycine (G), Proline (P), Serine 
(S) and Tyrosine (Y). Each amino acid has its own name, abbreviation, as well as its own letter. 






Figure 1: Scheme explaining the structure of peptides. Left and Middle: The structure of an 
amino acid, aspartic acid, with both its L (Left) and D (Right) chiral forms are shown. Right: 
Structural scheme showing a peptide chain formed of 4 amino acids; Alanine (A), 
Phenylalanine (F), Cysteine (C) and Glutamine (Q). The amide bond between the carboxylic 
acid and amino acid groups of different amino acids is highlighted in red. All structural 
formulas are drawn as zwitterions and were made with ChemDraw Professional. 
The amino acid R groups range from being hydrophilic to hydrophobic. They can also be 
inherently basic or acidic due to variation in R groups. The amino acid group can also be further 
diversified by having a chiral centre, meaning they can be either right- (D) or left-handed (L). 
When considering amino acids for their receptor binding role in drug efficacy it is important to 
note that the proteins found throughout the body mainly exist in the (L) configuration, with 
only cysteine having a different absolute stereochemistry, while still being (L), and glycine 
being exempt due to its non-chirality (two hydrogens).7 Different R groups can also be 
protonated or deprotonated, which gives rise to zwitterions. A zwitterion is where the amines 
of an amino acid’s functional groups become protonated and the carboxylic acids become 
deprotonated respectively at a specific pH.8 
Proteins are typically formed by more than 50 amino acids that are covalently bonded in a 
polymer like structure, and which exhibit a specific function that is derived from its sequence. 
Examples of these functions include protease that breaks down polypeptides and proteins in 
shorter fragments, or DNA helicase that destabilises the DNA helix so that the separate strands 
can be replicated by other proteins.9-13 Dipeptides and tripeptides define peptides with two and 
three amino acids, respectively. A polypeptide or short peptide is defined as having 4 to 50 
amino acids within its structure.14-15 Peptides and proteins are found within every cell and tissue 
throughout the human body. In the body they function as enzymes, messenger hormones or 
antioxidants. The ability to maintain peptide levels in the human body is extremely important 





sugar levels, from increased insulin production), high blood pressure (from loss of oxytocin 
production that helps regulates blood pressure), and hyper-fight or flight responses (triggered 
by the overproduction of epinephrine). Peptides form the sub-unit for most human hormones 
produced in various glands, including the stomach, intestine, and brain. A few examples of 
peptide hormones include, insulin, Glucagon-Like-Peptide (GLP-1) and ghrelin. Target cells 
contain hormone specific receptors located in their cell membranes and respond to the binding 
of specific hormones, causing cascading biological events in the cell, which enable the 
hormone to produce its effect on the body. An example of this would be GLP-1 that causes β 
cells in the pancreas to release insulin.16-22 
1.3 Primary, Secondary and Tertiary Structure 
A peptide can have four distinct levels of structure. The primary structure describes the 
individual amino acid sequence forming the peptide. This sequence can be described in various 
ways, but the most common approach is using single letters, such as KKVF, which would 
describe a Lysine-Lysine-Valine-Phenylalanine chain.  
The three main secondary structures of peptides are α-helices, β-sheets, and turns or loops.23 
α-helices are a right-handed spiral configuration of amino acids, where a backbone 
electropositive NH moiety electrostatically bonds a hydrogen atom to an electronegative, lone 
pair available C=O group, four amino acids away from the NH moiety along the primary 
sequence. β-Sheets are regular strands of polypeptides connected laterally, between strands, by 
hydrogen bonding. There is normally between three to ten amino acids per strand, with one 
intramolecular hydrogen bond per amino acid on the strand.24 The β-sheets can be in parallel 
or anti-parallel form, meaning the primary strand runs in the same/or alternating direction to 
each other respectively. Turns and loops are strands of amino acids that allow the peptide chain 
to bend and change its direction. These turns or loops are also known as random coil formations 
as they display no structural order. The secondary structure of peptides are caused by the intra-
polymeric bonding via hydrogen bonds, disulphide bridges or in some cases by π-π stacking.25-
27 Hydrogen bonds can be formed between several polar amino acid moieties (for instance Glu, 
Asp, Ser, Asn and Lys) as these contain negatively charge oxygen (O-) as proton acceptors and 
positively charged hydrogens (H+) as proton donators, required for this interaction. Disulphide 
bridges occur when two thiol groups of cysteines oxidise to form a covalent sulphur bridge (-
S-S-). Aromatic stacking can also influence the secondary structure as it is weaker when 





and His. Electrostatic interactions, mainly caused by solvents, can also cause changes to the 
secondary structure, such as is seen between water (polar) and benzene or diethyl ether (non-
polar), or by changes in pH.28-33 The bonding methods listed above are responsible for peptides 
having different secondary structures.  
The tertiary structure defines the 3D arrangement of all the secondary and primary structures 
in space. This definition includes the orientation, location, and any further bonding between all 
the secondary structure components and other amino acids in the peptide chain. The further 
bonding between the secondary structures gives rise to its final 3D arrangement. These form 
via hydrogen bonds, disulphide bridges, electrostatic interactions, and aromatic stacking but 
only on the edges of the secondary structures for the free peptide chains. This intermolecular 
bonding (bonding between different molecules) leads to more structural changes until the 
peptide, or protein, has reached a specific conformation that typically occurs at the peptide’s 
lowest energy state.  
Finally, the quaternary structure refers the assemblies of proteins, e.g., dimers and trimers, 
which is crucial for the protein complex to function properly.34-40  
1.4 Bioactive Peptides 
Bioactive peptides refer to the peptides found throughout the body that are vital for the human 
body’s well-being. These peptides have a range of functions from homeostatic, anti-fungal, 
anti-viral and anti-tumour properties. Bioactive peptides control many of the human body’s 
functions as they serve as transporters across membranes and act as hormones for a variety of 
glands and organs. Examples of the use of bioactive peptides in the body include helping to 
maintain the ion concentration within cells (through ion channels), cell-penetrating peptides 
facilitating cellular uptake of an agent into the cell, such as short fragments of DNA, and to 
help the growth of lean muscle mass.41-43 A few notable named examples include: Oxytocin, a 
nine amino acid peptide hormone that is essential in social bonding, reproduction, and 
childbirth.44-45 Glutathione, a tripeptide that is found throughout most organisms and is an 
important antioxidant.46-47 Finally, Somatosatin that is a cyclic 14 amino acid peptide hormone 
which regulates the endocrine system, also known as the growth hormone-inhibiting 





1.5 Uses of Natural and Synthetic Bioactive Peptides 
As mentioned above, there are many native peptides that have important functions within the 
human body and, since their discovery, some bioactive peptides have been employed as anti-
microbial agents. These peptides have become the basis for a new and powerful field in the 
pharmaceutical industry. These peptides can be formed naturally by the body or synthetically, 
although many synthetic peptides are based on the structure of naturally occurring peptides. 
Over 60 peptide drugs are now available on the market which combat a range of conditions 
from advanced prostate cancer (e.g. Goserelin by AstraZeneca, or Degarelix by Ferring), 
hypertension (e.g. Enalapril by Merck & Co), glycaemic control (e.g. Exenatide from 
Amylin/Lilly) to severe infections (e.g. NeosporinTM which is a combination of three 
antibiotics, neomycin (polysaccharide), polymyxin B (cyclic polypeptide), and bacitracin 
(cyclic polypeptide), produced by Johnson & Johnson).50-60 
Anti-Microbial Peptides (AMPs). As part of the innate human immune system, small cationic 
peptides have been used to combat microbial infections throughout the body, such as 
daptomycin (Figure 2).61-65 Similar to daptomycin, bacitracin is another commercial cyclic anti-
microbial peptide. Given topically, it interferes with the cell wall and causes cell death, like 
that seen by daptomycin.66-67 Another AMP, specifically a glycopeptide, is vancomycin. This 
medication is given intravenously and has been shown to block the construction of the cell 
wall.68-69 Applications of AMPs is receiving growing interest as common molecule-based anti-
microbial drugs are experiencing growing bacterial resistance and consequently are requiring 
higher doses or are completely losing their ability to function. Investigation into these anti-
microbiological peptides is, unsurprisingly, a rapidly developing field and, with over 90 years 
of history, has the potential to help combat the bacteria resistance problem facing the current 






Figure 2: The structural formula of the anti-microbial peptide daptomycin. Stereocenters 
defined using R and S. The scheme shows the lipid tail, the amino acid building blocks, and 
the cyclic peptide nature that has been demonstrated to be important in its anti-microbial 
properties (the structural formula was made with ChemDraw Professional). 
Peptides in Healing. The ability to heal is another innate process of the human body and one 
that is sometimes taken for granted, yet it is a critical aspect in homeostasis. The body’s healing 
capabilities, which copes with a variety of internal and external damage to the body, contains 
a small number of peptides that enable the healing to occur. A few have a variety of functions, 
from growth hormones (stimulating muscle formation) to bone formation. These peptides make 
an interesting prospect for new healing methods that hijack the body’s innate healing methods 
to improve and speed up healing.71-72 A readily available human growth hormone drug that is 
sold under many brand names, is Somatropin, and a drug developed by Æterna Zentaris for 
growth hormone deficiency is Macimorelin.    
Peptide Drugs and Diet. As has been seen, many functions in the body are regulated by 
peptides and their role in such functions as hormone release, memory retention, hunger and 
homeostasis. This ability for peptides to be multi-functional allows for the adaptation and 
implementation of these peptides for the creation of novel drugs. As per previous uses, novel 
drug development using peptides will have the inherent benefits of them being biologically 






Peptide hormones are a sub-set of the body’s messaging systems. Many of these systems relate 
to the gut-brain interaction that is involved in controlling important mechanisms such as 
glucose levels and satiety (hunger levels).73-74 Ghrelin, for example, is produced in the stomach 
and stimulates the hypothalamus in the brain to produce a feeling of hunger.75 This messenger 
hormone is always present in the blood and its level controls its efficacy and hunger simulation. 
More of it increases hunger, less the opposite. Glucagon-Like Peptide 1 (GLP-1), 
oxyntomodulin, uroguanylin, and finally the Peptide Tyrosine-Tyrosine (PYY) are all peptide 
hormones produced in the small bowel and interact with a variety of neuro-receptors in the 
brain reducing appetite.21, 74, 76-83 From a structural perspective, they contain a different amount 
of amino acids, 30 for GLP-1, 37 for oxyntomodulin, 16 for uroguanylin and 36 for PYY, 
respectively. There are many drugs based on GLP-1, however the majority are currently 
undergoing clinical trials, examples of such include Dulaglutide and Cpd86 from Lilly, ZPGG-
72 and ZP3022 from Zealand Pharma, ITCA by Intarcia, and MOD-6030 by Prolor.  
PYY is of particular interest as it was found to reduce appetite in rodents and primates when 
injected or used as a nasal spray.84 This effect was analysed further in human studies which 
showed a decrease of caloric intake by 30% when PYY was given orally.85 The study also 
compared obese subjects alongside non-obese subjects which demonstrated the same level of 
caloric intake decrease. Leptin, another peptide under study for obesity treatment, shows 
decreased effectiveness in obese subjects as a resistance was gained.86 This observation was 
not observed in the case of PYY, making it an extremely promising drug candidate for obesity 
treatment.  
PYY is produced in L-cells of the gastrointestinal tract and circulates through the blood stream 
to neuropeptide Y-receptors in the brain. PYY is cleaved in the blood circuit by the enzyme 
Dipeptidyl Peptidase 4 (DDP-4), eliminating two amino acids leading to the truncated PYY3-36 
form. Both PYY and PYY3-36 act upon the Y-receptors, but the majority of interacting peptides 
are found in the 34 amino acid form. There are five known Y-receptors, named Y1 to Y5, which 
are understood to be linked with appetite, anxiety, and blood pressure. PYY and PYY3-36 have 
different selectivity for these five receptors with PYY3-36 being highly selective to receptor 
Y2.






1.6 Limitations and Methods to Improve Peptide Drug Delivery  
Many peptide drugs have suffered from a disadvantage that, during the evolution of the human 
species, the body has developed to be very efficient at removing peptide messengers from its 
system. The body, in responding this way to peptides messengers, ensures that key triggers, 
such as hunger and growth are regulated and managed. This means that the body will remove 
a bioactive peptide drug faster than a synthetic drug as these are not as readily known to the 
body and its biological protection mechanisms. The body uses proteins, enzymes, and pathways 
to cleave, neutralise, or remove the peptide from the human body, which will be less efficient 
against a synthetic drug. Another important effect is that peptide drugs need to be designed 
extremely precisely to a particular receptor, or set of receptors, to guarantee a very a very 
targeted and specific binding relationship. Any treatment, amendment or change to the 
structure of the peptide, if primary, secondary, or tertiary, could have a detrimental effect on 
the efficacy of the drug.  
The body’s protection mechanisms reduce the time the peptide is retained in the body and 
increases the chance of enzyme cleavage. There are three main ways of improving body 
retention time and reducing enzyme cleavage. The first method is to co-administer the drug 
with a stabilising molecule, this hinders enzyme attack and also might help to reduce the 
effects of pH on the molecule. A commercial example of co-administering with a stabilising 
molecule is the modified cyclodextrin ring marketed under the trade name of Captisol. This 
stabilising molecule has been shown to improve solubility, stability, and bioavailability of the 
co-administered drugs. 88-95 Another way is to form or use a gel to encapsulate the peptide 
drug.96-106 This allows for a slow release mechanism as well as protects the drug from enzyme 
attack. There are a few commercial examples of these gels on the market, including Geloil, 
Gelucire, and Peceol. Finally, a peptide can be lipidated, forming a lipopeptide, or similarly, 
polyethylene glycol (PEG) chains that can covalently be bound to peptides, forming a so-called 
PEGylated peptide. These treatments increase the molecular weight that in turn reduces the 
peptide’s clearance rate from the body, as well as hindering specific enzyme binding that 
consequently lowers enzyme cleavage.107-110 One highly valuable side effect of this lipidation 
is the formation of self-assembled structures that are thought to help reduce clearance and 
enzyme attack.111-113 Lipidation has been used for the commercial anti-bacterial drug 
Daptomycin, though all methods (co-administration, gel, or lipidation) are still being 
researched with a number of new drugs and drug formulations currently undergoing preclinical 





molecule to a receptor. Therefore cell, preclinical, and clinical studies are extremely important 
to ensure the lipidation, or PEG-lation, has not affected the drug efficacy.  
1.7 Peptide Amphiphiles and Lipopeptides 
Peptide amphiphile (PA) describes a broad range of peptides with amphiphilic (having both 
hydrophilic, water-loving, and hydrophobic, water-fearing) properties. PAs fall in to three 
different classes of peptides. The first class are peptides containing polar and non-polar sections 
arising from its amino acid’s segments that are pure peptide amphiphiles. The second class are 
hydrophilic peptides attached to hydrophobic alkyl chains. These lipopeptides also give rise to 
amphiphilic properties. The third class concerns peptide co-polymers. These are polymers 
partially consisting of a peptide backbone which is covalently bound to a conventional 
polymer. As a result, the design of PAs inherently allows to produce an amphiphilic molecule, 
as both the conventional polymer and the peptide can be tuned to have hydrophilic and/or 
hydrophobic properties.108, 114-117  
There are many molecules in the human body which owe their functionality to their 
amphiphilic properties such as phospholipids in bilayers, membrane proteins and various fatty 
acids. For instance, the amphiphilic nature of fatty acid is an extremely important property that 
supports continued body functions such as cell signalling, energy storage and providing some 
of the building blocks for cell membranes.118-120 The coexisting hydrophobic and hydrophilic 
segments allows an amphiphilic surfactant molecule to exist at water and oil interface as well 
as, more importantly for this research, self-assemble in an aqueous environment into ordered 







Figure 3: Lipopeptide amphiphiles. A) and B) display the chemical formula and calotte model 
of the lipopeptide pentadecenoyl-CCCCGGGS(phosphorylated)RGD. C) Self-assembled rod-
like aggregate of the lipopeptide pentadecenoyl-CCCCGGGS(phosphorylated)RGD in 
aqueous environment. Note, the polar groups RGD of the peptide are in contact with water, 
while the hydrophobic hydrocarbon chains are shielded from the water phase and located in 
the core of the aggregate. This figure has been adapted from reference 122.122  
1.8 Self-Assembly 
Methods of Self-Assembly. Self-assembly is a relatively old research area (>100 years)123 that 
carries with it a vast amount of literature on theoretical, experimental and applied research.23, 
33, 115, 123-157  
Self-assembly occurs through the intermolecular forces causing a favourable structural change 
to an ordered system. This effect is dependent on many variables, including surfactant 
concentration, pH, ionic strengths, temperature, hydrophobic and hydrophilic interactions, 
intermolecular bonding types, (such as hydrogen bonding or van der Waals forces), electric 
and magnetic fields.  Self-assembly can also be assisted by 2D or 3D templates.158-161 All these 
forces take some effect on either the enthalpy and/or entropy of aggregation.  
Amphiphilic molecules such as PAs and lipopeptides self-assemble at a critical concentration, 
known as the Critical Aggregation Concentration (CAC).162 Similarly, the Critical Micelle 





micelles. It should be noted that CMC is not applicable to all self-assembling molecules, as 
structures other than micelles can be formed. 
Lipopeptides and PAs self-assembly has been investigated under various conditions, including 
their concentration, pH, temperature and ionic strength characteristics.116, 146, 163-166 In aqueous 
solutions the hydrophobic section, the alkyl chain predominantly for lipopeptides and the 
hydrophobic amino acid groups or the co-polymer in PAs, aggregate to form different self-
assembled structures, where the hydrophobic moieties are found in the core of the aggregates 
due to the hydrophobic effect. This results in a screened hydrophobic environment with the 
hydrophilic, sometimes bioactive, peptide located at the polar and apolar interface. The reverse 
occurs when PAs are immersed into a hydrophobic environment (non-polar solvents), resulting 
in the hydrophilic moieties being located at the core of the aggregate.167-169 This reverse process 
is not investigated extensively, since the human body, being made up of 60% water,  provides 
a predominately aqueous environment for lipopeptides and PAs.  
3D Self-Assembled Structures. The self-assembled structures of PAs and lipopeptides are 
defined by a number of structural categories. These include micelles, liposomes, nanotubes, 
nanotapes, fibrils, ribbons, and bilayers. Micelles are often spherically shaped organisations of 
molecules. In aqueous solutions the hydrophobic tail sections point inwards forming a 
hydrophobic pocket protected by the hydrophilic head groups or segments on the outside. If 
the hydrophilic parts are formed of bioactive segments, this will form very bioactive external 
surface.152, 170  
Nanotubes and tapes are distinct structures that can be formed by specific PAs and lipopeptides. 
These tapes and tubes are able to transfer oxygen, encapsulate carbon particles and are able to 
be aligned by shear force.171-174  
Fibrils is a term used to describe a fibre-like structure that can have various linkages and off-
shoots.175-176 They are normally tubular in shape and can have various thicknesses. There are 
specific detrimental types of β-sheet secondary structure fibrils, called amyloid fibrils that are 
heavily associated with neurodegenerative diseases, such as Alzheimer’s disease.176-180 
Ribbons, or nanoribbons, are 2D planar regularly ordered structures that can be flat or twisted 
along their main axis, and in the case of twists, they may exhibit a variety of different spacings 





Bilayers are composed by two sheets of amphiphiles, where the surfaces are commonly polar, 
and its core is hydrophobic.181-184 These structures can then become building blocks for further 
structures.  
Liposomes refer to vesicle formation, which are normally spherical in shape, and can contain 
a differing solvent inside their body. This gives them the potential transporting various 
substances.185-186 Liposomes can either be multilamellar vesicles (MLV) formed from many 
bilayers stacked in radial direction or are unilamellar vesicles (ULV) which have only one 
bilayer. Solid supported films are multilamellar bilayers being typically formed on a solid-
supported wafer, e.g. on a silica wafer. 
All the self-assemblies described above can be formulated with lipopeptide and peptide 
amphiphiles, equipping them with the benefits of increasing the bioavailability of the drug, 
supporting the administration of regenerative medicine and the potential treatments for 
diseases. 
1.9 Applications of Self-Assembling Peptide Systems 
Skincare. PAs and lipopeptides have found many applications with some pertinent examples 
being discussed within this section. A commercially available lipopeptide with the trade name 
MatrixylTM (C16-KTTKS) has been used in anti-wrinkle creams. This lipopeptide has been 
shown to self-assemble into a β-sheet, fibrillary-like superstructure via CD and TEM. Hamley 
et al. investigated this fibrillar structure and found it to have a bilayer spacing of 5.3 nm using 
small angle X-ray scattering (SAXS).108 Further investigations using human dermal fibroblasts 
suggest that the KTTKS polypeptide increase the skin’s collagen production by forming a 
similar self-assembled structure to that of the skins extracellular matrix (ECM), but the 
mechanism for the anti-wrinkle effect is not fully understood.187 ECM is the outer region of a 
cell, which supports the cell and those around it. This ECM has also shown to form parallel 
arrays of polydisperse fibrils, similar in structure to that of the lipopeptide. The combined 
KTTKS peptide motif with the C16 chain has also shown to assist the skin permeability, and 
further, the self-assembled structures produce a highly peptide-rich surface. The combination 
of this similar parallel structure and the increase skin permeability, all add to the increased 
collagen production, making it a highly effective skincare additive. This lipopeptide’s effect 
happens at a low concentration, which is close to its CAC, 0.002 wt%.188 Other lipopeptides, 





collagen stimulating effects with similar β-sheet nanostructures, but were not as highly ordered 
or as long as those of C16-KTTKS.
108 This observation has not been fully understood but does 
lend evidence to the self-assembled structure being important in allowing increased collagen 
production. However, the high order and length of the fibrillar structures do not seem to be as 
important as the secondary structure in collagen stimulating effects. 
Tissue Scaffolds. Various research groups have investigated the use of PA and lipopeptides as 
scaffolds to produce tissue or other cells. For instance, the linear RGD amino acid sequence 
was linked with dialkyl lipid chains. This scaffold allowed for spreading of melanoma and 
endothelial cells when it was carboxyl-coupled but inhibited spreading with amino-attached 
PAs. It was concluded that the resultant amino-attached PA self-assembled structure was 
poorly packed and the RGD active peptide head was less accessible to the cells.189 Another 
group managed to encapsulate cells within nano-fibrils made up of PAs with the IKVAV 
peptide group.190 These PAs were shown to be effective at treating spinal cord injury in mice. 
This was due to the nano-fibrils inhibiting scar formation which helped to lessen the injury. 
Guo et al. suggest this is because of the nano-fibrils allowing for robust migration of host repair 
cells, growth of blood vessels and axons (nerve fibre cells). This migration of host repair cells 
shows that this self-assembled peptide nanofibre scaffold (SAPNS) mimicked a friendly 3D 
cell environment. This observation invites further research as it could lead to a greater use of 
SAPNSs in healing and the reduction of scar formation.190 
Antimicrobial Applications. The area of antimicrobial and antibacterial materials and agents 
has probably received most of the research attention with regards to PA and lipopeptide self-
assembly. Lipidation of peptides has shown to improve the uptake of the peptide into the cell 
wall. This was investigated with a range of gram-negative or positive bacteria and two common 
fungal strains. This improved uptake into the cell wall and subsequent disruption of the cell 
membrane was found to be an efficient mode of action, causing bacterial leakage and cell 
death.61 An amphiphilic TAT peptide was found to work as an effective antimicrobial agent in 
a similar way. It was  further demonstrated that the PA can also be transported across the blood-
brain barrier, potentially having brain infection combating potential.191 Possibly one of the 
best-known lipopeptides used in treating infections is daptomycin. Daptomycin has been so 
successful in its ability to combat systemic and life-threating infections that it is now marketed 
under the trademarked name of Cubicin®. It is a cyclic peptide group joined by an amide 
linkage to a lipid chain (Figure 2). The mechanism by which daptomycin acts on bacteria has 





the cell wall. The daptomycins then aggregate within the cell membrane causing pores to form, 
leaking internal cell ions. This in turn causes cell depolarization, resulting in the inhibition of 
various synthesises, including that of DNA, RNA and protein. These effects combine to cause 
cell death. The self-assembly of daptomycin was studied in aqueous conditions, outside the 
cell, and was shown to form micelles.65 This aggregation process in the bacterial cell membrane 
makes it one of the best lipopeptide drugs to treat gram-positive organisms; it also causes 
limited side effects when not administered in the right dosages. The common side-effects 
include hypotension (low blood pressure), insomnia and dyspnoea (shortness of breath), 
making it vital to monitor patients going through daptomycin therapy as well as controlling the 
dosages.199-200 Caspofungin and amphotericin B are other commercial antimicrobial drugs that 
have had very high success rates on fungal infections.201-202 Both work in different ways, 
caspofungin by inhibiting glucan synthesis, while amphotericin B works by ion leakage 
coupled with oxidative stress production inside the cell. The examples given here represent a 
small sample of the lipopeptide drugs that are commercially available, with many more 
currently undergoing trials.196, 203-204 
Drug Delivery. Drug delivery has been investigated with PAs and lipopeptides.113, 142, 205-223 In 
this thesis the two main approaches of drug delivery were looked at. The first approach makes 
use of the self-assembled structure of PAs and loading hydrophobic drug molecules in the 
hydrophobic core of the self-assembled structures such as micelles, uni/multilamellar vesicles 
or fibres. This method allows for the transport of the drug in highly aqueous environments to 
reach the target cells. An instructive example is TAT PA, a single layer fibre nanostructure 
with a hydrophobic inner core that is due to the high number of octanoic acid (hydrophobic) 
groups and the high length to head group ratio. It was shown that the PAs with the highest 
amount of octanoic acid groups could encapsulate and retain the drug paclitaxel, to help with 
the treatment of oesophageal, breast and lung cancer. This PA is still under research, but looks 
very promising for drug formulation for the treatment of cancer.224 The high hydrophobicity of 
the octanoic acid groups made this drug delivery system highly efficient because it was able to 
protect the hydrophobic drug in an aqueous environment. The other main use of PA for drug 
delivery concerns the lipidation of specific peptide head groups. While the peptide head groups 
define their binding capacity to specific receptors, the attached lipid group allows the PA to 
cross various membranes, thereby increasing its bioactivity as well as reducing the probability 
of it becoming metabolised. A good example of this is an amphiphilic design of the commercial 





circulation times, and more importantly, they were able to cross the blood-brain barrier. This 
allowed the normally hydrophobic cancer drug to reach cancer-tumours within the brain. 
In summary, lipopeptides and peptides have many useful applications that include (i) additives 
to skin care products, helping with collagen stimulation, (ii) tissue scaffolds, differentiating 
stems cells before injection, (iii) anti-microbial peptide drugs, most notably Daptomycin or 
Caspofungin and finally, (vi) promising drug-carrier developments, with promising cases 
increasing the circulation times in the body and improvements in delivery of drugs across the 
blood brain barrier.65, 187, 193, 196, 201, 217, 225-230  
Even though some of the applications of lipopeptides and peptides are clearly less clinically 
critical than others, they all make use of the two different but important aspects of peptide 
amphiphiles and lipopeptides; namely the ability of amino acids to be tuneable to specific 
functions and their ability to self-assemble. 
1.10 Hydrogels 
Structure and Functions. Hydrogel is a term used to define hydrophilic (water-loving) 
polymer chain networks that are highly water-absorbent with some hydrogel configurations 
allowing for over 90% water retention. The polymers are classified homopolymer, copolymer 
or multi-polymer gels which defines the monomer base unit, i.e. it contains one, two or more 
monomers, respectively. These polymer networks can be natural or synthetic and are held 
together by covalent bonds and/or crosslinks, van der Waals’ forces and hydrogen bonding.142, 
231 Due to the hydrophilic nature of the polymer chains they also contain charged species that 
are either anionic, cationic and ampholytic (both charges present). Hydrogels are commonly 
amorphous polymers, meaning that its overall structure has a random organisation, though 
some hydrogels can be cross-linked which does impart some crystallinity to the hydrogel. 
Furthermore, semi-crystalline polymers have local areas of order but the overall structure is 
still random. Lastly, crystalline polymers are typically highly ordered systems with only a small 
fraction of amorphous material. 
Hydrogels are highly susceptible to environmental factors such as pH, temperature and 
pressure.232 To tailor a hydrogel in a specific function, all three factors can be exploited for the 





The ability to vary hydrophilic and hydrophobic polymers, along with their individual 
properties, allows for hydrogels to be used in an extensive range of applications. 
Applications of Hydrogels. There is a growing interest in the use of hydrogels as scaffolds for 
tissue engineering. A study carried out in 2014 used a biodegradable thermosensitive hydrogel 
to mimic microenvironments for the differentiation of stem cells, with the potential to improve 
in vivo (human) injection.233 The stem cells injected would already be selective to the location 
needed, thus having higher acceptance and success rates when injected.233 Apart from applying 
responsive hydrogels under variable environmental conditions, they are widely used for their 
capacity to absorb large quantities of liquid. Biodegradable cellulose-based hydrogels are being 
designed to combat the ever-increasing use of disposable nappies, hopefully leading to a 
sustainable way of degradation, and the returning of substances to landfills in a non-toxic way. 
Another use for hydrogels is given in the production of water-gel explosives. These water-gel 
explosives are composed of a mixture of aqueous ammonium nitrate solution in a gel-like 
mixture, normally polyvinyl alcohol, dextran gums, or urea-formaldehyde. These water-gel 
explosives have almost completely taken over the use of dynamite as they are cheaper to make, 
can be manufactured to be less toxic and are substantially less hazardous to produce, transport 
and store.234 Recent research efforts have focused on the use of hydrogels to potentially 
function as an artificial cornea scaffold.235 Hydrogels guarantee good retention of liquid, thus 
reducing the probability of the artificial cornea from drying out and it allows the polymer to be 
customised, being able to create varied segments. These can be used to protect the eye from 
sunlight or to prevent bacterial growth.235-236 A few variants have been developed, including, 
PHEMA (poly(HEMA-co-methacrylic acid copolymers), PVA based co-polymers, collagen 
polymer variants and interpenetrating polymer networks, the last of which are hydrogels with 
two entangled non-covalent bonded polymeric systems.237 Gels have also been made for the 
cholesterol lowering drug Atorvastatin that is injected intramuscularly (into deep muscle tissue) 
as a in situ gel.238 Gels can also be injected subcutaneously (under the skin layer, but above the 
muscular layers), such as with the cholesterol lowering drug Simvastatin, which uses a chitosan 






Figure 4: Image showing the process of self-assembly to materials. Left – Individual organic 
molecules, which could be either peptide amphiphiles, lipopeptides or any amphiphilic 
molecule with an organic base self-assemble. Second and third from left – Larger nano-scale 
formation of layers or films as observed by TEM. Fourth from left – A stiff gel in a vial 
produced by the self-assembly and nano-scale ordering. The figure is taken from reference.240 
 
Gels from Self-Assembly. Gel formation of self-assembling systems is a promising research 
field, finding applications in hydrogen bond donors and acceptor systems and novel fibril 
formations. In particular, lipidation of peptides and PAs can used for the formation of hydrogels 
(Figure 4).232, 241 Hydrogels formed from self-assembly show similar structures to those of 
common polymeric hydrogels and exhibit similar responses to pH, temperature and light.242-245 
Generally, drug delivery has to cope with a delicate balance of sustained release, efficacy and 
stability. It has been demonstrated that the incorporation of a biological molecule into a large 
self-assembled structure leads to slow and sustained release profiles (slow release over a long 
time) and drug stability.212, 246-250 The main issue with self-assembled systems is the potential 
for loss of drug effectiveness. This issue can be caused by self-assembly limiting the drug’s 
interactions with blood proteins, i.e. potentially limiting its ability to get to its active site by 
retention within the self-assembled drug carrier. Another reason for a reduction in efficacy is 
that the drug candidate needs the ability to self-assemble or to be held within the self-assembled 
drug carrier, which could mean a modification to the bioactive drug molecule itself. These 
modifications, through the addition of a lipid, polysaccharide, or other molecule, could change 
the efficacy of the molecule. Any decrease or increase in charge, amino acid sequence, 
secondary structure, or tertiary structure could also have a large impact on the efficacy of the 





properties, as long as the drug molecule is not modified beyond its ability to create the 
necessary bio-response. 
1.11 Endocrine Peptides 
Figure 5: Diagram showing the main peptides involved in the control of hunger. The figure 
has been taken from reference255. 
The endocrine system is a large network of glands within the body that creates a multitude of 
peptide hormones, helping to control moods, growth and development of cells, metabolism and 
reproduction.256-260 A few of the glands involved in this network are the hypothalamus, 
pituitary, pineal gland, thyroid gland, adrenal glands, pancreas and ovaries or testes. One area 
that the endocrine system controls is the satiety level (hunger). As shown in Figure 5, there are 
different peptides produced by the human body for the control of satiation and glucose 
homeostasis.255, 261 
Produced in the oxyntic glands within the stomach, Ghrelin is a 28-amino acid peptide that has 
the ability to stimulate calorie intake. Studies have shown within rats that were injected via 
their cerebrospinal fluid (to by-pass the blood brain barrier), they were resistant to induced 
obesity when fed a high-fat diet. This was related to the rats eating less and therefore utilising 
stored triglycerides and lipids as the main energy source.262 
Leptin, another well-known peptide hormone, is produced by the adipose cells that control 





bone formation. Another valuable effect is that leptin limits food intake by binding to key 
regulatory centres within the brain. This helps maintain the energy balance within the body and 
overall homeostasis. Various studies show leptin activity is linked strongly to the hypothalamus 
that controls the expression of various appetite-stimulating and supressing peptide 
hormones.263 
Glucagon-Like Peptide 1 (GLP-1) is a 30-amino acid peptide that stimulates insulin secretion. 
Further to this, GLP-1 has been linked to inhibiting gastric emptying and reducing appetite. 
Produced in the L-cells within the small bowel and colon, GLP-1 circulates within the body 
and is cleaved by the enzyme Dipeptidyl Peptidase IV (DDP-4), making it inactive.73 DDP-4 
is produced by the body in large quantities, thus making the half-life of GLP-1 limited to a few 
minutes. Even with the poor half-life, developments towards a GLP-1 drug and formation have 
been heavily researched. The GLP-1 receptor is also of great interest for targeted drug design 
as it can be activated by an agonist that leads to the same satiety increasing effects, as seen 
when activated with the peptide hormone GLP-1.22 Various GLP -1 receptor agonist drugs have 
been on the market since 2014, with one under the trade name of SemaglutideTM showing a 
20% body mass reduction.264-267  
Pancreatic Polypeptide (PP) is a 36 amino acid peptide that belongs to the PP-fold family.268 
Pancreatic polypeptide, in a similar manner to GLP-1, is released after consumption of food 
and is linked to the modulation of gastric acid secretion and gastric emptying.269 Further studies 
have shown the level of PP is dependent on the blood glucose levels, insulin levels and on the 
digestive state the body is in. This shows that pancreatic polypeptide could play an important 
role in energy homeostasis and feeding behaviour, leading to a potential drug candidate for the 








1.12 Peptide YY 
Structure and Activity. Polypeptide YY, or Peptide YY (PYY), as it is more commonly known, 
is a gastrointestinal hormone belonging to the neuropeptide family. The primary structure of 
its various forms is described as follows: 
PYY - YPIKPEAPGEDASPEELNRYYASLRHYLNLVTRQRY 
PYY3-36 - IKPEAPGEDASPEELNRYYASLRHYLNLVTRQRY 
This peptide family includes PYY as well as the Neuropeptide Y (NPY) and Pancreatic 
Polypeptide (PP).268 The PP-fold motif is found throughout this family and is formed through 
the incorporation of certain residues that are predominately Pro2, Pro5, Pro8, Gly9 and Tyr20 
and Tyr27 (Figure 20). This PP-fold has been found to protect the peptide against enzyme 
attack as well as producing a hydrophobic pocket that reduces the hydrophobic residues 
interaction to the aqueous environment.270 As well as containing the PP-fold motif, PYY and 
its derivative PYY3-36 also have a high C-terminal α-helix proportion that has been suggested 
to be extremely important for structural integrity of PYY.271 
Figure 6: Illustrations of binding sites for Y1 and Y2 with hPYY + hPYY(3-36). Red box 
highlights the PP-fold, characteristic for the neuropeptide family. For further details, refer to 
the main text. The image has been taken from reference.271 
PYY is a native peptide produced predominately by the colon after food intake. After secretion 
into the body, the 36-amino acid PYY is cleaved by the Dipeptidyl Peptidase IV (DPP-IV) 
protein, leading to PYY3-36, i.e. losing the Tyrosine-Proline residues from the N-terminus. 





large proteins that detect molecules on the outside of the cell and produce an internal cell 
response, termed the neuropeptide Y receptors. There are currently five known Y receptors, 
Y1, Y2, Y3, Y4 and Y5. Only four receptors (1, 2, 4, and 5) have been found to have significant 
effects on the human body.272-273 These receptors have varied actions including reducing 
appetite, controlling circadian rhythm, and influencing anxiety levels. NPY, PYY and PYY3-36 
have varied binding affinities to these Y receptors. PYY binds to all Y receptors with equal 
affinity but PYY(3-36) binds selectively to the Y2 receptor.
87, 271 This change in binding affinity 
has been hypothesised to be due to the structural loss of the tyrosine and proline amino acids.271 
It is thought that the Y1 receptor requires both the C-terminus and N-terminus for recognition, 
binding and subsequent activation. The Y2 receptor is thought to have a smaller receptor site 
and only requires the C-terminus for recognition (as shown in Figure 6). This could explain the 
reduced affinity for PYY3-36 for any other Y receptor than Y2.
271 Other studies that replaced the 
amide bonds with ester bonds also confirm the role of the end section and its significance in 
binding and activation.274 
Effects on the Human Body. Research into the PYY and PYY3-36 effects on the body have 
been completed, although predominately in the food and biological science fields.84, 275-278 A 
study in 2002 commented on the potential for acute peripheral administration of PYY3-36 to 
inhibit food intake.279 PYY3-36 was injected into fasted (for 24 hr) rats’ hypothalamuses and 
showed a significant decrease in food intake, even at low 100 fmol doses.280 This effect was 
initially controversial with only a very few other researchers being able to repeat the results.281 
A theory behind the proposed controversy was that the mice used in the repeat tests were 
unaccustomed to a laboratory environment and as such they experienced increased their stress 
levels. Stress inherently reduces baseline food intake and, as such, it makes any investigations 
on anorectic (appetite suppressing) agents difficult to assess.281 Further research into its use in 
human studies has found that obese subjects showed normal levels of sensitivity to the appetite 
reducing effects of PYY3-36, meaning PYY3-36 is a good candidate for use in the reduction of  
appetite for obese patients.282 
Potential Applications and Problems. The ability of PYY and PYY3-36 to reduce food intake 
has made it of great interest as an anti-obesity or chronic eating disorder medication. A few 
studies have shown that even though it works as an appetite suppressant, it does have some 
drawbacks that need to be overcome. Studies that used high doses of PYY have reported taste 
aversion in animals and caused humans to be nauseous.283 This effect was compounded 





at a steady and controlled infusion rate mainly through intravenous injections.284 The two main 
problems with the administration of PYY seem to be both the dosage and how it is 
administered; low doses intravenously administered seem to be the optimum dose path.285 This 
however is inconvenient for patients, as they must inject themselves with low doses multiple 
times during the program and this can cause irritation and/or damage to the veins; it can also 
build up patient reluctance to keep injecting regularly. Oral and nasal dosage overcome these 
issues, but with both methods the efficacy drops off as the nose or stomach drug barriers limit 
uptake into the body. 
Peptide lipidation and gelation, with their ability to better protect the drug within the human 
body, could overcome the issues of the efficacy drop off, and therefore allow for the application 
of PYY3-36 as an effective satiety drug. The development of a greater understanding of PYY3-
36 lipidation could potentially advance the field of the use of large peptides and lipidation for 
drug delivery, which in turn, would expand the potential drug candidate list for the treatment 
of a greater number of health issues. 
1.13 Research Aims and Objective 
The overall aims of this project are to investigate the effects of (i) lipidation on structure the 
hunger-suppressing hormone PYY3-36 and (ii) to investigate strategies for the development of 
prolonged release methods. Applied methods embrace different approaches such as the 
formation of a gel, the complexation of PYY3-36 to another moiety such as β-cyclodextrin and 
incorporation of other stabilisers used within the formulation research area. While there is 
already an extensive body of research going on in PYY in the fields of medicine and biology, 
investigations have still not been carried out on lipopeptide conjugates, making these studies 
novel and highly interesting to many fundamental and applied research fields. The first set of 
studies in this body of work were planned to compare the structural differences between the 
novel lipidated versions and the un-lipidated version. 
The first set of planned studies were: 
- Investigate the secondary structure changes caused by the addition of a lipid to the 
peptide hormone at room temperature using Circular Dichroism spectroscopy (CD) 





- Investigation of the differences in position of lipidation on the secondary structure and 
the differences in self-assembled structure formed, using Cryo-TEM and SAXS 
methods (Methodology in Chapter 2.2.1 and 2.2.2). 
- Once determined at room temperature, to investigate their stability to temperature by 
completing a thermal denaturation experiment (Methodology in Chapter 2.2.3). 
- Investigate the effect of a selection of physiological pHs on the secondary structure and 
self-assembled structure of the lipidated PYY3-36, using a combination of CD and SAXS 
techniques (Methodology in Chapter 2.2.2 and 2.2.3). 
- Using critical aggregation concentration methods to understand the concentrations at 
which the determined self-assembled structures form (Methodology in Chapter 2.2.6). 
- Further investigation of pH effects on the critical aggregation concentrations 
(Methodology in Chapter 2.2.6). 
- Investigate the potential for the formation of gels using the lipidated peptide hormone 
self-assembled structures (Methodology in Chapter 2.1.2). 
- If hydrogels form, investigate the macro-structure using transmission electron 
microscopy (TEM) (Methodology in Chapter 2.2.1). 
- Investigate, using SAXS, the self-assembled structure with comparison to the non-gel 
structure (Methodology in Chapter 2.2.2). 
- Investigations of the secondary structure changes between the gel and non-gel form by 
CD (Methodology in Chapter 2.2.3). 
With these differences determined and the potential hydrogel investigated, this allowed further 
research into the potential use of these lipidated hormones as potential drug candidates. This 
second research section was planned to focus on the structural investigation of these novel 
lipopeptides, using a variety of scientific methods to explore new avenues of drug design and 
formulation. 
The second set of planned studies were: 
- Investigate a synthesis route for a sugar complexation to the peptide hormone PYY3-36. 
- Investigate the known complexation properties of β-cyclodextrin and improve its drug 
formulation and delivery potential of PYY3-36 (Methodology in Chapters 2.2.1 to 2.2.7). 
Wider investigations of the interaction of the lipidated peptide hormone with a well-researched 
bacterial cell wall endotoxin LPS, including co-self-assembly studies, and comparisons to a 





2. Materials and Methods 
This chapter details the materials and methods applied throughout this thesis. This includes 
explaining in detail the experimental design and the experimental strategy for the subsequent 
result chapters. Methods that will be covered are Transmission Electron Microscopy (TEM), 
with a particular focus on Cryo-TEM, Small Angle X-ray Scattering (SAXS), with the showing 
of SAXS fitting methods, Circular Dichroism (CD), Pyrene Critical-aggregation Concentration 
(CAC) experiments, lipopolysaccharide specific dye 4,4-difluoro-4-bora-3a,4a-diaza-s-
indacene (BODIPY-TR) experiment, UV absorbance concentration measurements and zeta 
potential experiments. 
2.1 Materials and Sample Preparations 
2.1.1 Materials 
PYY3-36, 11PYY3-36, 17PYY3-36 and 23PYY3-36 acetate salts were custom synthesised by 
Bachem, Bubendorf, Switzerland. The design and specific location of the lipidation was 
determined by the industrial sponsor MedImmune Ltd prior the commencement of this thesis. 
The molecular mass was measured using matrix-assisted laser desorption/ionisation - mass 
spectrometry (MALDI-MS) by the supplier using a Axima-CFR instrument (Shimadzu, Kyoto, 
Japan) and found to be 4049.61, 4458.19, 4389.13, 4389.27 gmol-1, respectively, with error 
values of ±0.10 gmol-1 for all acetates (theoretical expected value, via chemical structure: 
4047.07, 4454.37, 4387.32, and 4387.32, respectively gmol-1). The molecular mass was 
checked by Electrospray Ionization – mass spectrometry (ESI-MS) separately by the University 
of Reading Chemical Analysis Facility (CAF) team using an LTQ-Orbitrap XL instrument 
(ThermoFisher Scientific, Waltham, MA, USA) and found to be 4049.07, 4458.41, 4389.32, 
and 4389.33 gmol-1, respectively, with error values of ±1-3 ppm for all measurements. The 
purity was 96.9, 95.4, 97.8, and 98.3%, respectably, with error values of ± 0.1% for all 
measurements, as determined using a Dionex UltiMate 3000 HPLC (ThermoFisher Scientific, 
Waltham, MA, USA) system with Vydac C18 column (Hesperia, CA, USA). 
All water used throughout these preparations and experiments was ultrapure water (18 MΩ 
Barnstead Nanopure, ThermoFisher Scientific, USA). All pH changes were completed using 
micropipette additions of 1 M HCl or 1 M NaOH, purchased reagent grade from Sigma-Aldrich 





All Lipopolysaccharide (LPS) used within this thesis was sourced from Sigma Aldrich (St. 
Louis, Missouri, USA). The LPS was biologically obtained from Escherichia coli 0111:B4 and 
was supplied purified by phenol extraction. Batches of 100 mg powder were purchased when 
required. It should be noted that LPS is extremely heterogeneous and, as this material was 
obtained from a biological source, its purity would be under question. This issue of LPS purity 
is addressed within Chapter 5.  
β-cyclodextrin and maltoheptaose used throughout this these was purchased from Sigma 
Aldrich (St. Louis, Missouri, USA). The β-cyclodextrin obtained was of 25 g and was supplied 
with greater than 97% purity, determined by the supplier. The maltoheptaose was purchased at 
the highest purity available, 60% determined by the supplier.  
The pyrene used for all CAC measurements was purchased from Sigma Aldrich (St. Louis, 
Missouri, USA). It was supplied at 98% purity. 
2.1.2 Sample Preparations 
Gel Sample Preparation 
Gels were prepared by making up 1−2 wt% peptide solutions in ultrapure water (18 MΩ 
Barnstead Nanopure, ThermoFisher Scientific, USA), and changing the pH accordingly using 
1 M HCl or 1 M NaOH (ThermoFisher Scientific, USA). The pH was recorded using an 
electronic pH meter, more details of the equipment used is provided below. The solutions were 
heated to 60 °C for approximately 2−10 h and then left to stand for 3 to 24 hours for the gelation 
to occur. The concentration of the gels was determined by Nanodrop experiments (Chapter 
2.24) and ranged from 1.6 to 2.4 wt%. The pH range studied was pH 2−8. 
Solution Sample Preparation 
Solutions were prepared using ultrapure water (18 MΩ Barnstead Nanopure, ThermoFisher 
Scientific, USA), and changes to the solutions pH values were completed using reagent grade 
1M HCL and 1M NaOH (ThermoFisher Scientific, USA). The pH values were recorded using 
an electronic lab-based pH meter, with a glass pH electrode and an internal calibrated electrode. 
The pH meter was calibrated before each experiment by using two buffer solutions of known 
pH. The pH meter can produce pH values for the samples to two decimal places, with an error 






Pyrene Sample Preparation 
Peptide concentrations of 1.3∙10-3 to 0.13 wt% were used with a constant 2.167∙10-5 wt% of 
pyrene within each sample. A 0.05 wt% pyrene in ethanol stock solution was prepared. 0.046 
mL of this stock solution was evaporated, confirmed to be completed by visual precipitation, 
on the inside edge of a glass vial then made up to 100 mL with water. This provided a 
concentration of 2.167∙10-5 wt% of pyrene in water. This concentration is at the upper threshold 
of pyrene’s dispersion within water. A higher concentration above this value would show the 
presence of precipitation of pyrene crystals and can affect the CAC measurements. 
BODIPY-TR Cadaverine and Lipopolysaccharide Sample Preparation 
The plan for these samples was make two peptides solutions, PYY3-36 and A9R, made up to the 
same molarity, and have a solution of LPS and BODIPY-TR Cadaverine to which they were 
added. To complete this 1 mg sample of BODIPY TR (InvitrogenTM, ThermoFisher, Waltham, 
MA, USA) was dissolved in a 200 mL volumetric flask with water (supplier mentioned 
previously), giving the solution a bright pink colouring (Figure 7A). A 20 mL aliquot was taken 
and to this 1 mg of Lipopolysaccharide (Sigma-Aldrich, Missouri, USA) was added, changing 
the solution to blue colour, as seen in Figure 7B. This solution was then used as the starting 
solution for all fluorescence readings, to which the same molarity peptide solutions were added. 
Figure 7: Visual colour shift, from pink to blue, from the complexation of LPS and the LPS 
specific dye BODIPY TR. A – Showing 1 mg of BODIPY TR in 200 mL H2O, giving a strong 







The effect of pH and the peptide concentration is extremely important in the determination of 
precise and reliable results for all the applied methods used in this thesis. A good example of 
this would be the CD methods as the results can be highly affected by both variables. For this 
method, if the pH is incorrectly recorded then the results cannot be confidently used to 
determine the secondary structure of the peptide. Though there are several reasons for a 
potential variation in pH e.g. pH variation through sample, and incorrectly calibrated 
electrodes, the risk of variation can be minimised by measuring the pH of a thoroughly mixed 
sample in solution, and not the solution before the sample was added. 
Another factor that can affect the accuracy of the applied methods would be if the lipopeptide 
provided was not purified correctly to remove reagents, such as the acid trifluoroacetic acid 
used in the manufacturing of the peptide. The presence of reagents can impact the purity and 
as a result can change the calculated concentration of the peptide in solution. To mitigate both 
issues, the pH was monitored by a doubly calibrated electronic pH meter and the lipopeptides 
studied were analysed by ESI-MS after delivery. The lowest purity of the measured 
lipopeptides was 95%. Even with the pH calibrations and measurement process used, and the 
high purity of the lipopeptides supplied, it is not possible to completely rule out pH or 
concentration variations in the results. However, with all the steps above in place, it is believed 
all parameters can be given with a high level of certainty. Further to this, any place where 
concentration or pH is not known, the data, processing, and discussion, is limited to only what 
can be verified, rather than relying on inference.   
2.2 Applied Methods 
2.2.1 Transmission Electron Microscopy 
Transmission Electron Microscopy (TEM) is a well-established technique, originally 
demonstrated in 1931 by Max Knoll and Ernst Ruska, followed by a commercial development 
of a first TEM apparatus in 1939.286 TEM utilises the scattering properties of electrons to obtain 
structural images with a nanometre scale resolution. A few instructive examples for the use of 
this technique are the visualisation of the structure of bacteria, pollen products or silica nano 
particles.287-289 This technique is particularly suitable at visualising self-assembled structures 
that do not need to be dissolved, which limits the technique of conventional TEM to solid self-





In Figure 8 an electron microscope diagram details the main TEM instrument components.290 
TEM instruments contain a set of lenses that confine the beam of electrons produced by the 
electron gun as described below. The complete instrument is under a high vacuum of 1∙10-6 Pa, 
minimizing the scattering produced by the electrons colliding with air molecules. The 
conventional TEM used for experiments on gel samples for this thesis (see Chapter 4), was a 
JEM 2100 plus (JEOL Ltd., Akishima-Tokyo, Japan). The TEM instrument is fitted with a 
lanthanum hexaboride (LaB6) crystal filament producing current density of 10 A/cm
2 @ 1800 
K within a narrow energy spread of 1-2 eV.291-292 Emitted electrons are accelerated at 200 kV 
and passed through the condenser lens. All lenses used in a typical TEM instrument are 
electromagnetic, meaning they use a magnetic field to deflect or correct the beam of electrons. 
The condenser lens focusses the beam of electrons onto the sample stage which are scattered 
by the sample structures present and afterwards focused by the objective lens. Finally, they are 
enlarged and projected onto the viewing stage. This image is then projected on to a fluorescent 
screen for focusing and alignment which is then replaced with a specialised 4.0-megapixel 
AMT XR-401 camera (Amtimaging, Woburn, MA, USA) set a range of different 
magnifications. The use of the camera allows for images to be taken and analysed, allowing 
for different parameters such as shape, size and weight of the structures to be recorded. 
Figure 8: Overall structure of a TEM machine with images of common studied samples. Left 
– Constructional diagram of a conventional TEM machine, showing the electron gun, the 
various lenses and their positions, sample airlock, and viewing chamber. Centre – Silica 
nanoparticles with an average diameter of 70 nm. Right – Ebola virus, negative stained with 
methylamine tungstate. From left to right images are taken from references 290, 293-294. 
The sample, which is placed into the TEM via an airlock, is fixed on a 3 mm diameter grid. 
There were two types of grids used, (i) a thin film carbon (Agar Scientific Ltd, Essex, UK) and 
(ii) silicon nitride grid (Agar Scientific Ltd, Essex, UK). Carbon film grids are made of a thin 
hexagonally perforated carbon film covering a copper frame, while the other grid is composed 





the two designs in more detail. Carbon grids were used for any experiment in which the sample 
was dry. The silicon nitride frames were only used for a single spin-coated gel sample. The use 
of carbon grids having troughs can give rise to large areas of dense material that the electron 
beam cannot pass through. Silicon nitride frames on the other hand do not have this issue but 
are more prone to damage and breaking. 
 
Figure 9: Two types of TEM sample discs used. A - Overall size and shape of a TEM grid or 
frame, B – A magnified “holey” carbon grid without film, C – Cross-section diagram of a 
carbon holey grid and the issue of varied window thickness. D – A magnified silicon frame 
without silicon nitride film window. E – Cross-section diagram of a silicon nitride frame with 
a thin continuous nitride film, making the gel cross-section thinner and the gel samples more 
TEM applicable. Image B amended from reference 295 and image D is amended from reference 
296. 
For the precise control of the electron energy (eV) and reducing in scattering of the electron 
beam, the samples and optical path need to be set under a minimum vacuum of 1∙10-6 Pa. This 





evaporate and potentially destroy alignment and/or structure, leading to incorrect images and 
interpretations.297 
The grids were prepared by allowing a concentrated solution of the sample to be dried on the 
grid. This process is explained in further detail in section 4.4, including the spin-drying method 
as well. 
Cryo-TEM is a variant of traditional TEM using cryogenic temperatures to “freeze” the 
solution, allowing for visualisation of dissolved or dispersed structures in its natural 
environment.156, 298-302 Cryo-TEM is extremely useful for imaging biological samples that can 
be unstable or destroyed without solvent, given the ultra-low vacuum conditions. Cryo-TEM 
is like that of conventional TEM except that this method is equipped with a modified airlock 
allowing for frozen samples to be loaded. The preparation steps of samples for Cryo-TEM are 
explained in Figure 9 below.303 After loading the sample onto the holey carbon grid the excess 
solution is removed with a filter paper. Thereafter the sample is shock frozen in liquid ethane 
(T = -188 °C), and then finally transferred to the airlock of the Cryo-TEM. While the Cryo-
TEM images have been taken by collaborators, Mehedi Reza, Jani Seitsonen, and Janne 
Ruokolainen from the Nanomicroscopy Center in The Aalto University in Finland, the analysis 
of the images was completed independently, unless clarification on technical imaging and 






Figure 10: Sample preparation for the Cryo-TEM method. Top left – first the sample is applied 
to the holey carbon grid, then excess solution is removed via blotting with filter paper, and 
finally the solution is frozen with liquid ethane at -188 °C. Bottom left – schematic showing 
frozen biomolecules, allowing for TEM visualization of samples with solvent. For further 
details please refer to the main text.303 Image was taken from ref 303. 
In detail, imaging was carried out using a field emission cryo-electron microscope (JEOL JEM-
3200FSC) operating at 200 kV. Images were taken using bright-field mode and zero loss energy 
filtering (omega type) with a slit width of 20 eV. Micrographs were recorded using a CCD 
camera (Gatan Ultrascan 4000, USA). The specimen temperature was maintained at -187 °C 
during the imaging. Vitrified specimens were prepared using an automated FEI Vitrobot device 
using Quantifoil 3.5/1 holey carbon copper grids, with a 3.5 μm hole sizes. Grids were cleaned 
using a Gatan Solarus 9500 plasma cleaner just prior to use and then transferred into the 
environmental chamber of a FEI Vitrobot at room temperature and 100% humidity. Following 
this, 3 μL of sample solution at 0.5 wt% concentration was applied on the grid, blotted once 
for 1 s, and then vitrified in a 1:1 mixture of liquid ethane and propane at -180 °C. Grids with 
vitrified sample solutions were maintained in a liquid nitrogen atmosphere and then cryo-





2.2.2 Small Angle X-ray Scattering 
Small Angle X-ray Scattering (SAXS) is another analysis methodology used extensively 
throughout this thesis for the characterisation of self-assembled structures or for the 
identification of potential complexation. SAXS is a widely used and useful technique that 
enables the understanding of structure at the nano-level. Uses include determining shape, size 
and distribution of macromolecules, determining pore sizes in porous material, and visualising 
and measuring partially ordered materials.304-310 Solution SAXS experiments within this report 
were completed at the beamlines B21 at the Diamond Light Source in Didcot, UK or at the 
BioSAXS BM29 beamline at the European Synchrotron Radiation Facility in Grenoble, France 
(Chapters 3, 5, and 6). The hydrogel SAXS experiments were completed at I22 and B21 at 
Diamond Light Source (Chapter 4). 
For solution SAXS experiments at the ESRF BM29 the sample-detector distance was 2.84 m, 
X-ray wavelength was 0.99 Å, and used a Pilatus 1M detector (Dectris Ltd, Switzerland). At 
Diamond B21, data was collected with a fixed sample-detector distance of 3.9 m with an X-
ray wavelength of 1 Å, using a Pilatus 2 M detector (Dectris Ltd, Switzerland). Silver behenate 
was used as a calibration standard in both cases. All peptides solutions with given 
concentrations of 0.1, 0.2 and 0.5 wt% of peptide in water were loaded into FisherbrandTM 0.2 
mL polypropylene tubes (Fisher Scientific, UK) in an automated sample changer (designed by 
the EMBL team in Grenoble) and fed through a single 100 µm thick quartz cell capillary via 
vacuum. This sample changer allowed for 8 to 16 samples to be run via an automated script, 
limiting the need for continual manual sample changing. The automatic sample changer is a 
standard part of the B21 and BM29 operation. A solvent was run before and after the sample, 
allowing for background scattering subtraction. This process was the same for both beamlines. 
As only a single quartz capillary was used throughout each experiment it was cleaned between 
the different samples and solvents. These cleaning steps were completed at both beamlines B21 
and BM29. 
On the B21, a custom-made gel holder using Kapton windows designed by Charlotte Edwards-
Gayle was used.311 The gel holder was 3D printed allowing for a “packet” of sample to be 
sandwiched between Kapton tape (used for its high transmittance of X-rays, as well as its 
stability to samples and temperatures). This 3D printed device can then be placed with repeated 
precision in the X-ray beam, allowing for both SAXS and WAXS (wide angle X-ray scattering) 
to be completed with consistency. The device can then be removed, cleaned and reused for 





of 3.9 m with a wavelength of 1 Å. Experiments on I22 used modified DSC pans with windows 
of Teflon or Kapton to allow for X-ray transmission through the DSC pan, while also being 
able to contain the gel sample. The sample to detector distance was 7.483 m and collected on 
Pilatus P3-2M detector (Dectris Ltd, Switzerland). Any Teflon or Kapton used for the DSC 
windows was corrected for with background subtraction as explained below.  
Two software packages DAWN (Data Analysis Software group, Diamond Light Source Ltd) 
and ScÅtter (Rob Rambo, Diamond Light Source Ltd) were used for data processing 
(subtraction and reduction).312-313 For all SAXS data gathered for solutions and gels, a direct 
beam scattering pattern and a cell scattering pattern were collected. Additionally, a scattering 
pattern for the background was also completed which, for the gels and solutions, was water. 
Both the empty cell and the background (water) scattering were subtracted from the sample 
scattering pattern. This produces a scattering pattern specifically for the sample and does not 
include any artefact scattering from the cell used (for example if Kapton is used) or the 
background. Once subtracted then the data was reduced by converting the large 2D detector 
scattering pattern to one pattern averaged in all directions around the beam position. This 
technique is explained in more detail below. Taking this approach allows the scattering pattern 
for the sample to be obtained and visualised. All these steps were and can be completed within 
Dawn and ScÅtter. 
The Figure 11 below illustrates the process by which a one-dimensional SAXS pattern is 
produced. When a monochromatic X-ray beam hits the sample part of the light is scattered 
producing a two-dimensional scattering pattern. Scattering can be isotropic (no specific 
alignment of scattering, scattering equally in all directions) or anisotropic (alignment in 
scattering, producing specific areas of scatter rather than radially equal). Typically, solution 
SAXS is isotropic as the molecules or self-assembled structures are randomly orientated. This 





Figure 11: Diagram illustrating SAXS measurements and a fitted form factor over 
experimental data. Clockwise from top left: After recording a full detector image with a 2D X-
ray detector, the image is radially integrated, resulting a 1D scattering curve. After background 
subtraction the scattered intensity (black curve) is fitted by a form-factor model function (red 
curve) to understand the underlying structure of the sample. 
With randomly orientated self-assembled structures the scattering can be radially averaged 
around the beam from the 2D scattering pattern recorded by the detector to produce a 1D 
pattern. This produces an “average” 1D scattering curve representing scattering intensity as a 
function of wave-vector, q, which is characteristic of the structure within the solution. The 
equation for q can be seen below, where 𝜆 is the wavelength of the incident beam and 𝜃 is half 
the angle of incidence (the difference between the incident and scattered radiation). The unit 




         (Eq. 1) 
The q-range (q-min equals the value closest to beam centre and q-max furthest from beam 
centre) is determined by the experiment set up, including the wavelength of X-ray used, pixel 
size of detector, sample-detector distance and the position of the X-ray beam upon the detector 
(note, a centrally placed beam will result in a smaller q-range, when compared to one placed 
in the corner). 
Another critical step for a SAXS experiment is the collection of a separate pure solvent 
scattering curve. This allows for the removal of the solvent’s scattering from that of the 





background data before completing any further analysis of the data as some lightly scattering 
structures, such as small proteins, can only be seen when the background is removed. 
Background noise can be a problem with solution SAXS, therefore the correct setting of all the 
SAXS parameters such as sample-detector distance, the concentration of the sample, buffer 
choice and sample environment set up (air or all vacuum) are important to obtain to reduce the 
noise and scattering of the background. 
Many self-assembled structures give characteristic 1D scattering patterns, the simulated fits of 
which are shown below in Figure 12. The 1D scattering pattern is also known as a form factor, 
which is a pattern of interference showing each scattered wave by the atoms within the 
structure. 
Figure 12: Different simulated fits of used models in this study. The scattered intensity, I(a.u.), 
is illustrated for the examples of diluted core shell cylinder, cylinders, and bilayer fits. Each 
having a 20 nm radius or thickness, and 1000 nm in length. Models simulated using the fitting 
software SasView. 
Using mathematical modelling, a form factor, such as sphere, hollow sphere, long or flat 
cylinder can be defined and its scattering pattern decerned. This allows for the comparison of 
a model’s scattering curve, fitted to user defined parameters, to that produced experimentally 
by the sample. Overall, this technique can provide further information on the structure such as 
size, length, electron density of the core or shell and the polydispersity of the structure. There 
are many form factors which have been mathematically modelled, including spheres, shells, 
rods, cylinders, bilayers, and dumbbells. All these models can be found within all fitting 





The samples within this thesis were novel and, as such, their structures were unknown. 
However, after visualisation by TEM, all samples, including the gels, were then analysed by 
SAXS and found to be largely fibre or sheet like in nature. The form factors applied to the data 
are listed below. 
Long Cylindrical Shell (References 314-315): 
𝐼𝐿𝑜𝑛𝑔𝐶𝑦𝑐𝑙𝑖𝑛𝑑𝑟𝑖𝑐𝑎𝑙𝑆ℎ𝑒𝑙𝑙(𝑞) =  𝑃












      (Eq. 2b) 





 𝑑𝑡        (Eq. 2c) 
𝑃𝑐𝑠(𝑞) =  (2
𝐽1(𝑞𝑅)
𝑞𝑅
(𝜌𝑐𝑜𝑟𝑒 −  𝜌𝑠ℎ𝑒𝑙𝑙)𝑅
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(𝜌𝑠ℎ𝑒𝑙𝑙 −  𝜌𝑠𝑜𝑙𝑣)(𝑅 + 𝑡)
2𝐿𝜋)
2
           (Eq. 2d) 
where R = radius of core, t = thickness of shell, L = length of cylinder, q = scattering vector, 
𝜌𝑐𝑜𝑟𝑒 = electron density of the core, 𝜌𝑠ℎ𝑒𝑙𝑙= electron density of the shell, 𝜌𝑠𝑜𝑙𝑣 = electron 
density of the solvent. This equation only holds true for cylinders of greater length than radius. 








Long Cylinder (Reference 316): 
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)      (Eq. 3a) 
Λ1(𝑥) =  
2
𝑥
𝐽1(𝑥)         Λ2(𝑥) =  
8
𝑥2
𝐽2(𝑥)     (Eq. 3b) 
𝜔(𝑥) =  
8
𝑥2
(3𝐽2(𝑥) + 𝐽0(𝑥) − 1)      (Eq. 3d) 
where 𝐽𝑛(𝑥) = are the regular cylindrical Bessel function of order n, R = radius and L is length 
of the cylinder and ∆𝜌 is the electron density contrast of the cylinder with respect to the solvent. 
The equation is only valid when L is greater than 2R. 






Gaussian Coil (Reference 317-318): 
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       (Eq. 4a) 
𝐺𝑎𝑚𝑚𝑎 𝐹𝑢𝑛𝑐𝑡𝑖𝑜𝑛 𝛾(𝑎, 𝑥) =  ∫ 𝑑𝑡 𝑡𝑎−1 exp (−𝑡)
𝑥
0
    (Eq. 4b) 
where RG = radius of gyration. v = excluded volume parameter and I0 = forward scattering. 
Note, the excluded volume parameter v =1/3 for partially precipitate in poor solvents, v = 1/2 
for thermally relaxed in "theta" solvent and v = 3/5 for swollen in good solvents. The specific 
volume parameter used is stated within each model’s parameter table.  











Bilayer Gaussian (References 319-320): 














2 )] + 𝑝𝑐𝑜𝑟𝑒𝑒𝑥𝑝 (
(𝑟)2
2𝜎𝑐𝑜𝑟𝑒
2 )  (Eq. 5) 
𝜇𝑜𝑢𝑡 =   𝑄𝜎𝑜𝑢𝑡 = ±t/2                     𝜇𝑐𝑜𝑟𝑒 = 𝑄𝜎𝑐𝑜𝑟𝑒 = ±t/2   (Eq. 5a) 
𝐹𝑜𝑢𝑡 =  √2𝜋 𝜎𝑜𝑢𝑡𝑝𝑜𝑢𝑡 𝑒𝑥𝑝(−𝜇𝑜𝑢𝑡
2 /2) 𝑐𝑜𝑠(𝑄𝑡/2)    (Eq. 5b) 
𝐹𝑐𝑜𝑟𝑒 =  √2𝜋 𝜎𝑐𝑜𝑟𝑒𝑝𝑐𝑜𝑟𝑒 𝑒𝑥𝑝(−𝜇𝑐𝑜𝑟𝑒
2 /2)      (Eq. 5c) 
𝑃𝑐𝑠(𝑞)  =  (𝐹𝑐𝑜𝑟𝑒 (𝑞) + 2𝐹𝑜𝑢𝑡(𝑞))
2      (Eq. 5d) 
Where: 𝜂(𝑟) = electron density profile of bilayer. 𝜎𝑜𝑢𝑡 = scattering length of outer Gaussians. 
𝑝𝑜𝑢𝑡 = electron density of the outer gaussians. 𝜎𝑐𝑜𝑟𝑒 = scattering length of inner gaussian, 𝑝𝑐𝑜𝑟𝑒 
= electron density of inner gaussians. t = bilayer thickness. D = diameter of disc (defines the 
unit cell), with 𝑃𝑐𝑠(𝑞) = scattering length density for the cross-section form factor. 
This model was used in Chapters 3 and 5, to fit the twisted sheets structures and coiled fibre 
structures from the co-assembly of two molecules. 
A simulated fit is found to be close to the experimental data by assessment through a residuum 
chi (𝜒) square test (Eq. 6). This compares the experimental data to that of the fit over all the 
points of the experimental data. A good 𝜒2fit value should be as close to 1 as possible. For all 
fits within this thesis the 𝜒2 was 0.9-1, indicating a high degree of coherence to the 
experimental data. Once a good fit was confirmed, the parameters (for which the simulated 
pattern was optimised) are recorded and can be compared with other models. These structural 













)𝑁𝑖=1       (Eq. 6) 
where N = number of data points, m is the number of fit parameters, 𝐼𝑒𝑥𝑝(𝑞𝑖) and 𝐼𝑡ℎ(𝑞𝑖) being 
the experimental data and fitting function, respectively. 
It should be noted that there are a few other methods available to analyse scattering patterns, 
such as the power law (that looks at overall dimensionality of the particles: for instance, 1D-
cylinders, 2D-planes and 3D-spheres) and Guinier analysis (approximations for size, 
interactions and the presence of oligomers). However only detailed form factor model fitting 
can provide such a large range of parameters for analysis for the formed structures. For this 
reason, detailed form factor modelling has been the prominent method used through all 
chapters of this thesis. All the fitting within the following chapters have been fitted using 
software called SASfit. There is other fitting software available, such as SasView, ScÅtter or 
FibreFix. SASfit was selected as it allows for greater control of the background and easier 
combination of form factors (which is used within this thesis for one co-assembly structure). 
2.2.3 Circular Dichroism Spectroscopy 
Circular Dichroism (CD) spectroscopy is an extremely useful technique in the field of 
biophysical chemistry as it can identify α-helical, β-sheet, random coil secondary structure as 
well as provide percentages of these structures within a polypeptide or protein. This is 
important in enabling an understanding of the physical structure of a peptide or protein and can 
give additional structural information about active sites or secondary structure specific binding 
areas of a peptide drug. This technique has other uses including investigating isomers and 
chirality in molecules, but within this thesis it was specifically used for the identification and 
percentage of secondary structure within PYY3-36 and 17PYY3-36 in all experimental Chapters 





Figure 13: Scheme illustrating the principle of CD data recording. A – Scheme illustrating the 
preferential absorption of a circularly polarized photon beam. B - Diagrams of α helical and β-
sheet secondary structures. C-Specific CD spectra for the α-helix, β-sheet, and random coil. 
Image taken from ref 321 
Secondary structure of a peptide produces a specific spectrum of the polarised light (Figure 13 
A) that allows for identification of α-helical, β-sheet or random coil secondary structures 
(Figure 13 B and C).321 Information about the secondary structure is extremely important as 
proteins and other chiral soft matter molecules produce these types of structure upon 
aggregation, assembly, or denaturation. CD thus allows for the visualisation of the 
intramolecular effects, structure, stability, monomer-oligomers and binding. 
Circular Dichroism works by the specific deferential absorption of right and left handed 
circularly polarised light passing through the sample, as shown in Figure 13. If the sample is 
optically active, this means it will preferentially absorb the right or left circularly polarised 
light. This difference can be measured which produces a characteristic CD-spectrum as a 
function of wavelength from which conclusions on the secondary structure can be drawn. 
A Photophysics Chirascan Circular Dichroism Spectrometer (Applied Photophysics, UK) was 
used to obtain all the CD data used throughout this thesis. Temperature studies were completed 
using a temperature controller and heated stage, the controller being an Α-Omega Instruments 





ramps from 20 to 70 °C with recording a CD spectrum every 5 °C were carried out. Before 
each measurement, the sample was equilibrated for 2 mins. After the maximum temperature of 
70 °C was reached the sample was cooled back to 20 °C, investigating the reversibility of the 
temperature effects on the sample. The Chirascan software (Applied Photophysics, UK) was 
used to control the variables of the experiment with the Pro Data Viewer (Applied 
Photophysics, UK) to visualise, in real-time, the data produced. Once the data was collected it 
was exported to Origin (OriginLab, Northampton, MA, USA) to complete the data 
manipulation following using Eq. 9. Some experimental results for CD have been smoothed 
using the Fast Fourier Transform function, which is available through the Chirascan 
software.322-324 When this function has been applied it will be noted and the number of points 
the data smoothed by will also be defined.     
Liquid samples were all run in Quartz Suprasil cells from Hellma Analytics (Southend-on-Sea, 
UK). The cells used are 0.1 mm or 0.01 mm in path length. The 0.1 mm quartz plaques were 
used for solutions and the 0.01 mm for gels. The reason for this variation in plate pathlength 
was to limit the absorbance to below 2. All samples were prepared with maximum absorbance 
values below 2 due to the limitations of the photomultiplier within the machine which records 
the light. The absorbance can be calculated via measuring the intensity of the light before and 
after the sample, according to: 
𝐴 = 𝐿𝑜𝑔10 (
𝐼0
𝐼
)         (Eq. 7) 
with 𝐴 = absorbance (unit-less), 𝐼0 = the intensity of the incident light, and 𝐼 is intensity of that 
light after it passed through the sample. Further, we have: 
𝐴 = 𝜀𝑐𝑙         (Eq. 8) 
with 𝐴 = absorbance (unit-less), 𝜀 = molar attenuation coefficient (L mol-1 cm-1), and 𝑙 = 
pathlength of cell (cm). 
Three separate runs were completed and then averaged to a single spectrum, but only if the 
scans and absorbance values did not change, showing a non-evaporating, stable sample. A 0.5 
nm step was used, with 1 nm bandwidth and a 1s collection time per step, for all samples. All 
samples within this thesis were recorded from 190-260 nm. The small step size was to obtain 
a larger set of data points (60 for 1s collection time versus 120 for 0.5s). The data was collected 





background subtracted, removing water and quartz cell contributions from the data. The degree 
of ellipticity, 𝜃, was then recorded for all CD samples and used to determine the molar 
ellipticity value, if the molar concentration of the sample was known.  
The CD method is only able to provide one molar ellipticity of the sample under test, given 
one unique molarity (Eq. 9). However, when the sample is a mixture that contains two or more 
components, one single molarity cannot be applied meaning that it is not possible to calculate 
or estimate the molar ellipticity of the mixture, or any of its components. The graphs have 
therefore been left as ellipticity (deg) to allow for a comparison with similar weight 
percentages. 
The equation used to calculate molar ellipticity is given by: 
𝑀𝑜𝑙𝑎𝑟 𝐸𝑙𝑙𝑖𝑝𝑡𝑖𝑐𝑖𝑡𝑦 (deg cm2 mol−1) =
𝜃 (𝑑𝑒𝑔)
10∙𝑀𝑜𝑙𝑎𝑟𝑖𝑡𝑦 (𝑚𝑜𝑙 𝑑𝑚−3)∙𝑃𝑎𝑡ℎ𝑙𝑒𝑛𝑔𝑡ℎ 𝑜𝑓 𝐶𝑒𝑙𝑙 (𝑐𝑚)
 (Eq. 9) 
Note, molar ellipticity is universal parameter, allowing for the comparison of different CD 
spectra completed on different machines, with different path length and concentrations.  
A theoretical based 100% α-helical peptide, of the same length, with a molar ellipticity of -
37,400 deg cm2 dmol-1 can be simulated using Eq. 9.  This spectrum can then be compared to 
the molar ellipticity recorded and a percentage of the α-helical structure obtained for each 
recorded peptide or lipopeptide. This can then allow for quantification of the α-helical content 
and better comparison between lipidated and native, along with any temperature dependencies.  
2.2.4 Ultraviolet (UV) Absorbance Concentration Measurements 
A small section of this thesis makes use of the Nanodrop One instrument (ThermoScientific, 
Massachusetts, USA) for the analysis of peptide concentrations and its function is described 
here briefly. The molar absorbance coefficient of a peptide with tyrosine (Y), tryptophan (W), 
and cysteine (C) can be calculated with the following equation: 
𝜀 = (𝑛𝑊 𝑥 5500) +  (𝑛𝑌 𝑥1490) + (𝑛𝐶 𝑥125)    (Eq. 10) 
This gives the weighted sum of the 280 nm molar absorption concentrations for these amino 
acids. Given that there are four tyrosine residues in each peptide the molar absorption 
coefficient becomes 5960 L mol-1 cm-1. Combined with the Beer-Lambert law (Eq. 8) this 
allows for a concentration to be determined. With the known molecular weights and volumes 





the use of the Nanodrop One instrument, compared to other spectrofluorometers, are the 
minimal sample used, approximately 2 μL, and a reduced path length of 0.03 to 1.0 mm that 
allows for more accurate measurements. These two advantages enable the measurement of 
extremely low sample concentrations with detection limits of 2 ng/µL. Furthermore, it reduces 
the experimental time to 8 secs for each sample.  
Further studies on tyrosine (Y), tryptophan (W), and cysteine (C) free peptides were completed 
with a wavelength 205 nm. The 205 nm wavelength arises from the absorbance band of the 
amino acid backbone bond and using the commonly used molar absorption coefficient of 31 
mL mg-1 cm-1 a concentration can be determined, via the Beer-Lambert law (Eq. 8).325-326 
All gel samples for the Nanodrop measurements were prepared using ultra-pure water (18 MΩ 
Barnstead Nanopure, ThermoScientific, USA). After cleaning the pedestal, running a blank 
and finally running a water sample, the samples were run using approx. 2 μL of sample (part 
of this sample preparation being shown in Figure 14). After each sample the sample pedestal 
(which creates the experiment’s pathlength) was cleaned and a new sample was placed on the 
pedestal via micropipette. This is all in accordance with the standard operating procedure 
(SOP) of the Nanodrop One found within the manual.  
Figure 14: Photos showing the use of a nanodrop to produce a small path length, which is 
useful for low concentration or low fluorescing molecules, and the application of a small 
amount of sample to the stage. Modified from ThermoFisher Nanodrop website, reference 327.  
Data for pure samples was used to predict the experimental values of mixtures. This was done 
by simple addition (for example A1 - 0.33, B1 – 0.52, Theoretical value of 1:1 A1: B1 mixture 






2.2.5 Zeta Potential Measurements 
Studies were completed using zeta potentials to observe the double layer charge of the particles 
within the solution, as shown in Figure 15. All studies were completed in the same manner 
following the experimental method detailed below. The zeta potential of a particle is an 
indicator of stability within the solution. A large zeta potential, greater than 60 mV, shows 
excellent stability, lower zeta potentials show reduced stability, with above 5 mV being the 
smallest magnitude for a stable molecule. With values below 5 mV particles are considered to 
only be briefly coagulating or flocculating and are not considered stable.328-330     
Figure 15: Diagram showing what zeta potential is and what this relates to, given a charged 
particle in solution. 
All experiments used a Zetasizer Nano series Nano-ZS machine (Malvern Instruments, 
Malvern (UK). 1 mL samples were made up within water (18 MΩ Barnstead Nanopure, 
ThermoFisher Scientific, USA) and put into Malvern Nano series disposable folded capillary 
cells (DTS1070). These were placed within the instrument and allowed to equilibrate for 120 
secs before 3 separate runs were completed to produce an average reading. The standard 50.0 
V was applied to each solution of molecules, the voltage of which defines the strength of 
electrical field (𝐸). This voltage causes the molecules to move with a velocity related to their 
zeta potential. This particle velocity (𝜈) is measured using a laser interferometric technique 




) and conductivity (𝜎) (via resistivity (Ωm)), and from this the zeta 
potential (𝜁). All values in the equations below are measured or calculated by the Zetasizer: 
𝜁 ≈ 4𝜋𝜂 (
𝜈
𝐸





 𝜎 =  
1
𝜌
          (Eq. 11) 
with 𝜁 = zeta potential (mV), 𝜂 = viscosity (N s/m2), 𝜈  = particle velocity (cm/s), 𝐸 = strength 
of electrical field (V/m), 𝜀 = dielectric constant (F/m), with 
𝜈
𝐸
 = electrophoretic mobility. The 
conductivity equation (with measurements of constant cross-sectional area and length) is given 
with 𝜎 = conductivity (S/m) and 𝜌 = resistivity (Ωm). 
2.2.6 Critical Aggregation Concentration (CAC) Experiments 
To determine the critical concentration at which a self-assembling molecule, such as a 
lipopeptide or peptide amphiphiles, aggregates, the aromatic probe pyrene was used. The 
assembly of these molecules is shown simply in Figure 16, with black and red denoting 
hydrophilic and hydrophobic sections respectively in an aqueous environment. 
 
Figure 16: Scheme showing monomers in solution below and above the CAC. The CAC being 
useful information for when the formation of aggregates can occur. 
Pyrene can function as a probe for this aggregation and allow for the identification of the 
concentration at which this occurs. Pyrene has a characteristic emission spectrum with 3 strong 
emission bands between 360-500 nm when excited at 339 nm. This emission spectra changes 
depending on environmental factors. If the pyrene is located within a largely hydrophobic or 
hydrophilic environment the emission spectra will change. Locations of hydrophobic nature, 
within an aqueous environment, occur when self-assembling amphiphilic monomers aggregate. 
The hydrophobic pocket could be located within a micelle sphere, in the wall of a vesicle, in 
the inner tube of a fibre or in the inner portion of a β-sheet. With pyrene present in the same 





show this effect namely, I1(373 nm) and I3 (383 nm). An I1/I3 intensity ratio versus 
concentration plot of the monomer with a constant pyrene concentration can be obtained. An 
increase in I3 and reduction in I1 intensities occur when pyrene is in a more hydrophobic 
environment and will reduce the I1/I3 ratio for that concentration of self-assembling monomer 
(From Figure 17 B to C). When measured across a large concentration range two linear lines 
of best fit can be used to show a “break point” that is when the environment changes from 
hydrophilic to hydrophobic, indicating the presence of self-assembly aggregates in the solution 
(Figure 17 D).    
Figure 17: Schemes explaining the process for using pyrene as a CAC probe. A – Chemical 
structure of pyrene. B – Simplified emission spectrum of pyrene in a hydrophilic aqueous 
environment. C – Simplified emission spectrum of pyrene in a hydrophobic environment, 
aggregated amphiphilic molecules. D – Ratios of the intensity at pyrene peak I1 and I3 versus 
concentration, showing the “break point” of aggregation by using two linear lines of best fit. 
The pyrene emission spectra will shift from an B spectrum to a C spectrum with self-assembly, 
and an increase in the hydrophobic environment. 
 
All the fluorescence spectra were recorded with a Varian Cary Eclipse FLR fluorescence 
spectrophotometer (Agilent, Santa Clara, CA) within the Reading University Chemical 
Analysis Facility. Samples were run within 4 mm inner-diameter quartz cuvettes (Hellma 







2.2.7 BODIPY TR Cadaverine Lipopolysaccharide Displacement Assay 
An experiment to investigate the potential aggregation of Lipopolysaccharides (LPS) to two 
different peptides was completed within this thesis, using the LPS specific dye BODIPY TR 
Cadaverine. The fluorescence methodology is similar to that used for CAC measurements, but 
instead of a ratio of peak intensities (such as 373/383 nm for pyrene), this technique uses the 
emission peak height of BODIPY TR Cadaverine (which is 620 nm) to determine if the 
BODIPY TR Cadaverine is being displaced from LPS. A higher intensity value relates to a free 
molecule, with a supressed and reduced peak relating to a complexed molecule.  
 
Figure 18: Chemical Structure of BODIPY TR Cadaverine. 
This method used a Varian Cary Eclipse FLR fluorescence spectrophotometer (Agilent, Santa 
Clara, CA) within the Reading University Chemical Analysis Facility. 1 mL of the BODIPY 
TR Cadaverine and LPS complex sample was taken and placed within the 4 mm inner diameter 
quartz cuvette (Hellma Analytics, Southend-on-Sea, UK). For all measurements, an excitation 
wavelength of 583 nm was used, with an emission range of 590-680 nm. The peak of interest 
is at 620 nm, which is the only emission peak of BODIPY, and within the range specified 
above. 
To this LPS and BODUPY TR solution 10 μL of the A9R or PYY3-36 peptide solution was 
added. The combined sample within the cuvette (Hellma Analytics, Southend-on-Sea, UK) was 
then allowed to equilibrate for 5 mins. This mixture was then placed within the Varian Cary 
Eclipse fluorescence spectrometer (Agilent, Santa Clara, CA) and a spectrum was recorded 
using the excitation (583 nm) and emission range (590-680 nm) stated above. This additional 
process was completed 10 times adding a total of 100 μL to the solution for each peptide PYY3-
36 and A9R. The peak maximum at 620 nm was taken from the fluorescence spectra at the 
beginning (pre-addition, only LPS – BODIPY TR) then for each 10 μL addition. This intensity 





An increase in peak intensity shows displacement of the BODIPY TR dye and incorporation 
with the peptide of interest. The BODIPY TR Cadaverine dye is highly specific to the lipid A 
section of LPS (lower segment).331 This would show a complexation between a peptide and the 
lower segment of LPS. A range of studies that have used LPS-BODIPY TR complexes and 
fluorescence have an estimated a ratio of 1:1.5 to 1:5 LPS to BODIPY TR probe.332 
 
2.3 Rational of Applied Methodologies 
This chapter has covered all the applied and complementary methodologies. For these studies 
the use of multiple complementing methodologies helps to provide a full picture of the self-
assembled systems or complexing solutions. This multiple method approach is an extremely 
important one and it is suggested that it be carried forward into further research into the 
molecular effects (CACs and β-sheets) of macro formations (such as gels). Below is a method 
overview table summarising the method, key parameter, sample type and which sections of this 
thesis it was used in. 
Table 1: Overview of applied methods. 
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3. Effects of Lipidation of PYY3-36 
This chapter was published in part in the paper, for which the full reference is as follows: 
Hutchinson, J. A.; Burholt, S.; Hamley, I. W.; Lundback, A.-K.; Uddin, S.; Gomes dos Santos, 
A.; Reza, M.; Seitsonen, J.; Ruokolainen, J., The Effect of Lipidation on the Self-Assembly of 
the Gut-Derived Peptide Hormone PYY3–36. Bioconjugate Chem. 2018, 29 (7), 2296-2308. 
3.1 Introduction to Peptide Hormone PYY3-36 and 17PYY3-36 
This chapter’s work relates to the lipidated form of PYY3-36 as a potential peptide hormone 
drug. As it will be referred to throughout this chapter and beyond, 17PYY3-36 is a 34 amino 
acid peptide based on PYY3-36 with a palmitoyl chain coupled at position 17 on the peptide 
chain. Three lipidated versions have been synthesised (Chapter 2.1), following the same amino 
acid replacement method but at position 11 (11PYY3-36), 17 (17PYY3-36) and 23 (23PYY3-36). 
This chapter’s work also compares the specific conformational changes between the native 
peptide PYY3-36 and that of the 17PYY3-36. Further studies within this thesis have been devoted 
to understanding any self-assembled structures that are formed by 17PYY3-36; specifically, their 
stability, structure, and morphology.  
By referring to Figure 19 of 17PYY3-36, it can be seen that an arginine amino acid at residue 17 
was replaced with a Lys-γ Glu Spacer-Palmitoyl Group (Figure 19). From an electrostatic 
viewpoint this has replaced a positively charged amino acid with a longer neutral and 
hydrophobic moiety. Combining this electrostatic change with the incorporation of the lipid 
chain into the end section of the α-helical section of the peptide chain will have a destabilising 
effect on the peptide’s overall helical content and peptide structure, reducing hydrogen bonding 
effects and adding steric bulk. This addition will also dramatically change the overall 
amphiphilicity of the molecule, potentially hindering its ability to self-assemble. The native 
PYY3-36, although highly hydrophilic, has a secondary structure that protects a hydrophobic 
pocket, this can be seen in the previous Figure 6, with the PP fold.271, 275, 333 Both of these 
aspects will be probed further in following sections (Chapters 3, 4 and 5) of this thesis that will 
set out to investigate their overall structure, the constraints that define these structures, their 








Figure 19: Full Structure of PYY3-36 and linker unit, with locations of lipidations. Top: 
Chemical structure with positions of lipidation on the amino acid chain shown by the arrows. 
Left to right of the arrow positions being 11PYY3-36, 17PYY3-36, and finally 23PYY3-36. 
Bottom: Amino acid sequence of native PYY3-6 with all three positions noted by X1, 2, and 3. 
A table of amino acids for that location and K being the Lys-γ Glu Spacer-Palmitoyl Group 
replacement. Amended from authored paper 4.305 
3.2 Cryo-TEM, Visualising Self-Assembled Structures 
Cryo-TEM allows in situ visualisation of self-assembled structures.178, 186, 309, 334-337 The first 
step was to observe if any self-assembly occurred. Second, the type of self-assembly was also 
verified by Cryo-TEM. Detailed information regarding the sample preparation, methodology 
and analysis are given in section 2.1.2 and 2.2.1, respectively. As mentioned previously in 
Chapter 2.1.2, all efforts to make sure the concentration and pH values studied are as precise 
as possible. 
The simple addition of PYY3-36 to ultrapure water (Chapter 2.1.2) can be seen in Figure 20 C, 
which shows twisted tape like structures at high concentrations. This is an extremely interesting 
and novel observation, as the self-assembly properties of this amphiphilic peptide has not been 
investigated before. Although the primary, secondary and tertiary structures of PYY3-36 have 





not been investigated.87, 338-343 With this hormone peptide being of interest as a potential drug, 
this larger nano-scale structure is important to investigate, as all levels of the self-assembled 
structure can affect a drug’s clearance from the body, its efficacy and its stability. 
Different pH values were investigated with pH 2, 4, 6 and 8 being selected as this range covers 
most the human body’s pH values.344 As this peptide could be potentially used as a new drug 
molecule, administered by ingestion, injection, or inhalation, the effect of this biological pH 
range on PYY3-36  is extremely important to be investigated and understood. 
Figure 20: Cryo-TEM images showing the twisted sheet self-assembled structures of 0.5 wt% 
PYY3-36 prepared in H2O at pH 2 (A), 4 (B), 6 (C), and 8 (D). Key observations include twisted 
sheets for A, B, and C, with a large disc structure formed for pH 8. The change in pH values 
clearly changes the overall self-assembled structures, with thinner twisted sheets for 2 and 4, 
with a complete structural change at pH 8.    
At pH 2 and 4 the self-assembled PYY3-36 structure changes from around a 4 nm to around 1 
nm thin fibres. Although being thinner, compared to the pH 6 PYY3-36 fibres, it can still be seen 





20 A, where a flat area of the twist can be seen. The size change of the fibres can be attributed 
to the change in pH increasing the positive charge throughout the amino acids within the 
peptide, making them less likely to aggregate and increasing the enthalpy of aggregation, 
compared to structure at pH 6. pH 8 on the other hand shows a large flat aggregation that is 
disk like and uniform. This is a much larger structure of 400 nm in diameter. As TEM is limited 
in its resolution, any internal structure of this disk, if present, could not be determined.  
 
Figure 21: Cryo-TEM Images showing the self-assembled elongated fibre structures of 
17PYY3-36, in water, at pH 2 (A), pH 4 (B), pH 6 (C) and pH 8 (D). 
The same concentrations and pH ranges were used for 17PYY3-36 and all pH values showed 
thin highly elongated entangled fibres, clearly seen in Figure 21. The presence of these thin 
fibres is in stark contrast to the native, unlipidated, peptide, showing that the addition of the 





The diameter of the fibres was found to be consistently about 4 nm. The fibres were also 
elongated with lengths well over 1 µm. The pH changes can also be seen to not have as much 
of an effect on the structures formed, unlike with pH 8 for PYY3-36 (Figure 20 D). pH 2 does 
show straighter and “crisp” fibres, without the entanglement that the other three pH values 
show. Without knowing the internal structure of this pH 2 structure it is difficult to suggest a 
reason for this observation, but the high positive charge at pH 2 could be limiting the flexibility 
of the peptide. This effect could potentially lock the peptide into a specific orientation, thus 
producing very linear and rigid fibres.  
With regards to the three other pH values, 4, 6 and 8, it was mentioned earlier in this section 
that a change in pH would affect the enthalpy of aggregation. This would allow different 
structures to form, but it seems here that the lipid and the hydrophobic effect are driving the 
assembly. If one factor overwhelmingly drives the assembly, it would make all subsequent 
structures similar in macrostructure and density regardless of changes in pH value.  
The elongated and entangled nature of the fibres is one of a few key factors that can cause 
fibrillar gel formation.222, 309, 345 This potential gel formation, as mentioned earlier, means that 
a gel formed from a peptide drug could be slow releasing and would be of great interest for 
drug formulation and drug delivery. These fibres do in fact form gels and their structures are 
explored in greater detail in Chapter 4. 
Cryo-TEM confirmed self-assembly of both the native (Figure 20) and lipidated (Figure 21) 
forms of PYY3-36. Now that these structures have been identified they should be investigated 
further, as the limitations of Cryo-TEM mean further methods, such as SAXS and CD, are 
needed to give these structures better definition and probe the internal structure that have 






3.3 Small Angle X-Ray Scattering of PYY3-36 and 17PYY3-36 Structures 
Small Angle X-ray Scattering (SAXS) is a highly versatile, non-invasive technique applied in 
soft matter science as well in other fields307, 310, 346-355  and is able to probe the internal structure 
of a multitude of materials and samples. SAXS was used to provide detailed information 
regarding the shape, size, thickness, density and orientation of PYY3-36 and 17PYY3-36 
aggregates using form factor fitting (Chapter 2.2.2). The sample preparation, measurement 
protocols and analysis methods, including form factor fitting are summarised in the sections 
2.2.1 and 2.2.2. 
Figure 22: All SAXS curves and form factor fitting curves for PYY3-36 at four different pH 
values (2, 4, 6 and 8). All samples were prepared in H2O at room temperature. Figure taken 
from authored paper 4.305 
For the three pH values 2, 4 and 6 the SAXS curves were all fitted to a generalised Gaussian 
coil form factor model (see 2.2.2, Eq. 4), this is a good approximation for a twisted sheet 
(Figure 20 C). On the other hand, the pH 8 SAXS sample showed large flat circular assemblies 
and as such was fitted to a Gaussian bilayer model form factor (Figure 20 D and 2.2.2 Eq. 5). 
Using q scaling, as mentioned at the end of Chapter 2.2.2, and superimposed, as shown in 
Figure 22, has confirmed the suggested 2D-planar structure by a q-2 scaling in the low q range. 
The form factor parameters used for these four fits at pH 2, 4, 6 and 8 can be seen below in 





Table 2: Gaussian coil and gaussian bilayer form factor fitting parameters for the PYY3-36 





















BG 0.70 0.75 0.021 BG 2.09 
N / arb. 
units 
0.10 0.15 1.01 N / arb. units 1.39 
Rg / nm 1.69 1.87 22.12 σ / nm 1.74 
ν 0.28 0.25 0.29 t 3.19 
I0 197.65 204.85 0.084 𝒑𝒐𝒖𝒕 0.597 
    bout 0.00086 
    𝒑𝐜𝐨𝐫𝐞 3.59 
    bcore -0.000135 
    D / nm 1000 
BG – Background. N - Scaling Factor. Rg - Radius of Gyration. ν – Flory Exponent. I0 – 
Forward Scattering. σ - Gaussian Width. t - Bilayer Thickness. 𝑝𝑜𝑢𝑡 - Electron density of the 
Outer Gaussians. bout - Width of Outer Gaussians. 𝑝𝑐𝑜𝑟𝑒 -  Electron density of the Inner 
Gaussian. bcore - Width of Inner Gaussians D - Diameter of Disc (constrained parameter, as a 
large disk was seen in cryo-TEM). 
From these SAXS fittings the pH 6 fitting parameters showed a large radius of gyration, Rg, of 
22 nm compared to the other pH values. This is comparable to the results from the cryo-TEM 
that also showed that pH 6 contained wider sheets, compared to the other values. pH values 2 
and 4 also confirmed a smaller radius ranging from 1.7-1.9 nm, which again is confirmed by 
the structures seen in cryo-TEM. pH 6, can now be confirmed to form larger, and potentially 
more stable aggregates, compared to the other pH values. The reason for this observation is 
that more stable self-assemblies normally have a low threshold to assembly, such as enthalpy 
(high charges), or entropy (small shape) that then allows for more to assemble, and stay 
assembled favourably. This is the first fitted SAXS data for the self-assembled structure of 
PYY3-36, making this a great addition to cumulative data surrounding the investigation of this 
molecule.  
Although the PYY3-36 samples formed in pH 8 water were circular and planar in shape (Figure 
20 D), the SAXS fitting (Chapter 2.2.2 Bilayer Gaussian) showed a similar bilayer thickness 
of 1.74 nm to samples of PYY3-36 formed at pH 2 and 4. This shows that the bilayer of pH 8 
PYY3-36 is as thick the two layers of similar fibres seen in pH 2, 4. Further work on this 
observation would be useful as the process by which these planar disks are formed cannot be 





17PYY3-36, as shown using Cryo-TEM, formed thin fibres and this has been confirmed through 
SAXS as well. When creating the pH 6 17PYY3-36 it was seen to produce a precipitate, as such 
it was not possible to complete SAXS analysis as the automated sample system could not 
retrieve the particulates from the bottom of the sample vial. Circular Dichroism has been used 
however to investigate this observation together with similar pH studies to understand this 
significant change. Following this methodology showed a total loss of secondary structure for 
pH 6, implying this was the isoelectric point for 17PYY3-36 (discussed more in Chapter 3.4).  
Three other pH values have been investigated, pH 2, 4 and 8. SAXS has shown 17PYY3-36 
formed thin fibres of extremely long length and that is consistent with the entangled elongated 
fibres seen previously using Cryo-TEM (Figure 21). 
Figure 23: SAXS curves for 17PYY3-36 at three different pH values, prepared in H2O, 2, 4 and 
8 including the long cylinder shell fitted curves. All samples were in water and at room 
temperature. Figure taken from authored paper 4.305 
The SAXS patterns can be seen in Figure 23 with constraints in Table 3. The parameters shown 
in Table 3 show a clear consistency through-out the pH values, compared to that of the native 
PYY3-36 that varied considerably. A small change can be seen in the radius values, but this can 





Table 3: Shows the fitting parameters used to fit the long cylinder shell model for the 3 
different pH samples of 17PYY3-36. 
BG - Background. N - Scaling Factor. σ - Gaussian Width. R - Inner Radius. DR - Shell 
Thickness. L - Length of cylinder. 𝑝𝑐𝑜𝑟𝑒- Electron density of the core. 𝑝𝑠ℎ𝑒𝑙𝑙 - Electron density 
of the shell. 𝑝𝑠𝑜𝑙𝑣- Electron density of the solvent. 
The values obtained above compare extremely well with the Cryo-TEM images of the lipidated 
peptide. They show a small radius value that was seen throughout the pH values. This contrasts 
with the native peptide that at pH 2 and 4 changed to thin fibres and at pH 8 showed large 
planar, while for the lipidated version they were all fibres, and this was enforced by SAXS 
fitting as well. Cryo-TEM also showed the loss of a twisted structure by lipidation and again, 
SAXS has confirm this loss for all the pH values, asides from pH 6 which precipitated. The fits 
also show that these fibres are low scattering cores of 1.3 - 1.6 nm, but more heavily scattering 
shells of between 0.113 – 0.271 nm. This is a helpful observation as the fibres seen in cryo-
TEM did not visibly show this inner core or an obvious outer shell. It would be difficult to 
determine the structure of these shells, as before with the native peptide, as more of the internal 
structure of the fibres is needed to be known. It is unknown if the inner core is just a 
hydrophobic pocket of the lipid chains or more solvent based (the values for scattering density 
are higher, suggesting the first, but this cannot be fully confirmed). 
In summary, the distinct change seen in the cryo-TEM results (for the pH values and lipidation) 
can be confirmed with SAXS as well. Further to this, SAXS has allow for more detailed 
parameters for the structures to be gleaned, such as the radius of the lipidated peptide fibres 
range from 1.3 to 1.6 nm. With cryo-TEM it is only possible to deduce these parameters by 
visual observation of the cryo-TEM image. The length of these fibres however was too long to 
be confirmed as SAXS is limited by the detector distance from the sample (which determines 
the observation of larger structures, such as 1000 nm fibre lengths). Though, in the above fits 









BG 0.9 0.9 0.8 
N / arb. units 0.258 0.267 0.286 
σ / nm 0.286 0.321 0.347 
R / nm 1.273 1.63 1.45 
DR / nm 0.113 0.151 0.271 
L / nm 500 500 500 
𝒑𝒄𝒐𝒓𝒆 0.0357 0.0408 0.0469 
𝒑𝒔𝒉𝒆𝒍𝒍 0.312 0.241 0.165 





the values (L) were constrained pre-emptively, before fitting, to 500 nm that gives a reasonable 
expectation of a long-extended fibre.    
3.4 Secondary Structure Investigation of 17PYY3-36 by Circular Dichroism 
A useful technique for enantiomer identification and for secondary structure investigation is 
Circular Dichroism spectroscopy (CD).309, 343, 356-362 For a detailed explanation of this technique 
and the process by which the data was recorded and analysed, please see section 2.2.3. One of 
the key observations that be been obtained from CD is if α-helical and β-sheet secondary 
structure is present. α-helical structure when present in a molecule present two minima at 
around 205 and 225 nm. β-sheets on the other hand only show one minimum around 215 nm. 
This allows for simple characterisation of the secondary structure and the observation of any 
changes from one to the other.  
In a first set of experiments CD was applied to investigate the effect of the lipidation on the 
secondary structure, followed by tests probing the unlipidated and lipidated peptide’s 
secondary structure’s stability to pH change. As mentioned previously in Chapter 2.1.2, all 
efforts to make sure the concentration and pH values studied are as precise as possible.  
Three pH values around 4, 6 and 8 were selected for the lipopeptide as the scope of this project 
was for drug formulation and these are three of the most common pH values found throughout 
the body. This also correlates well to the range mentioned earlier in Chapter 3.2 344, the reason  
being that for injectable or consumables purposes formulations above or below these values 













Figure 24: CD spectrum comparing 0.5 wt% PYY3-36 at pH 3.3, 4.6, and 6.8 to 17PYY3-36 at 
pH values, 4.4, 6.0, and 8.2. 17PYY3-36 at pH 6.0 shows no secondary structure as this pH is 
its isoelectric point and precipitated out of solution, native PYY3-36 did not show this effect at 
any selected pH. All samples prepared in water and at room temperature. All run at room 
temperature. 
The first observation from Figure 24 is in keeping with the previous studies mentioned in the 
introduction (Chapter 1.13) and showed that PYY3-36 (black, red and green in Figure 25) 
contained α-helical secondary structure at all pH values. The second observation for the native 
peptide here is that pH 4.6 has the largest content of α-helical secondary structure, estimated 
45% (red), then the two other pH values investigated for it, 35% content at pH 6.8 (green) and 
30% content at pH 3.3 (black). These percentages coming from the comparison with a 100% 
α-helical peptide of a similar length, as mentioned within the CD method Chapter 2.2.3. The 
percentage α-helical content of PYY3-36 is 45%, which is more than double previous studies 
estimates, which showed PYY3-36 having 24% content.
341 Interestingly, the previous study (by 
Keire et al.)341 also estimated the percentage of α-helical content of PYY to be 45%, which is 
closer to that was observed in these studies.  
The loss of α-helical content is not uncommon in peptide secondary structures as both α-helices 






The lipidated peptide 17PYY3-36 also shows α-helical content similar to the native peptide, 
however its α-helical content is reduced when compared to its unlipidated form. This was 
hypothesised at the beginning of this chapter as the placement of the lipid for 17PYY3-36 is 
within the beginning of the α-helical coil (Chapter 3.1 Figure 19).  
pH 6.0 for 17PYY3-36 can be seen to have created no secondary structure as it has produced a 
spectrum without any large minima. This was because when the sample was changed to pH 6.0 
the solution turned cloudy, and a precipitate formed which fell out of solution. An aliquot with 
these precipitates were gathered and the CD light blue results of these precipitates can be seen 
in Figure 24. The results seem to suggest that the precipitate has lost all secondary structure 
when at this pH value, pointing to evidence of this being 17PYY3-36’s isoelectric point (the 
point of the molecule having zero charge). This isoelectric point would make sense that the 
secondary structure is lost as most secondary structure (α-helical and β-sheets) requires charged 
amino acid interactions, and in this case, there are none, so the structure does not form. This 
precipitation affect at the pI is common and found throughout peptide and other chemistry 
fields.8, 367-370 Although a loss of secondary structure is possible at the pI, it is also highly 
probable that with the precipitation at the pI there would be no peptide present to be able to 
record a CD spectrum. The specific collection of the precipitate, and the thin (0.1mm) 
pathlength, should have alleviated this outcome, but this collection process is not infallible and 
therefore further CD and pI experiments would be needed to rule out the effect of precipitation 
at the pI.  
A more significant observation, from a drug delivery perspective, relates to the differences in 
the stability of the native and lipidated forms. The CD shows that the native peptide’s α helical 
structure is reduced when not at pH 4.6. Aside from the precipitation at pH 6.0, the α-helical 
content of the lipidated peptide at pH 4.4, estimated to be 35% content (dark blue), and pH 8.2 
with 32.6% content (Pink) are extremely similar. This suggests that the lipidation has helped 
limit the interaction of pH on the secondary structure, although the α-helical content of the 
lipopeptide was lower than that of the native peptide. 
In a second set of experiments, temperature studies were completed to probe both PYY3-36 and 
17PYY3-36 secondary structure stability to temperature changes. This was completed for 
temperatures 20 °C to 60/70 °C, taking measurements every 5 °C or 10 °C, allowing the sample 
to equilibrate for 5 minutes. A cooling step was also completed and another 20 °C measurement 





recovered fully or if the temperature had affected the secondary structure. Further information 
regarding these temperature experiments can be found in the methodology CD-section 2.2.3. 
Figure 25: CD spectra for a 0.5 wt% PYY3-36 sample prepared in H2O at pH 4.6. Temperature 
study of 20-60 °C. 
A temperature CD experiment for PYY3-36 was completed first and, as there are many previous 
secondary structure characterisation studies of PYY3-36, it was only completed on  a sample at 
pH 4.6, using 10 °C temperature steps.271, 275, 280 The main observation from Figure 25 is that 
the α-helical structure of the peptide decreases as the temperature increases, from 45% to 
22.5%. This is to be expected as the hydrogen bonds within α-helices are affected by changes 
in temperature. As temperature increases, the kinetic energy of the hydrogen bond components 
increase. This energy increase will reduce the interactions of the donating and accepting 
hydrogen bond moieties and subsequently reduce the overall bond stability. This reduction in 
stability reduces the chances of an interaction between the two moieties and gives further 
kinetic energy to the bond to dissociate, further reducing the duration of a stable hydrogen 
bond. Again, in a similar way to that of pH, this effect can be seen across all hydrogen bonding 
complexes.371-375   
Three pH values, 4.4, 6.0 and 8.2, were used to complete temperature studies for 17PYY3-36. 





detailed temperature experiment is needed to help fully characterise the molecule and to avoid 
overlooking any possible changes that might occur because of temperature change.  
As seen in Figure 26 A, a similar effect of temperature on the self-assembled α-helix can be 
seen to that of 17PYY3-36 for pH 4.4, with an overall reduction in the α-helical content presented 
by the two minima of 205 and 225 nm. This effect can also be seen to be reversible, back to 
around 32.5% content, although not back to its original 35% α-helical content at 20 °C (A – 
black line). This reversibility (A – dark green line) seems to only reach structure comparable 
to its content at the 35 °C measurement (32.5% content) (A - dark blue). Most notably, 17PYY3-
36 at pH 4.4 retains an α-helical structure throughout the temperature ramps. This is important 
information for drug formulation as large changes in secondary structure can inhibit activity, 
induce gelation, and affect the removal of the peptide hormone from the body.359, 376-382 
Figure 26: pH-dependent CD spectra of 17PYY3-36 observed from 20-70 °C. A - CD spectra 
for 0.5 wt% 17PYY3-36, pH 4.4 H2O. B - CD spectra for 0.5 wt% 17PYY3-36, pH 8.2 H2O. C - 
CD study of 0.5 wt% 17PYY3-36 pH 6.0, showing the lack of secondary structure of the 
precipitate formed (graph scaled to be similar to A and B).  
A similar observation can be seen in Figure 26 B for the pH 8.20 17PYY3-36 sample for the first 





the first few temperature points, from 32.5% to around 25%, but after temperature 55 °C this 
has transformed into a β-sheet type structure with the characteristic one minimum at 215 nm.336, 
383-391 This change can be seen to be slowly forming at 50 °C. This β-sheet structure can also 
be seen to the dominate the structure even after cooling back to 20 °C.   
At 200 nm and after cooling (Figure 26 B), an observable increase between the 70 °C result 
and that of the cooled 20 °C result was produced. There are two potential reasons for this. The 
first being a time factor, as the sample will take time to cool down from 70 to 20 °C this could 
provide time for the β-sheet structure to continue forming. In this case, the β-sheet structure 
seen to be forming around 50-55 °C could have continued to arrange, producing a larger CD 
signal. The second reason behind this observation is that some of the α-helical structure was 
reformed during cooling, but in this case the structure remained predominately β-sheet with the 
only part of the spectrum to observe this α-helical reformation being at the 200 nm wavelength. 
A maxima at 200 nm is one of the characteristics of α-helical secondary structure, as seen in 
the other experiments in this chapter (Figure 24, 25, and 26). It is unknown which of these 
potential reasons caused this effect, but the β-sheet structure is slightly more difficult to form 
than that of α-helix, requiring inter (between strands) and intramolecular bonding (within 
strands) unlike α-helical which only requires intramolecular bonding.392-394 This would suggest 
that the α-helix structure reforms while cooling and represents a more favourable hypothesis at 
these higher temperature ranges. To help substantiate this hypothesis a selection of known 
alpha-helical peptides could be subjected to the same temperature denaturing to enable a fuller 
comparison. Examples of well characterised alpha-helical peptides include Melittin (bee-sting 
component peptide) and Pardaxins (fish produced shark repellent).   
The results for pH 5.99 are shown in Figure 26 C, for completeness, but the experiment showed 
no secondary structure at all, as previously mentioned in this chapter. 17PYY3-36 has an 
isoelectric point at this value and precipitated out of solution. A single room temperature result 
can be seen in Figure 24, and this pH 5.99 17PYY3-36 experiment was then continued for all 
temperature values showing no changes and no structure. This “loss” of structure, as mentioned 
earlier, was attributed to the isoelectric point with the lipopeptide falling out of solution at, or 
close to, neutral charge. The graph was scaled to that of A and B to give a useful understanding 
of the amount of structure that was present in relation to the other pH values. The results again 
show little structure, neither α-helical nor β-sheet. This effect was commented on earlier and is 
related to the impact of the charge removing the possibility of there being charged amino acids 





The most valuable observation from these temperature studies has been the transition of the 
lipidated 17PYY3-36 from a dominate α-helical secondary structure to that of a strong β-sheet 
structure. β-sheet secondary structure, when combined with that of the fibre macro-structure 
seen in cryo-TEM and SAXS, invited an investigation into the potential for gelation to occur 
(Chapter 4). β-sheets have been known to be highly favourable for gelation as well as for 
elongated and entangled fibres.23, 142, 206, 222, 309, 363, 385-387, 395-407 This is hypothesised to be due 
to the ability of self-assembled β-sheets to form repeating structures. α-helical structure is 
limited in structure in one dimension, along the helix, but β-sheets can form tubes, sheets and 
“cross link” between strands to form a much more rigid and expansive network than compared 
to that of just α-helix structures. This is not to say all hydrogels are β-sheet as some have been 
formed from α-helixes.408-411 In Chapter 4 the question of gelation with this peptide hormone, 
PYY3-36, and lipopeptides 11, 17, and 23PYY3-36 is dealt with and have been found to form 
elongated fibre structured hydrogels.  
3.5 Critical Aggregation Concentration (CAC) Determination of 17PYY3-36 Self-
Assembled Structures 
Using Cryo-TEM, SAXS and CD the macromolecular structure of 17PYY3-36 has been 
confirmed and the internal structure investigated, the next question is that of aggregation. 
Aggregation can be identified by a variety of methods all of which measure different physical 
factors such as surface tension, conductivity and fluorescence to determine a critical 
aggregation concentration (CAC). The critical aggregation concentration is defined as when 
the surfactant is no longer suspended as free molecules and the point at which they form 
aggregates, which sometimes are well ordered. One of the CAC methods uses pyrene as a 
fluorescence probe. This method uses the intensities of two characteristic pyrene emission 
bands, after being excited using light of 339 nm, to determine the surfactant’s concentration 
point of aggregation. Pyrene’s emission peaks at 373 nm and 383 nm are sensitive to its 
environment, which means a hydrophobic or hydrophilic environment will change the emission 
pattern that is measured. In particular, the I383/I373 intensity ratio can be plotted against the 
surfactant concentration revealing a “break point” at which the pyrene changes from a 
hydrophilic to hydrophobic environment. A more in-depth explanation can be found in the 






Figure 27: Pyrene fluorescence vs. concentration of 17PYY3-36 at pH 2.12, 4.35, 6.73 and 8.21. 
I1 and I3 being Pyrene vibronic bands at 373 nm and 383 nm, respectively. The intersection of 
linear fits defines the CAC. 
Previous studies have focused on PYY3-36 but they have been solely focused on physiological 
effects and receptor binding.74, 412-422 To understand the self-assembly structure of the lipidated 
peptides when injected or consumed, a CAC study at different pH values has been completed 
on the lipidated peptide. These pH values are like those found throughout the body and are 
important to study, as previously mentioned in the CD and SAXS sections. The values of 4 to 
8 pH are also relevant for drug administration as these are safe injectable pH values.  Any 
changes to aggregation, structure and bioactivity due to these pH values would therefore be of 
use for understanding potential drug applications. The most significant observation seen from 
Figure 27 is the increase in the critical aggregation concentration away from pH 4.35 (formed 
by the simple addition of the lipopeptide to pH 7 water). At pH 4.35 17PYY3-36 showed an 
extremely low CAC of 0.0068 wt%. This low critical aggregation concentration shows that the 
assembling concentration of the lipopeptide is highly affected by the lipid addition. Any 
increases or decreases in pH value show an increase in the CAC at which the fibres form 
(Figure 21). pH 6.73 shows an almost 4 times greater increase in the CAC as compared to the 
pH 4.35 concentration. This increases further for pH 2.12 and pH 8.20 by almost 10-fold. This 
was not unexpected as increases to pH affect the enthalpy of assembly and, as the lipopeptide 





seen in Figure 27, is caused by the two “extremes” of the pHs tested. This result indicates that 
changes in pH on the charged moieties have caused the molecules to repel each other with 
greater force that, will in turn, reduce the ability of the molecules to aggregate.  
These observations conclude that the pH of the environment does affect 17PYY3-36’s self-
assembling properties. Changes in pH also show that the charges of the peptide are an 
extremely important requirement for the fibre formation of this lipopeptide. This affect is 
clearly one of the critical methods of self-assembly, via charged motifs and moieties (as 
previously mentioned in the introduction Chapter 1.8). Furthermore, these pH values show 
injection or consumption of the lipopeptide within the human body, with its varied pH values, 
will affect the critical aggregation concentration, as well as the assembly properties already 
highlighted by CD, SAXS and cryo-TEM. An awareness of this impact of pH on 17PYY3-36 
will be an important consideration for 17PYY3-36 drug formulation, manufacture and delivery. 
As mentioned previously in Chapter 2.1.2, all efforts to make sure the concentration and pH 
values studied are as precise as possible. 
3.6 Comparison of 17PYY3-36,11PYY3-36 and 23PYY3-36 
As part of this study, and as mentioned previously, three lipidated forms of the peptide hormone 
PYY3-36 were prepared. These were 11PYY3-36, 17PYY3-36 and 23PYY3-36. 17PYY3-36, each of 
which have been investigated within this report. 11PYY3-36 and 23PYY3-36 were investigated 
separately by a fellow PhD student of the Hamley group, Jessica Hutchinson. This 
collaboration has allowed for a faster completion of the methods and has provided a 
comparison of the three lipopeptides. The comparison between the three lipopeptides has 
proved valuable as it added to the lipidation and peptide scientific understanding of the 
characteristics and differences in the self-assembled structures between the different lipidated 
positioned lipopeptides. This has led to an improvement in the understanding of the 
implications of the lipidation of larger (36 amino acids) peptides.   
 
A summary is provided below but for the full data on 11PYY3-36 and 23PYY3-36 please refer to 
the authored paper referenced at the beginning of this chapter.305 This paper has also been 
referenced (paper number 4) in the publications chapter of this thesis. This published paper 
gives a greater and more in-depth comparison of the three lipopeptides.305 At pH 4 all 
lipopeptides (11, 17 and 23) formed fibres, but when the pH was changed to pH 2 both 11PYY3-





of fibres at all pH values (Figure 20). This is a clear change that can be assigned to the 
difference in lipidation position.   
 
SAXS fitting applied a spherical shell form factor to both the 11PYY3-36 and 23PYY3-36, 
resulting micellar radii of about 2 nm. The secondary structure of these micelles was confirmed 
to be α-helical in secondary structure, which is the same secondary structure found for the 
fibres at pH 2, 4, 6 and 8 values. 
 
11 and 23PYY3-36 showed similar increases in critical aggregation concentrations for higher 
and lower pH values when compared to the CACs that arose following the simple addition of 
each of the lipopeptides to water. This was a 3-to-4-fold increases from pH values around 4.5, 
11 being 0.013 wt% and 23 being 0.0093 wt%, to that of pH 2 and 8, resulting in 0.038 and 
0.033 wt% for 11 and 23PYY3-36 respectably. This is consistent with the charge of the solution 
having a large effect on the aggregation concentration, seen similarly with 17PYY3-36, and 
explained earlier in Chapter 3.5. 
The precipitation affects seen at around pH 6 for 17PYY3-36 was also seen at around pH 6 for 
the other two lipidated peptides. This effect was investigated further, by PhD student Jessica 
Hutchinson, using an acid titration experiment with the addition of small amounts of dilute HCl 
to 2 wt% samples of the three lipopeptides. Starting at pH 10 and ending at pH 2, it was 
observed at around pH 5.5 a pH plateau formed even with multiple additions of HCl, indicating 
an isoelectric point (pI). This precipitation effect for the other two lipopeptides 11 and 23 
showed similar effects in the form of a cloudy sample and precipitation to that of 17PYY3-36 at 
pH 6. This lends evidence to all three lipopeptides being at zero charge at around pH 6.   
CD of all the lipopeptides showed α-helical secondary structure for all pH values (2-8) even 
with the above self-assembly structure change (fibre to micelle). 
As shown previously, temperature ramps of 20-70 °C were completed on 17PYY3-36 as well as 
the other lipopeptides. Interestingly, both 17 and 23PYY3-36, at pH 6 or 8, showed a β-sheet 
transformation at around 45-55 °C, but 11PYY3-36 does not. This, akin to the micelle formation 
at pH 2, shows that the difference in the lipidation anchor-point is decisive for the formation 
of distinct macro-structures as well as important for the conservation of secondary structures 






Table 4: Summary of self-assembly structures. Secondary structures are colour coded: α-
helix (light orange background) and β-sheet (grey-blue background). Temperature of the 
experiment is at room temperature, unless otherwise stated.   
3.7 Conclusions of the Lipidation of PYY3-36 at Position 17 
PYY3-36 has an extremely valuable potential use as a peptide drug.
281-282, 423-425 for obesity or 
for eating disorders. The larger self-assembled aggregates of PYY3-36 have not been shown 
before, with many studies limiting themselves to drug binding or secondary structure 
studies.271, 273, 333, 338, 340-342, 426-432  
Within this thesis it has been demonstrated for the first time that PYY3-36 forms twisted tape-
like structures, with small changes in structure when the pH is changed. 17PYY3-36, a novel 
lipopeptide, has been characterised from its macrostructure to its secondary structure together 
with its critical aggregation concentrations. The experiments and subsequent analysis have 
shown a change in 17PYY3-36’s self-assembly structure from twisted tapes to fibres. The 
secondary structure, although α-helical like the native peptide, was reduced by 10%. This 
finding is consistent with the incorporation of the palmitoyl functional group, as its location 
disrupts the beginning of the helix (Figure 19). The studies carried out with pH changes and 
temperature ranges have also shown a secondary structure change, from α-helical to β-sheet, at 
around 45 °C. The macro-structure is still of a fibre like nature, but an internal rearrangement 
has occurred allowing for this secondary structure change. Once changed to β-sheet, 17PYY3-
36 remains with this structure when cooled back to 20 °C. It was also observed through a 
comparison between the three lipopeptides 11PYY3-36, 17PYY3-36 and 23PYY3-36 that they 
show different macrostructure and secondary structural differences. Each lipopeptide, although 
based on the same peptide backbone show similarities and differences when exposed to the 
same environments and processes. 
 11PYY3-36 17PYY3-36 23PYY3-36 
pH 2  micelles fibres micelles 
pH 4 (Native) fibres fibres fibres 
pH 8  fibres fibres fibres 
pH 6/8: 20-40 °C fibres fibres fibres 
pH 6/8: 40-50 °C fibres fibres fibres 





These observations demonstrate two things; firstly although lipidation, with its bio-acceptance 
and slow release qualities, is seen as a good route to overcome current drug delivery and 
formulation draw backs, the lipidation point on a large peptide requires careful consideration. 
Secondarily, if the lipidation of PYY3-36 does not affect the efficacy, these three lipopeptides 
(11, 17, and 23PYY3-36) could improve overall drug delivery, as lipidation has been shown to 






4. Lipopeptide PYY3-36 Gels 
This chapter was published in part in the paper: Hutchinson, J. A.; Burholt, S.; Hamley, I. W.; 
Lundback, A.-K.; Uddin, S.; Gomes dos Santos, A.; Reza, M.; Seitsonen, J.; Ruokolainen, J., 
The Effect of Lipidation on the Self-Assembly of the Gut-Derived Peptide Hormone PYY3–
36. Bioconjugate Chem. 2018, 29 (7), 2296-2308.  
4.1 Introduction to Lipopeptide and Peptide Gels 
Gels, as mentioned previously in the Introduction (Chapter 1.11), are solvent swollen highly 
extended assembled networks of polymeric molecules.142, 309, 363, 395, 403, 406, 408, 433-441 These large 
networks of polymeric molecules are normally formed through intra-molecular bonding 
mechanisms, such as hydrogen bonding or π-π interactions, but can also be formed by 
intermolecular bonding such as cross-linking.96, 231, 442-446 Many dispersion mediums can be 
used to form these gels from water or other organic molecules, such as hexane or petrol.231, 406, 
433, 436, 447-448 There are many defining attributes for gels, including; charge, type of monomers, 
monomeric or co-polymeric networks, and their organisation such as amorphous or 
crystalline.32, 150, 208, 335, 345, 349, 449-457  
Peptides and lipopeptides can form self-assembled structures capable of hydrogel formation.363, 
395, 458-459 Studies of these have included both the drug (peptide or lipopeptide) itself forming 
the gel network, as well as the peptide or lipopeptide network allowing encapsulation and 
retention of drug molecules.213, 241, 460-464 Both methods lead to different advantages, but the 
formation of a hydrogel can be difficult, especially for gels formed from the drug molecule.  
The intention of this project was to investigate these lipopeptides for drug delivery and 
formulation. For this reason, hydrogels, specifically gels formed using water as the swelling 










4.2 Formation of Hydrogels 
The β-sheet formation, and their stability to temperature, seen in Chapter 3.4 prompted a further 
investigation into hydrogels. Many β-sheet forming gels are formed from peptides or 
lipopeptides by using charges and temperatures.23, 178, 386, 396, 398 This was seen in the previous 
chapter at 45 °C and pH 8 when both 17 and 23PYY3-36 transitioned to that of β-sheet, which 
is highly beneficial to gel formation (Chapter 3.4 Figure 26 B for 17PYY3-36). 11PYY3-36 did 
not show this transition; neither did studies of native PYY3-36. These two significant 
observations indicate the most important changes caused by lipidation and the position of 
lipidation. Even without showing the β-sheet secondary structure transition, both 11 and native 
PYY3-36 were tested for hydrogel formation for completeness.     
Samples were made using the dehydration method (Chapter 2.1.2 Gel Sample Preparations). 
The potential critical gelation concentration (CGC), the concentration at which the sample 
gelled, was unknown for these novel lipopeptides, which is why a dehydration experiment 
would help define the concentration and probe the potential gel formation properties. By using 
the method within Chapter 2.1.2 gels were readily formed of 11, 17, and 23PYY3-36. The gels 
were confirmed by the inverted vial test (inverting a vial and visually observing a lack of 
movement and rigidity characteristics of a gel like network). Photos of the clear gels that were 





Figure 28: Four photos demonstrating the inverted vial tests for gel formation. A, B - Hydrogel 
B formed from 17PYY3-36 at pH 8.88, C, D – Another hydrogel formed from 23PYY3-36 at pH 
6.09.  
Once the singular gel formation had been observed a variety of different pH values were 
experimented with. The range of 4 – 8 was used, as previously stated (Chapter 3.2), because 
this is within the limits of injectable as well as consumable medication (i.e. pills and tablets). 
To make these studies more biologically relatable the pH values were kept within this 
boundary. A separation of 1 pH per gel was used to help provide a good range to observe any 
trends from the formation. Some gels were remade at specific pHs known to form gels, so 
multiple close values around one pH value can be seen. A full table of the formed gels can be 
seen in Table 5 below. From Table 5, it can be observed that gels were not made with pH values 
around pH 4 – 5.8, at which the solutions showed precipitation or cloudy solutions. pH 5.0 – 6 
values are linked heavily to the pI observation in the previous chapter (Chapter 3.1 to 3.7), 
making the failure to form gels understandable with zero charge and precipitation.  
The most critical observation was seen when trying to make a gel using the native PYY3-36 
peptide. All attempts at making a gel with the native, un-lipidated, peptide failed, this shows 






Table 5: Summary of lipidated PYY3-36 samples that formed gels for given pH values. Error 







Suggested future work that would improve the confidence in the gel formation hypothesis 
would be to compare the three lipopeptide gels to a range of well-known standard gel forming 
chemicals. Suggested examples include cellulose, collagen, chitosan, or synthetic 
poly(ethylene gycol), or poly(vinyl alcohol), all of which would add more information into 
what is causing the structural change and gel formation.  
4.3 Gel Concentration Determination using A280 nm. 
After confirming the conditions needed to form them, the next step in investigating these gels 
was to characterise their macro and internal structure. This experiment would help address how 
and why these gels form. As the gel formation is completed by dehydrating the sample it was 
not clear what the end concentration of the gels would be. Again, dehydration and gel formation 
could be highly varied so a range of concentrations would be useful to understand. For this, 
two simple methods were used, namely a weighing method and by the use of a Nanodrop 
spectrometer. The weighing method was extremely simple, by weighing the sample before and 
after dehydration an overall mass loss of water could be calculated and then a concentration 
determined. This method showed around a 1.7 wt% for the gels tested. The second 
methodology, explained in more detail in the Materials and Methodology Chapter 2.2.4, was 
the A280 nm peptide method used by the Nanodrop spectrometer. This A280 nm method uses 
the wavelength 280 nm to measure the aromatic amino acids in the peptide, explained further 
in Chapter 2.2.4. Fortunately, in PYY3-36 and the lipopeptides, there are multiple tyrosine’s that 
can be detected using this method (Chapter 2.2.4). With the absorbance value obtained this can 
be used to calculate the concentrations of the gels (Chapter 2.2.4 Eq. 10). A benefit of using 
the Nanodrop spectrometer is that it requires around 2 µL of sample so that the formed gel 
could be used for further experiments (Chapter 2.2.4 Fig. 15).  
11PYY3-36 17PYY3-36 23PYY3-36 
8.47 3.80 3.19 
8.76 7.35 6.09 
 7.77 6.11 
 8.67 6.56 
 8.88 7.16 
  8.57 





The weighing method showed a concentration of 1.7 wt%, showing a loss of around 80 µL of 
water by dehydration. The Nanodrop experiment produced a range of concentrations from 1.6 
wt% to 2.4 wt%. This range is rather large (0.8 wt%) confirming what was mentioned earlier 
that this dehydration method produces a variety of concentrations, but is shown to be around 2 
wt%.  
4.4 Transmission Electron Microscopy to Visualise Hydrogel Structure 
With the concentration investigated an examination of the internal structure of the gel is now 
needed. Transmission Electron Microscopy (TEM) is a powerful microscopy technique used 
to probe thin layers of material for structure. This method, explained in greater detail in the 
Methodology Chapter 2.2.1, and is capable of visualising self-assembled structures.156, 186, 297, 
334, 465-466 Two methods were used for preparation for the gels, the first spin coating on silicon 
nitride membrane grids (Chapter 2.2.1 Fig 9 D and E): the other breaking the gel up and using 
a standard TEM preparation method (Chapter 2.2.1), but with a higher viscosity sample. 
Figure 29: Overall diagram showing the method of thin layer gel formation, showing the 
preparation (left), deposition (middle) and layer (right) formation. 
The spin coating method requires dropping a droplet of the gel from a height onto a rotating 
silicon nitrite membrane on a glass slide (as seen in Figure 29). These grids were then allowed 
to dry and be stained, if needed, using uranyl acetate, which is a heavy metal staining agent 






Figure 30: Drop coating method used for gel TEM. Left – Preparation stage by dispensing a 
gel and water droplet onto a parafilm tape, center – deposition stage that was transferring some 
of the hydrogel onto the holey grid by surface contact, and finally right – the washing stage 
with the gel covered TEM grid in surface contact with the water droplet. This was used to 
remove excess hydrogel from the grid, reducing the thickness of the gel, thus not limiting the 
scattering of electrons (as mentioned within Chapter 2.2.1).  
For the second methodology, small amounts of the gel were transferred out of their vials and 
placed onto para-film tape with a droplet of ultrapure water (Figure 30). A carbon holey grid 
(Chapter 2.2.1 Fig. 9 B), the physical vehicle for the TEM, was placed on top of the droplet for 
1 minute to allow for gel deposition onto the grid. This grid was then taken and placed on top 
of the water droplet for 30 seconds to allow for a washing step. This step is mainly used during 
staining as well to remove any unused uranyl acetate. In this case the washing step is used 
because gels can deposit heavily onto the grid and the structures cannot be seen. Washing 
reduces this effect, allowing for easier TEM visualisation. This is also the reason the gels were 
not stained as the uranyl acetate increases the contrast between the structure and the 
background but now, with a heavily concentrated gel structure, the structure is harder to 
interpret. Unless otherwise stated all further TEM photos are not stained. After each 
methodology, spin or drop, the sample is dried for a few minutes and then placed into the TEM 
for imaging. 
Transmission Electron Microscopy allows for the visualisation of the structure of the gels, but 
only if the constraints of concentration, thickness, water content, contrast and stability are met. 
In this case 11, 17 and 23PYY3-36 were all prepared for TEM in a way that produced the best 





36 versions readily produced gels at this pH. Other pH values were investigated such as pH 7 
and 3. These all showed the same structure seen at pH 8. 
Figure 31: Three TEM Images showing highly elongated and entwined fibres from different 
lipopeptides hydrogels at pH 8. i) 11PYY3-36 ii) 17PYY3-36 iii) 23PYY3-36. Figure taken from 
paper referenced at the beginning of the chapter, and in the publication chapter, paper numbered 
4.305 
Figure 31 shows that all the pH 8 gels, for all the lipopeptides (11, 17 and 23), produced thin, 
roughly 10-20 nm, fibre like structures. These are extremely structurally similar to that of the 
pre-gel samples of the lipopeptides (17PYY3-36 fibres seen in Chapter 3.2 Figure 21), though 
larger in diameter. The lipopeptides remain very entangled and elongated. The TEM images 
do not show any intermolecular structure such as repeating sheets or crystal-like structures. As 
mentioned earlier these grids were not stained so the contrast shown here is produced from the 
molecules and the structures themselves. Although cryo-TEM/TEM results are more visual and 
easier to be interpreted than other scientific methods, it is suggested that two comparison 
molecules were investigated to provide additional experimental insight into the fibres seen 
(Figure 31). Large fibrous hydrogel Gelatine, and the extended fibres of Cellulose, would be 











4.5 Small Angle X-Ray Scattering Investigation into Hydrogel Fibres 
To assign more parameters to these fibres, Small Angle X-ray Scattering (SAXS) was 
completed. SAXS, as previously mentioned in Chapter 3.3 before and in the Methodology 
Chapter 2.2.2, allows for assigning structures as well understanding their parameters based on 
their sample scattering patterns.  
As the samples for the SAXS analysis were gels, the regular high-throughput system was not 
used as this normally requires low viscosity samples that can be drawn up via needle under 
pressure. Further information on this technique can be found within Chapter 2.2.2 and as 
mentioned there, a specific “Gel Cell”, designed by Charlotte Edwards-Gayle, was used for 
these samples of gels (see further details in methodology Chapter 2.2.2).  
Figure 32: Small Angle X-Ray Scattering comparison graph showing al pH 8 gels of 11, 17 
and 23PYY3-36. All fitted with a long cylindrical shell model (Chapter 2.2.2 Eq 2).  
It was interesting to observe that all three gels showed different structures even with the TEM 
images showing similar structures of long entangled fibres and with their pre-gel samples 
showing a similar SAXS pattern (Chapter 3.3 Figure 23). The red lines in the graph above 
indicate the separate form factor fits that were applied to each of the gel scattering patterns. 
The applied fits show a close relationship to their scattering patterns, having a residuum chi 
square of 0.8 – 0.9 (Chapter 2.2.2 Eq. 6). A long cylindrical shell model was used for all three 
































the models allow for a variety of inner radii and shell thicknesses, which can be viewed in the 
Table 6. In comparison with hydrogel structures already found in scientific literature, this 
entangled fibre or long cylinder shell structure is found to be extremely common amongst 
different hydrogelator compounds.23, 387, 396, 453 
Table 6: Summary of all three long cylindrical shell models (Chapter 2.2.2 Eq. 2) with fitting 
parameters resulting from the 11, 17 and 23PYY3-36 hydrogels SAXS patterns. 
BG = Background, N = Scaling Factor, 𝜎 = Gaussian Width, R = Inner Radius, DR = Shell 
Thickness, L = Length of Cylinder, 𝒑core = electron density of core, 𝒑shell = electron density of 
shell and 𝒑solv = electron density of the solvent. L was constrained to 5000 for 11/23, and 1000 
for 17, to simulate elongated fibres.  
The SAXS fitting parameters show that, although they all have the same structural design, the 
internal structure of the fibres differs. 23PYY3-36 seems to show the greatest change with the 
inner radius being almost twice the size of the other lipidated peptides, from 22.59/30.01 nm 
to 55.21 nm. 23PYY3-36 also has a much smaller shell thickness with 6.55 nm compared to 
28.05/48.55 nm for 11 and 17PYY3-36. These large radii are seen in the TEM images that seem 
to show smaller fibres of 10-20 nm in radius, however this could be an issue related to the 
drying effect of the TEM. The fibres seen in the TEM maybe be “solvent removed” due to the 
high vacuum levels used, whereas the SAXS results are showing fibres that remain solvent 
swelled, which would explain the larger radii observed. The changes in structure, with 
differences in location of lipidation on the peptide, is clear within Table 6. Each of these model 
fits show differences that were not noticeable in the TEM images. It was also good to confirm 
the hydrated radius of the gels as TEM does suffer from the dehydration of the sample, thus 
potentially changing the sample’s structure.   
Parameters 11PYY3-36 pH 8.5  
2 wt% 
17PYY3-36 pH 8.2 
2 wt% 
23PYY3-36 pH 7.2 
2 wt% 
Background 0.00158 0.0102 8.26 ∙ 10-6 
N / arb. units 5.37 ∙ 10-9 1.01 ∙ 10-5 1.447 ∙ 10-7 
𝝈 / nm 12.96 23.12 14.75 
R / nm 22.59 30.01 55.21 
DR / nm 28.05 48.55 6.55 
L / nm 5000 1000 5000 
𝒑core / nm -3.677 ∙ 10-5 2.70 ∙ 10-4 1.098 ∙ 10-3 
𝒑shell / nm -5.49 ∙ 10-4 -6.91 ∙ 10-5 3.57 ∙ 10-3 





The internal structure of these fibres was investigated by Circular Dichroism (CD). Combined 
with the previous solution studies this technique can give a good insight into the internal 
structure of the fibres. As all gels are formed via the same process, all methodologies can be 
compared, however there is a natural variability in gel concentrations that will need to be 
considered before a final comparison between the methodologies is made.    
4.6 Secondary Structure Investigation of Fibres using Circular Dichroism 
Circular Dichroism has been mentioned before in the Methodology Chapter 2.2.3 as well as 
the Chapter 3.4 about PYY3-36. The method of sample preparation was similar to that of the 
solutions but instead of a small quantity of solution (20 µL), a small quantity of gel was 
removed and pressed between the two plates (Chapter 2.2.3). The plates were then placed into 
the sample chamber as normal.  
Figure 33: CD Spectra for 11, 17 and 23PYY3-36 hydrogels at pH 8. All hydrogels show varied 
amounts of β-sheet secondary structure (with minima around 220 nm) with 17PYY3-36 having 
the highest content, and 23 having the lowest. 
CD showed β-sheet structure with a minimum ellipticity appearing at around 220 nm, 
characteristic for this secondary structure.180 This secondary structure is like the β-sheet 
structure seen for the solutions (17 PYY3-36 shown previously in Chapter 3.4 Figure 26 B) when 
heated and the pH changed. This secondary structure change, from α-helical to β-sheet, does 
seem to be indicative of gel formation as none of the gels that were tested showed an α-helical 
structure. Gels from α-helical peptides have however been evidenced in scientific literature.408, 
467 11PYY3-36 and 17PYY3-36 showed higher β-sheet concentration compared to that of 

































23PYY3-36. This can be compared to what was seen in the SAXS. SAXS showed a larger but 
thinner cylindrical shell model that seems to be formed from a less structured secondary 
environment, as informed by CD. As mentioned earlier, a more detailed analysis is needed of 
these gels to really probe the differences between them, but as CD shows around a 50% 
decrease in β-sheet secondary structure between 11, 17 and 23PYY3-36 this indicates a large 
structural difference. This change could be due to a concentration difference between samples, 
but as this decrease is as much as 50%, some of this could be due to concentration variance, 





Figure 34: Temperature CD studies on the 17PYY3-36 pH 8 gel (A) and on the 23PYY3-36 pH 
8 gel (B) from 20-70 °C. Both show the visual loss of β-sheet secondary structure as 
temperature increases. This loss is then shown to be permanent with the 20 °C cooled 
measurement showing similar structure to the 70 °C measurement. 
Further studies were completed to investigate the gel’s stability to temperature. Previously, it 
has been shown (in Chapter 3.4) that even after cooling back to 20 °C the β-sheet structure of 
17PYY3-36 is still retained and does not revert. These gels were put through the same test with 





This sheet formation trend can be seen again in the temperature CD studies of two of the gels. 
17PYY3-36 shows a loss of structure but only after the jump to 40 °C. After this temperature 
jump the loss is consistent up to 70 °C. This shows that the secondary structure is weak to 
temperature and once the structure is removed it is not reversible. Similar effects can be seen 
with temperature increases for the 23PYY3-36 gel with a loss of β-sheet structure with an 
increase in temperature up to 70 °C yet with no secondary structure reforming after cooling.  
It should be noted that all gel CD spectra have been reported in Ellipticity (mdeg) and, although 
a concentration between 1.1 – 2.1 wt% was calculated, a precise concentration of each of these 
gels is not possible to determine as the concentration varied by ±0.4 wt% from gel sample to 
gel sample made. Furthermore, molar ellipticity requires a reliable concentration to be able to 
compare spectra (Chapter 2.2.3 Eq. 9). This would mean that a gel made with the same 
lipopeptide, at the same pH, and starting concentration could produce different final gel 
concentrations. As multiple gels were made to run these experiments, the concentration values 
cannot be transferred between all the experiments but can provide a rough concentration range.    
A gel sample of 11PYY3-36 was also studied by temperature range using CD by another PhD 
student within the group, Jessica Hutchinson. The experiment however did not set out to 
understand 11PYY3-36’s stability to temperature but to understand the gel’s formation. It was 
known that the β-sheet structure formation is incredibly important and that the samples would 
not form gels of α-helical structures, as seen in the native peptide with other pH values failing 
to gel. This experiment was to show that these two events, β-sheet formation and gelation 
happens coherently. As seen in paper 4 (referenced at the beginning of this chapter), gel 
formation was related to the increase in β-sheet formation and a loss of α-helical strucutre305 
after a pH change and as CD was taken at 5 °C steps of increase in temperature. 
4.7 11, 17 and 23PYY3-36 Gel Conclusions 
In conclusion, the novel lipopeptides 11PYY3-36, 17PYY3-36 and 23PYY3-36 can form gels by 
simple dehydration at different pH values, expect at that of their pIs. It has been shown that 
without lipidation PYY3-36 does not form gels at any pH value. This shows clear evidence that 
the lipidation has enabled the formation of gels, although lipidation did result in a decrease of 
the overall secondary structure (Chapter 3.4).  
The gels analysed have been characterised through a multitude of experiments, including TEM, 





1.7 wt% with a variance of ±0.4 wt%. Their overall network was seen by TEM to be large, 
with entangled networks of long fibre like structures and with a variety of radii from 20 to 50 
nm, similar to, but much larger than, those seen for their solution counterparts.  
An investigation into these fibres enabled the fibres to be defined, using SAXS, to give radii 
and radius thicknesses, combined with circular dichroism spectroscopy to show a β-sheet 
secondary structure. These gels were also tested for temperature stability that showed a loss of 
structure upon heating that was not regained upon cooling. It was also shown that this transition 
from α-helical to β-sheet is the driving factor for the gel formation, as no gels were formed 
under the same conditions with α-helical secondary structure fibres. Further support for this 
observation is that the gel transition occurred at the same transition point for β-sheet formation.   
As lipidation is a common method for elongating a drug’s half-life and helps in reducing 
degradation pathways in the body, this analysis will add valuable information to the research 
field of lipidation and gel formation. If these findings are applied to other peptide and non-
peptide drugs the potential for the application of lipidation could make for an extremely 
important area for further investigation. It would also be of interest to the gel research field as 
the formation of a gel using only the drug component could be highly valuable in saving 







5. 17PYY3-36, PYY3-36 and A9R interactions with Lipopolysaccharide 
5.1 Introduction to A9R and LPS 
Peptide self-assembly has been an ever-growing, mainly academically focused, field that is 
now gaining interest in their use in biomedical applications through drug treatment, delivery, 
and formulation.152, 468-471 Many parameters can affect the process of assembly, stability, and 
structure of the self-assembled system. These include temperature; pH, ionic strengths, 
concentration, and excipients.307, 472-474 Peptide YY3-36 (PYY3-36) (as mentioned in the previous 
Chapter 1.13 and 3.1) is a 36 amino-acid peptide hormone produced from the cleavage of 
another stomach hormone Peptide YY (PYY) by the enzyme DDP4.475  
Lipopolysaccharide (LPS) is a large amphiphilic molecule originating from the outer 
membrane of bacteria, also known as an endotoxin.476 LPS is formed of two sections, 
polysaccharide and lipid. The polysaccharide section has three parts, O antigen, outer and inner 
cores. Bacteria use LPS to support the cell membrane and to protect against attack from foreign 
bodies. For this reason, LPS’s exhibit strong immune responses in animals as they are found 
on various disease-causing bacteria. The human immune system uses LPS as a detector 
molecule.477 Similar to PYY3-36, LPS has also been studied extensively with a focus on 
structure and biological activity.478-495 Current studies focus heavily on bioactivity, with many 
studying inhibitor effects, such as cationic peptides, or cationic metals.254, 486, 496-502 Only a few 
studies include self-assembly or co-assembly of LPS with other peptides or lipopeptides.482, 497, 
503-504  
Papers and reviews have commented on the potential for positively charged peptides to be used 
as an antibacterial target or for complexation with LPS.94, 195, 230 A9R is a nine alanine amino 
acids then one arginine in a positively charged peptide that has also been shown to have anti-
bacterial properties (Figure 39).505 As A9R potentially interacts with the bacterial cell wall it 
makes for an useful comparison molecule for LPS complexation and as such will help give 
further information on complexation experiments with PYY3-36 and 17PYY3-36.
505 This LPS 
complexation is of interest to drug companies as this effect can cause a reduced activity of a 





5.2 17PYY3-36 complexation to LPS Cryo-TEM Observations 
A preliminary test of a mixture of 1:1 weight ratio of 17PYY3-36: LPS was completed in tandem 
with other experiments (Chapters 3 and 4). This experiment was undertaken to visualise any 
useful observations occurring from the complexation. After simply mixing the two compounds 
it formed a white precipitate that would fall to the bottom of the sample tube after a few hours. 
Photos of the samples can be seen in Figure 35 with the change in turbidity clearly seen.  
Figure 35: Visual turbidity from the mixing of LPS and 17PYY3-36. Left to right: 0.5 wt% LPS, 
mix 0.5:0.5 wt% LPS:17PYY3-36 and 0.5 wt% 17PYY3-36. All samples and mix in water, at 
room temperature, and pH unchanged. 
This result caused an interest in what was being formed, as these lipidated peptides are novel 
and any potential co-assembly would be useful to characterise. For the precipitate to be 
visualised the samples were sent off for Cryo-TEM analysis with instructions to mix the sample 
vials before they were sampled. Through this approach it was hoped to “capture” the precipitate 
for visualisation. All three vials were visualised to allow for comparison between the separate 
molecules and the mixture.  
Firstly the 0.5 wt% sample of 17PYY3-36 can be seen in Figure 36 A. This showed the same 
type of structure similar to that seen in the previous Chapters 3.2 and 4.4. The fibre nature can 
be seen to be thin radius, elongated and entangled with length greater than 1000 nm.  
Previous LPS studies have shown the self-assembled structure to be short fibre like assemblies. 
These structures can be seen in Figure 36 B showing similar properties to those shown 
previously in scientific literature.501, 506 Another interesting observation from this experiment 
is the seemingly regular spacing between the fibre like structures. This is starkly different to 
that of 17PYY3-36, which shows a tangled fibre like nature. 
As the LPS used for this thesis has an inherently high variance in molecular weight, caused by 
it being manufactured using bacteria and its purification by phenol extraction, it is not possible 
to provide a precise view on the actual molecular weight of the LPS used. However, by using 
the typical average molecular weight of 1,000,000 g/mol (1000 kilodaltons) for LPS, this would 





17PYY3-36 and PYY3-36 used in this experiment is 4047.07 and 4387.32 g/mol, the molarity 
will be 1.235 and 1.140 mmol, respectably. As can be seen there are, in broad terms, 250 times 
as many peptide/lipopeptide molecules than LPS molecules in the mixtures. As proposed later 
in this chapter, 17PYY3-36 and PYY3-36 are physically interacting with LPS via co-assembly 
(FIGURE 36 and 37). With the difference in the estimated molarities, this is likely to mean that 
the peptide/lipopeptide is in higher concentration, and thus has a higher impact on the co-
assembly process. However, it is worth remembering that as self-assembly and aggregation 
does not necessarily require a 1:1 bonding of the components, the calculation of a ratio of 
molecules can only, at best, be an estimate. 
Figure 36: Cryo-TEM images showing the odd co-assembly of 17PYY3-36 and the bacteria 
endotoxin LPS. A – The first comparison image showing 0.5 wt% 17PYY3-36 in H2O scaled at 
100 nm to visualise the thin elongated fibres, structure similar to that seen previously in 
Chapters 3 and 4. B – The second comparison image of 0.5 wt% LPS in H2O, with the short 





of the mixture 0.5:0.5 wt% (250:1 estimated molarity) 17PYY3-36: LPS in H2O, C showing a 
smaller one, and D larger ones, both at 100 nm scale.  
The mixture of these two compounds showed a similar fibular nature but rather than being 
short and regularly spaced, such as LPS (Figure 36 B), or entangled and lengthy such as 
17PYY3-36 (Figure 36 A), Figures 35 C and D show “circular” aggregates of fibres. These 
aggregates are of different sizes, from 400 – 100 nm diameters, but regardless of size, they all 
seem to show the same type of aggregation. It is unclear what the underlying effects of these 
aggregations are. Although what is noticeably clear is that there is an interaction between the 
two molecules. Studies about the aggregation of peptides, specifically AMPs, with LPS, have 
not reached a consensus on why some peptides promote aggregation and others negate LPS 
aggregation.486, 507-512  
5.3 SAXS Investigation of 17PYY3-36/LPS Aggregation Structures 
To investigate these aggregates, small samples were taken for SAXS measurements. SAXS, as 
mentioned previously, can obtain more precise parameters for the structures formed. The first 
thing that can be noticed from the scattering patterns of the samples (Figure 37) is that each 
showed different structures are being formed.  
Figure 37: Comparison spectrum of SAXS patterns for 17PYY3-36, fitted with a long cylindrical 





























1:1 wt% (250:1 estimated molarity ratio) mixture, which was fitted with a bilayer model (2.2.2 
Eq 5). All samples are 0.5 wt% with H2O as the solvent. 
17PYY3-36 has been fitted to a long cylindrical shell model, as seen in Figure 23 of the previous 
Chapter 3.3. Lipopolysaccharide showed a different scattering pattern, with a peak at around 1 
nm-1 compared to that of 17PYY3-36 (1.4 nm
-1). A form factor of bilayer gaussian (2.2.2 Eq. 5) 
combined with a long cylindrical shell model (2.2.2 Eq. 2) showed to fit the experimental 
scattering pattern for LPS. The parameters for this fitting are shown in the Table 7. The mixture 
of LPS and 17PYY3-36 showed a further different scattering pattern, indicating the formation 
of a different structure. This finding adds information to academic research and helps confirm 
the co-assembly of LPS and 17PYY3-36. A bilayer gaussian form factor was used to fit the 
SAXS pattern of the 1:1 wt% ratio 17PYY3-36 and LPS mixture (250:1 estimate molarity ratio) 
as can be seen in Figure 37. This result also showed a good correlation to the data of 0.8 – 0.9 
chi square residuum fit. This gaussian bilayer form factor is similar to that used for LPS but 
showed some differences in parameters, particularly in the bilayer thickness (around 0.5 nm 

















Table 7: SAXS form factor fitting parameters for LPS, 17PYY3-36 and a 0.5:0.5 wt% (250:1 
estimate molarity ratio) mixture. All samples are in H2O. 
N - scaling factor. σ - gaussian width. R = radius of core, t = thickness of shell, L = length of 
cylinder, q = scattering vector, ρ_core = electron density of the core, ρ_shell= electron density 
of the shell, ρ_solv = electron density of the solvent. 𝜎𝑜𝑢𝑡 = scattering length of outer gaussians. 
𝑝𝑜𝑢𝑡 = electron density of the outer gaussians. 𝜎𝑐𝑜𝑟𝑒 = scattering length of inner gaussian, 𝑝𝑐𝑜𝑟𝑒 
= electron density of inner gaussians. t = bilayer thickness. D = diameter of disc (defines the 
unit cell). 
Predictably, the form factors for the fitted SAXS data showed that three different structures 
formed. This was expected from the cryo-TEM images (Figure 36) as the incorporation of the 
LPS into the 17PYY3-36 fibres would change the structure of the fibres. In this case it seems 
that the radius of the fibres is the major affected parameter.  
All three form factors have had their length or the diameter of the disk constrained to that of 
500 nm for 17PYY3-36, or 1000 nm for the LPS and mixture models. This is because they all 
show an elongated structure. Both the LPS and 17PYY3-36 also show similar radii with 1 nm 
and 1.45 nm respectively. This can be seen to be reduced by looking at the bilayer thickness 
Sample 17PYY3-36 LPS 






Gaussian Bilayer and 




N / arb. units 0.294 0.000645 0.000551 




Parameters    
R / nm 1.45 1  
DR / nm 0.271 0.2  
L / nm 500 1000  
𝝆𝒄𝒐𝒓𝒆 0.0567 0.023  
𝝆𝒔𝒉𝒆𝒍𝒍 0.165 -0.03  
𝝆𝒔𝒐𝒍𝒗 0.0354 0.002  
Gaussian 
Bilayer 
Parameters    
σout  0.455 0.282 
𝒑𝒐𝒖𝒕  0.0376 0.094 
σcore  0.342 0.590 
 𝒑𝒄𝒐𝒓𝒆  -0.0154 -0.0328 
t / nm  -0.03 0.50 





value (t) for the mixture which shows a value of 0.5 nm. The other values change as well, but 
what is clear to see is that these structures, aside from their length, have changed scattering 
densities (𝜎𝑜𝑢𝑡,𝑝𝑜𝑢𝑡, 𝜎𝑐𝑜𝑟𝑒 ,  𝑝𝑐𝑜𝑟𝑒) as well as the width values of the self-assembled structures.   
5.4 Circular Dichroism Study of 17PYY3-36 and LPS Aggregates  
The previous Chapters 3 and 4 show that 17PYY3-36 has a reduced α-helical secondary structure 
compared to that of the unlipidated form (Figure 24).305 Lipopolysaccharide has also been 
shown to form self-assembled structures (Figure 36 B). A simple mixing experiment, using a 
wt% ratio, allowed for the secondary structure of the un-mixed molecules to be further 
confirmed.   
Figure 38: CD spectrum of 0.5 wt% 17PYY3-36 (black), 0.5 wt% LPS (red), and a 1:1 wt% 
ratio (250:1 estimated molarity ratio) mixture of the two samples (green). All samples and 
mixtures were made in D2O. The mixture shows reduced α-helical secondary content. LPS 
showed no secondary structure.  
The CD spectra, see Figure 38, shows a further reduced α-helical nature for the mixture. This 
was to be expected as an incorporation of a large molecule without secondary structure reduces 
the overall solution’s ellipticity. Therefore, the reduced α-helical secondary structure can be 
either caused by the presence of both self-assembled structures or through the incorporation of 
the LPS into the 17PYY3-36 self-assembled structure, which would reduce its overall secondary 
structure, and in doing so reduce the recorded ellipticity. Unlike for 17PYY3-36 at pH 6 this 
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reduction in α-helical content was not caused by precipitation, as the solution became cloudy 
but did not settle out of solution, this effect can be seen in the Figure 35.  
CD by itself would not have given a clear view of the reason behind the α-helical reduction as 
the results could have occurred from the averaging out of two samples where no co-assembly 
had occurred. However, as it has been evidenced before by cryo-TEM (Figure 36), co-self-
assembly has occurred. It can be deduced therefore that this reduction in α-helical content is 
due to the incorporation of LPS into the fibres. The radius of the fibre, as measured by SAXS, 
has been seen to reduce to 0.5 nm compared to the original 1.5 nm. This compacting effect 
could be produced by LPS incorporation, along with the denaturing of the α-helical content.  
5.5 Further Investigations with PYY3-36 and A9R Complexing to LPS 
Even with these observations, which are seen from the fitting of the SAXS parameters and 
Cryo-TEM, a complexation effect cannot be fully confirmed. Small Angle X-Ray Scattering 
takes an average “shot” of the solution, so if, as seen in the Cryo-TEM, the observation could 
be an interaction between the two self-assembled structures and not a complexation for the two 
molecules into a distinctly different structure. This is a difficult theory to investigate as it 
requires specific molecules that show binding to LPS or PYY3-36 that can also be quantified.  
Further experiments with A9R were suggested to complement these studies for two reasons. 
Firstly, to experiment with the reason for complexation. A9R is a different molecule in terms 
of size (10 amino acids vs. 33) and charge and overall function (anti-bacterial vs. hormone). 
A9R is a 10 amino acid chain, with only one charged group, arginine. A9R has also been shown 
to have anti-bacterial properties and, given the presence of LPS on the cell wall of bacteria, the 
interaction between the two molecules would be of further interest to anti-bacterial drug 
research.505 
 
Figure 39: Chemical Structure of A9R. A9R is a known anti-bacterial peptide and readily self-





120 mg of 17PYY3-36 was originally supplied for the experimentation for this thesis; however, 
17PYY3-36 is expensive and as a result of budget constraints, no further supplies could be 
acquired. This meant that, after only a small number of experiments, further studies into the 
interactions between 17PYY3-36 and LPS, and its complexations, had to be suspended. The 
potential work that could have been completed with further amounts of 17PYY3-36 has been 
suggested for future work (Chapter 7.2). 
The use of the available 17PYY3-36 was however focussed on the aforementioned studies into 
the characterisation and gelation of 17PYY3-36 that are contained within this thesis. In addition, 
a selection of LPS studies were completed using the available quantity of 17PYY3-36.  
To enable to continuation of the LPS studies, native PYY3-36 was used as a substitute for 
17PYY3-36. The replacement with PYY3-36 was chosen as it has a similar 34 amino acid peptide 
chain, similar charged and uncharged groups, size and secondary structure. This approach 
allowed for more information to be gathered on the observations seen to occur between 
17PYY3-36 and LPS in the Cryo-TEM.  
To follow the molarity estimation from before, using A9R’s mr of 814 gmol-1, for the following 
experiments LPS is still at 5 µmol, while A9R is 6.142 mmol. This means there is a ratio of 
around 1:1228 of LPS to A9R. As proposed earlier in this chapter, 17PYY3-36 and PYY3-36 are 
physically interacting with LPS via co-assembly (FIGURE 36 and 37). With the difference in 
the estimated molarities, this means that A9R is in a much higher concentration, and thus has 
a higher impact on the co-assembly process. Again however, it is worth remembering that as 
self-assembly and aggregation does not necessarily require a 1:1 molarity bonding of the 
components, the calculation of a ratio of molecules can only, at best, be an estimate. 
5.6 Cryo-TEM Investigation of the interaction between A9R and LPS 
The first step in observing an interaction between the two molecules is to complete Cryo-TEM. 
This approach would allow for comparison to that of 17PYY3-36 and LPS, which did show an 
interaction. Investigation into whether it is the lipid or the peptide that is responsible for the 
co-assembly effects seen in cryo-TEM, CD and SAXS would need to be undertaken. A9R has 
been studied before, by PhD student Charlotte Edwards-Gayle, and has been confirmed to have 
a fibular like structure.505 The structure of LPS has also been seen to be fibular in nature, as 





Figure 40: Cryo-TEM showing the formation of two distinct self-assembly structures of 0.5 
wt%: 0.5 wt% (1228:1 estimated molarity ratio) A9R: LPS in H2O. Both A and B belonging to 
the same sample and are at the same magnification. Red squares on B are indicating the 
different structures formed, left fibres for LPS, and right being A9R fibres (similar to previous 
A9R structures seen505).  
The first observation, in Figure 40, is that there are two visually different self-assembled 
structures formed within the same sample. The first structure is highly similar to that of LPS, 
seen previously as being fibre like, but theses fibres are shown to be longer and not as dispersed 
as before (seen in Figure 36 B). The second self-assembled structure seen is that of short fibres 
“sharp or needle like” in nature.  
These structures are similar to that seen in a paper to be published by the Professor Ian Hamley 
group on A9R with bacterial studies.505 This separation between the two structures clearly 
shows no interaction when compared to that of 17PYY3-36 and LPS. As cryo-TEM is limited 
in resolution the internal structure of these two fibres is unknown. This limitation of cryo-TEM 
means further experiments are required to probe the internal structure to determine if any self-





5.7 A9R with LPS, SAXS Investigation 
As seen with other studies (Chapter 3 and 4), small angle X-ray scattering analysis has been 
carried out to probe the formed self-assembled structures (Chapter 3.3). As SAXS produces an 
average scattering pattern of a sample, it is not easy to accurately determine the individual 
structures contained within these mixtures of A9R and LPS. It is however known that A9R and 
LPS have formed separately, as seen in cryo-TEM Figure 40. This in turn means that any SAXS 
scattering patterns from the mixtures would only be the average view of both structures.   
Figure 41: SAXS patterns for 0.1 wt% A9R, 0.1 wt% LPS and 0.1: 0.1 (1228:1 estimated 
molarity ratio), 0.2: 0.1 (2456:1 estimated molarity ratio), 0.1: 0.2 wt% (614:1 estimated 
molarity ratio) mixtures in H2O. All these samples were run on B21 at Diamond (Chapter 
2.2.2). Samples and mixtures with LPS showed a peak for 0.1 A-1 and very similar scattering 
patterns, A9R did not show this 0.1 A-1 peak but showed similar patterns to each other.    
This averaging effect seen in SAXS was confirmed by the spectra shown above in Figure 41. 
A 0.1 wt% sample of A9R showed a fibre type scattering pattern with little features within 
(black - Figure 41). This scattering pattern has been reported before, and was fitted to a long 
cylindrical shell model.513  The 0.1 wt% LPS sample did show a similar pattern to previous 
experiments, which can be attributed to that of a fibre-like self-assembly structure (Figure 37). 
The concept of an average scattering pattern can be clearly seen in the mixtures used (red, 
green, and dark blue). The SAXS pattern for 0.1 wt%: 0.1 wt% (1228:1 estimated molarity 
ratio) A9R: LPS showed a small structural feature at 0.1 A-1. This feature is attributed to that 
of the 0.1 wt% LPS sample, which showed a similar profile (Figure 37). This feature can also 
be seen in the 0.1 wt%: 0.2 wt% A9R: LPS sample (614:1 estimated molarity ratio), showing 
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and dark blue). The 0.1 A-1 LPS structural feature was lost in the 0.2 wt%: 0.1 wt% (2456:1 
estimated molarity ratio) A9R: LPS sample (dark blue). This shows a specific issue with SAXS 
where the average picture of the sample is taken and, even with a 2456:1 molarity ratio sample, 
the structures cannot be fully accessed, identified, or separated.   
If we compare these A9R: LPS SAXS patterns to the difference seen in the mixing of just 250:1 
(estimated molarity) of 17PYY3-36 and LPS it is very clear that the structure’s shape changed 
upon mixing (Figure 36), which was not seen with A9R and LPS (Figure 40). This was also 
confirmed by the cryo-TEM images of the 250:1 molarity mixture, with 17PYY3-36 and LPS, 
showing a clear aggregation effect (Figure 35) while A9R and LPS show clear separation of 
self-assembly (Figure 39).  
5.8 Circular Dichroism Study PYY3-36 and A9R with LPS 
As PYY3-36 and 17PYY3-36 both contain an α-helix segment, circular dichroism spectroscopy 
was used again to investigate the effect of potential LPS incorporation on this α-helical section. 
A9R does form a β-sheet structure at high weight percentages, (1 wt% - to higher), which could 
be investigated by CD spectroscopy.505 As the weight percentages under investigation were 
lower than this (0.5 wt%), the CD spectra for A9R incorporation with LPS showed minimal 
structure at low concentrations. For this reason, the A9R and LPS spectra will not be 
commented on as it did not add any valuable information to the investigation, asides from 
showing a loss in the minimal β-sheet structure seen. This is consistent with an averaging effect 





Figure 42: Comparison CD spectra of PYY3-36, 17PYY3-36 and mixtures with LPS. All samples 
prepared in D2O, at room temperature, and ratios are in wt%. Both convert to around 250:1 in 
molarity ratios. Data smoothed using FTT smooth fit by 5 points, and kept in mdeg as mixtures 
can not be converted to molar ellipticity.  
A study comparing PYY3-36 with LPS and 17PYY3-36 with LPS was completed to investigate 
the use of PYY3-36 as a good replacement molecule for the studies, as seen in Figure 42.  
A few observations can be gathered just from viewing this CD spectrum. Firstly, LPS shows 
little secondary structure that has been confirm in previous CD experiments (Figure 38). This 
means any changes in secondary structure can be attributed to that of either PYY3-36 or 17PYY3-
36.  
Secondly, to highlight the actual changes in secondary structure and compare the two mixtures 
and their separate components, the ellipticities at key wavelengths have been noted. These 
values are specific to the α-helical secondary structure of PYY3-36 and have been used to 
compare the loss of structure upon LPS addition, which can be seen in Table 8 and 9 below.  
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Table 8: Ellipticities values at 190, 210 and 222 nm wavelength for CD spectrums of 0.5 
wt% PYY3-36, 17PYY3-36, LPS and estimated 250:1 mixtures. All values are in mdeg, errors 
are the last number recorded (±0.01 mdeg).   
Table 9: Difference in ellipticities values at 190, 210 and 222 nm wavelength for CD spectrums 
of PYY3-36, 17PYY3-36, LPS and estimated 250:1 mixture. All values are in mdeg, errors are 




The wavelengths of 190, 210 and 222 nm have been chosen because both PYY3-36 and 17PYY3-
36 have α-helical structure, which will have reduced upon the addition of LPS and will not 
change to a different structure upon addition. This α-helical structure has three key data points, 
a large positive maximum at around 190 nm and then two minima at around 210 and 222 nm. 
These three points can be clearly seen in Figure 42. 
From Figure 42 and Table 9 above it can be seen that there is a much larger decrease in structure 
when LPS is added to that of 17PYY3-36 over PYY3-36. This observation indicates that the lipid 
of 17PYY3-36 is important to the potential binding or co-aggregation that was found within 
these samples.  
Finally, although PYY3-36 does not show to the fullest extent the reduction of the α-helix 
compared to 17PYY3-36, it still shows a reduction. This has then confirmed PYY3-36 as a 






Wavelength PYY3-36 17PYY3-36 LPS PYY3-36/LPS 17PYY3-36/LPS 
190 10.25 13.26 0.84 8.06 3.57 
210 -7.88 -7.22 -0.86 -4.37 -2.43 
222 -8.05 -7.59 -0.45 -5.13 -2.99 
Wavelength PYY3-36 to Mixture 17PYY3-36 to Mixture 
190 2.19 9.69 
210 -3.51 -4.79 





5.9 A280 and A200 Absorbance Studies of PYY3-36 and A9R with LPS  
PYY3-36 and 17PYY3-36 both contain tyrosine amino acid groups that, as shown in Figure 19 in 
Chapter 3.1, can be used, thanks to their absorbance at 280 nm, to work out the concentration 
of a sample (Chapter 2.2.4). The environment of the tyrosine, as with pyrene, can be used to 
identify if the tyrosine is in a hydrophobic or hydrophilic environment. If a protein denatures, 
for example upon the addition of a certain metal ion, this can be shown as a decrease of 
absorbance at the 280 nm wavelength with the concentration of the protein being kept constant, 
indicating that the hydrophobic pocket has been lost, reducing the intensity.  
Figure 43: UV absorbance experiment showing the A280 Nanodrop concentration results 
combined with the predicted results. The predicted results using results from the starting 
materials, PYY3-36 and LPS, to predict the combined absorbance, when mixed. All samples 
were in H2O, and ratios given in wt%. The ratios convert to 250:1, 500:1, 750:1, 125:1, and 
75:1 estimated molarity ratios, respectively. 
The first observation that can be seen from Figure 43 is the increase in the A280 absorbance, 
which is related to the mg/mL, when LPS is added to PYY3-36. To study this effect the PYY3-
36 average and the LPS absorbance were used to predict the mg/mL value of the other samples. 
The experimental values recorded can be seen to be either similar, or larger than their predicted 
values. This would suggest a shift in the tyrosine environment that only occurs from the 
interaction with LPS.  
LPS did show an absorbance value that given LPS’s lack of aromaticity, was not expected 
(Figure 43). Investigation into the extraction methods of LPS (from bacteria) used in this study 
showed that the samples had been extracted using the phenol method, contaminating the sample 





only by more expensive and time-consuming methods. The data showed that our sample, 
purchased through Sigma Aldrich, contained around a 1 mg/mL concentration of proteins 
and/or peptides (Chapter 2.1).  
When working out the actual difference between the predicted and measured values, there does 
not appear to be any consistent effect which happens with the addition of LPS (Figure 43). An 
increase in absorbance is what would have been hypothesised, as the tyrosine residues would 
be “shielded” further within a hydrophobic pocket. This effect would also be seen even if the 
tyrosine residues were to be “shielded” from the solution by the larger LPS molecules. In this 
case, this method has not shown a clear result, with some mixtures showing an increase while 
others shown little to none.  
This method works for absorbance studies for aromatic amino acids, such as tyrosine, 
phenylalanine, or tryptophan, but as A9R is also under investigation another method needs to 
be used to try and understand if there are any binding interactions. Another absorbance of 205 
nm was used to work out the concentration of peptides using the peptide backbone as an 
identifying aspect (Chapter 2.2.4). This wavelength is the specific absorbance value for the 
peptide bond so can be related to the concentration of the peptide in solution (Chapter 2.2.4). 
Therefore, given no other absorbance method an experiment with this wavelength, 205 nm, 
was completed to see if the absorbance value would change upon the addition of LPS. 
After completing the study and processing it in a similar way to that of the 280 nm study 
completed earlier, this 205 nm study did not show a consistent change in absorbance with 
increasing mixture ratios. This was to be expected as the peptide bond is not being changed, 












Figure 44: Showing the results for the A205 nm experiment on the Nanodrop. All samples are 
prepared with water, and ratios are in wt%. Blue being the predicted values calculated using 
the separate results from the singular samples (A9R, and LPS). Ratios convert to 1228:1, 618:1, 
309:1, 2456:1, and 3864:1 in estimated molarity, respectively.  
It can be seen in Figure 44 above that even though some of the complexes show an increased 
concentration; others show negative or minimal differences which make this technique similar 
in result to that of the 280 nm study. These inconclusive results suggest that another approach 
is needed to ascertain if complexation does occur, such as the LPS specific dye BODIPY TR.   
5.10 LPS Specific Dye Absorbance Study using PYY3-36 and A9R 
A dye called BODIPYTM TR Cadaverine was found to be a specific dye that complexes to the 
Lipid A segment of the LPS. This complex then allows for a highly sensitive and robust 
fluorescent displacement assay (Chapter 2.2.7). This dye allows for a substitution experiment 
to be completed where a small amount of PYY3-36 or A9R is added and if the absorbance of the 
sample increases this indicates a release of the BODIPYTM TR Cadaverine molecule, thus 
showing a complexation between these molecules and LPS. The methodology behind this 
experiment has been explained in larger detail in the Methodology Chapter 2.2.7, including 
concentrations, specific volumes and parameters used. The chemical structure of BODIPYTM 







































Figure 45: Chemical structure drawing of BODIPYTM TR cadaverine. 
An interesting observation seen during the preparation was a colour change between the 
prepared BODIPYTM TR Cadaverine solution and when mixed with LPS from a bright pink 
solution to one of a blue solution after addition. Images were taken to show this contrast and 
can be seen in the materials and methods section (Figure 45 and Section 2.2.7). 
BODIPYTM TR Cadaverine has an excitation wavelength of 580 nm and has a specific emission 
wavelength of 620 nm. For this study, the intensity of this wavelength was plotted against the 
addition of the excipient, PYY3-36 or A9R, with additions of 10 µL (20 μM). Both the PYY3-36 
and A9R sample have been made to the same concentration of 20 μM, with all samples (A9R, 
PYY and LPS + BODIPY) being made to the previous study’s concentrations.   
A clear increase in the intensity at 620 nm was seen (Figure 46) with the addition of the PYY3-36 
solution. After each 10 µL addition the intensity at 620 nm increased. This increase can be 
attributed to the substitution of the BODIPYTM TR Cadaverine from the LPS with PYY3-36 














Figure 46: Comparison of BODIPYTM TR cadaverine release with complexation of A9R and 
PYY3-36 to Lipopolysaccharide. Intensity values at 620 nm were recorded with the addition of 
10 µL (20 μM) of each solution. Both solutions were the same molarity. The intensity values 
were then fitted linearly to show a trend line and help show the gradient of increase. 
This adds evidence to the complexation of the 17PYY3-36 with LPS as even the unlipidated 
form, PYY3-36, complexes to LPS. The addition of the lipid chain would benefit the 
complexation as the dye used BODIPY TR is shown to specifically complex to the Lipid A 
section of LPS. The Lipid A section of LPS is highly hydrophobic and could help complexation 
or aggregation of a lipopeptide, such as 17PYY3-36, via the hydrophobic effect.  
Without a clear reference the PYY3-36 and LPS result seen cannot be stated to be useful as this 
could be the action of BODIPY TR and LPS regardless of the additional molecule. To test this 
an antimicrobial peptide A9R is also tested to see if it complexes in the same way as PYY3-36 
shown above in Figure 46. As mentioned previously all concentrations were kept the same to 
allow for comparison. If A9R does complexes to LPS, this could be helpful in determining its 
mode of action against bacteria, however this area is still under investigation.505 Complexation 
to LPS could be of importance as this result shows that LPS is critical in A9R’s anti-bacterial 
pathway. 
Between the two molecules there is a clear difference in the intensity at 620 nm for the two 
samples over the 10 µL additions. The graph (Figure 46) suggests that A9R does not, or does 
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in an extremely limited way, interact with LPS. This is clear as the slope of the A9R data is 
shallow and suggests little displacement of the BODIPYTM TR Cadaverine dye. PYY3-36 shows 
the opposite with a larger gradient and having large increases in intensity from one 10 µL 
addition.  
A control was not run for this experiment, if it had been the control would have been in the 
form of the addition of 10 µL of ultra-pure water to the LPS-BODIPY TR complex solution to 
observe any intensity changes. It can be assumed that if this LPS-BODIPY TR complex is 
stable, then the solution will become more dilute, thus reducing the intensity value over the 
additions (Eq. 8). Although this is the most logical outcome, without completing this control 
experiment, the above data should not be taken as clear evidence of complexation but could be 
used as evidence for further experiments. 
In conclusion, these LPS specific dye experiments have shown, to a limited effect that PYY3-
36 does interact with the Lipid A section of LPS, while A9R, a known anti-bacterial, does not 
interact. This means A9R’s interaction with bacteria could be by other methods, and that 
17PYY3-36’s interaction, as seen earlier, is related to the Lipid A section. Fundamentally, these 
observations are of extreme interest and potential value in developing alternative forms of drug 
delivery, however further tests are needed, including a control experiment and the carrying out 
of a comparison with other molecules of interest.  
5.11 Zeta Potentials of A9R or PYY3-36 and LPS Complexes 
A further study to try and understand the complexation of A9R and PYY3-36 with LPS is to 
measure the zeta potential of the complexed samples compared to their separate molecules. As 
with many of these experiments the full methodology can be found within the Methodology 
Chapter 2.2.5. Zeta potential is, simplistically, the measurement of the charge of the molecules 
within the sample. This method can be used for many reasons from self-assembly, charged 
species, coordination chemistry and neutralisation experiments.90, 514-521 In this case it is being 
used to understand the charges that are part of the self-assembled structures of A9R, PYY3-36 
and LPS.  
In Table 10, both PYY3-36 and A9R showed a large positive value that is consistent with a stable 
self-assembled structure, both being above positive 20. Values of above a positive or negative 
5 have been shown to represent stable, large, structures in solution.522-523 LPS shows a negative 





zeta potentials findings are set out below, also with the comparing of theoretical and measured 
findings of zeta potentials. The three main observations seen from Table 10 is;  
1. The addition of LPS to PYY3-36 markedly changed the charge of the sample even after 
1:1 (250:1 PYY3-36: LPS estimated molarity) addition (from 25.5 to -0.6848), which is 
still seen for A9R (25.5 to 12.3) but not as severe.  
2. The 2:1 (and 3:1 ratio of PYY3-36 showed a continued near zero value but the ratios of 
the A9R showed higher values, indicating similar charged species to the 1:1 ratio. This 
effect can also be seen in the mobility results.  
3. The final effect seen is that the mixtures of PYY3-36 and LPS, after the 1:1 ratio, are 
more negative that suggests these structures are slightly more stable compared to the 
similar A9R: LPS ratios. These results do not add much information to the reason for 
complexation. They do suggest that PYY3-36 and LPS do complex, furthermore the 
structures are reasonably stable. The differences in the 2:1 (500:1 molarity) and 3:1 
(750:1) ratio between the two molecules is of further interest and an area that could be 
investigated further.  
Table 10: Zeta potential, Mobility, and Conductivity results for PYY3-36, A9R and estimated 
ratio of mixtures with LPS. Errors being last value, ±0.001. Theoretical zetapotential values 
calculated from the separate samples (PYY, A9R, and LPS).    
ZP = Zeta potential, Mob = Mobility, Cond = Conductivity and TheoZeta = Theoretical Zeta 
value given separate sample values. 






PYY3-36: LPS 250:1 -0.648 -0.051 0.217 19.907 
PYY3-36: LPS 125:1 -4.053 -0.317 0.198 14.680 
PYY3-36: LPS 83:1 -3.807 -0.298 0.230 9.453 
PYY3-36: LPS 65:1 -2.673 -0.210 0.293 4.227 
PYY3-36: LPS 500:1 0.172 0.013 0.192 45.040 
PYY3-36: LPS 750:1 -0.344 -0.344 0.213 70.173 
A9R: LPS 1228:1 12.367 0.969 0.242 17.340 
A9R: LPS 614:1 -0.349 -0.027 0.206 12.113 
A9R: LPS 409:1 -0.905 -0.071 0.271 6.887 
A9R: LPS 307:1 -0.675 -0.053 0.271 1.660 
A9R: LPS 2456:1 13.000 1.020 0.439 39.907 
A9R: LPS 3684:1 14.667 1.150 0.609 62.473 
PYY3-36 25.133 1.971 0.119 
 
A9R 22.567 1.769 0.212 
 






5.12 Conclusion of LPS interaction with comparison of 17PYY3-36 and A9R 
All these studies have investigated an unusual observation of precipitation and large 
“aggregation” between 17PYY3-36 fibres and the short LPS structures. Cryo-TEM confirmed 
the presence of these aggregates. Further studies used A9R for comparison and PYY3-36 for 
similarity.  
Using SAXS and CD it was shown that a mixture of 17PYY3-36 and LPS reduced the α-helical 
structure of the peptide. SAXS analysis of the same mixture showed a shift of form factor from 
fibre to bilayer gaussian. This shift shows a significant change in self-assembled structure, but 
to confirm this, further studies are needed.  
Cryo-TEM of A9R and LPS, in comparison, showed two separate self-assembled structures 
being formed. This was seen again through SAXS, but as the technique is an average of values, 
it only showed an average of the scattering patterns.  
A study of the fluorescent amino acids within PYY3-36, using the 280 nm wavelength, did not 
show any trends, as the residues are not affected by the co-self-assembly. This was also the 
case with A9R and LPS as the 205 nm wavelength did not show any change, or trend, from the 
mixtures.  
The specific study using BODIPYTM TR Cadaverine, which is a specific dye that complexes to 
the Lipid A section of LPS, was undertaken. This dye showed a large increase in intensity with 
the addition of PYY3-36, which is an indicator of BODIPY release, and PYY3-36 complexation 
to LPS. A9R on the other hand, showed a reduced gradient, but nowhere near as marked as 
PYY3-36. Upon further reflection, carrying out a control experiment, and expanding the 
molecules investigated, would help to provide further confirmation of the above BODIPY TR 
dye hypothesis.  
The final study with Zeta-potential showed a few notable observations with A9R or PYY3-36 
and LPS with the most noticeable being the difference in charge that can be seen between the 
two mixtures of PYY: LPS and A9R: LPS at 1:1 wt% ratios. Further studies and controls using 
well characterised short peptide chains would be needed to add to these experiments and further 
probe this complexation. A9Rs analogues, such as RA9R, or AR9, or modified A9R with 
different amino acids such as Glutamic Acid (E), or Phenylalamine (F), would be suggested to 





antibiotic Fusaricidin, would also be of interest to explore whether the cyclic nature of the 






6. Synthesis and Inclusion Potential for Polysaccharides with PYY3-36 
using β-cyclodextrin. 
6.1 Introduction to Synthesis and Inclusion of PYY3-36 with β-cyclodextrin.  
In previous chapters lipidation has been the key factor in either causing different forms of self-
assembly and changes in secondary structure (Chapter 3 and 4).  Lipidation has been used by 
many other research groups for this reason, with the aim of making useful 3D networked 
structures for use in different fields of science.108, 191, 472 Polysaccharides, which are multiple 
sugar units bonded together (as seen in Figure 47), are also a potentially useful molecule for 
gel formation and self-assembly as they contain multiple hydroxyl groups that can facilitate 
hydrogen bonding. This characteristic creates the potential for the addition of a polysaccharide 
chain to PYY3-36 to create a novel conjugate. The addition of polysaccharides would be 
beneficial as they are bio-recognised, easily broken down within the body and the potential 
resultant hydrogen bonding that occurs could readily form a gel.  
 
Figure 47: Example saccharide unit, n denoting chain possibility. n=1 is glucose, n=2 
disaccharide, n>3 oligosaccharides, n>5 polysaccharides. 
Within the literature many conjugates have been formed between PYY or PYY3-36 and other 
species, these include the conjugation with Vitamin B-12 and Albumin with both conjugates 
(Vitamin B-12 and Albumin) influencing food intake.342, 426, 524-525 The conjugation of a 7 
membered polysaccharide to PYY3-36 has not been found within the literature, so this synthesis 
experiment would be of interest from a drug formulation perspective, as well as providing the 
potential for further drug conjugates to be explored.  
For this novel conjugate synthesis, a readily found sugar β-cyclodextrin was used as the starting 
point. This sugar is formed of a 7 membered ring of glucose units (Figure 47). The 
polysaccharide ring formation has characteristics worth exploring when included with PYY3-





with a primary and secondary hydroxyl group. Previous studies have used the internal cavity 
to produce self-assembled structures with surfactants, such as SDS.32, 451, 518, 526-530 Further 
studies have shown the incorporation of small drug molecules within the β-cyclodextrin 
structure that showed delayed release profiles.518, 531-541 
The experimental methodology used was found within a previous paper that detailed the use 
of thiol-ene click chemistry.542 This paper proposed the use of β-cyclodextrin as the starting 
material, breaking it with acid to form the 7 membered oligosaccharide, named Maltoheptaose, 
which could then, with simple chemical modifications, be functionalised with an alkene group.  
 
Figure 48: First reaction: Simplistic ring opening using HCl. Found in paper reference542 
Second reaction step: oxidation of anomeric hydroxyl. Third reaction stage: Adding the alkene 
functionality to the polysaccharide. Final reaction step: thio-ene click reaction. R1 and R2 being 
additional functionality. 
This alkene functional group would then be used in the thiol-ene click reaction with a sulphur 
containing group, in this case, a cysteine function group can be incorporated into the peptide 
chain during synthesis. A simplified thiol-ene click reaction can be seen in Figure 48. The thiol-





selective and highly useful reaction for gel formation, lipid addition and further 
functionality.111, 543-545  
 
In addition to creating this synthetic target it would be useful to investigate the mixing effects 
of β-cyclodextrin with native PYY3-36 as this could be provide insight into the complexation 
possibilities. The possibility stems from the hydrophobic pocket found within the β-
cyclodextrin that could interact with the peptide or part of the chain.  
 
Figure 49: Mesh diagram of β-cyclodextrin showing pocket formed by the 7 membered ring. 
6.2 Polysaccharide Conjugate Synthesis   
Using the cheaper starting product, β-cyclodextrin, and breaking it with the use of HCl, proved 
to be more difficult than first suggested in the paper.542 The issue stemmed from the problem 
of selectively controlling the acid hydrolysis. It was suggested through the paper that a solution 
of 0.1M HCl was used to break down the cyclic polysaccharide.542 Multiple experiments were 
completed under different reaction conditions yet the breaking down of the cyclic 
polysaccharide was difficult to achieve and, as such, the synthetic pathway purposed in the 
introduction above could only produce Maltoheptaose in quantities too small for experimental 
and measurement purposes. 
To attempt to break β-cyclodextrin, experiments were completed at higher temperatures, under 
more concentrated acid conditions and by changing the acids used. Under milder acidic 
conditions (such as 0.1M HCl) a mixture of compounds was found by thin layer 
chromatography (TLC). These compounds were determined to be the 7 different possible 
products from an acid hydrolysis (1 to 7 polysaccharide). As there is no way to properly control 
the selectivity of the ring opening and hydrolysis, the method produced all 7 different 
polysaccharides. Further difficulties were found in the amount of Maltoheptaose that was 
produced, as the acid hydrolysis produced a higher percentage of glucose (1) compared to very 





even starting with a large amount of the β-cyclodextrin, only a very small amount of the specific 
7 membered ring opened product was available. The 7 different polysaccharide products 
identified were found when completing a timed TLC experiment. Attempts at separating these 
7 products by column chromatography failed to separate these compounds as they are 
extremely similar in polarity.  
To continue the project a small amount of the 7 membered polysaccharide, Maltoheptaose, was 
purchased and the oxidation was then attempted (Chapter 2.1). Further complications were 
found with this step as the method suggesting the use of bromine and calcium carbonate (Figure 
48) showed limited success. An attempt to use NMR to identify a single hydrogen loss in the 
oxidation reaction product was carried out however, with such a large molecule and such a 
small change, NMR was unable to differentiate between the two molecules. Another issue was 
found to relate to the impurities introduced during its manufacturing process. The purchased 
Maltoheptaose was rated at 60% purity which negatively impacted the oxidation reaction 
outcome and made any subsequent NMR analysis more difficult to achieve than originally 
hypothesised. Due to the complexities that were experienced and the danger that the project 
would encounter a significant overrun (by at least 4 months), it was decided that the synthesis 
section of this work should be halted and that the complexation studies using the hydrophobic 
pocket were focused on instead. Synthesis of these novel polysaccharide conjugates to PYY3-
36 remains of high interest particularly to drug formation and self-assembly science fields as β-
cyclodextrin is a cheap material that could help facilitate PYY3-36 drug delivery or improve 
PYY3-36 circulation times.  It is suggested therefore that the level of work required would make 
it a suitable for a project with a longer timeframe in the future.  
6.3 Circular Dichroism for Complexation of PYY3-36 and β-cyclodextrin 
Before continuing with CD, and following the same molarity estimations from before, using β-
cyclodextrin’s mr of 814 gmol-1, for the following experiments PYY3-36 is 2.469 mmol, while 
β-cyclodextrin is 8.811 mmol. This means there is a ratio of around 1:3.6 of β-cyclodextrin to 
PYY3-36. With this difference in the molarities, this means that β-cyclodextrin is in a slightly 
higher concentration, and thus could have a greater impact on the co-assembly process. Again 
however, it is worth remembering that as self-assembly and aggregation does not necessarily 






PYY3-36, as shown in all the other chapters contains a segment of α-helical structure (Chapters 
3.1, 3.4, 5.4, and 5.8). This was shown in the circular dichroism results with further studies 
showing the disruption of this secondary structure by lipidation (Chapter 3.4). To test the 
possibility for complexation CD was completed on β-cyclodextrin with PYY3-36. Application 
of this method would show if the β-cyclodextrin interacts with the secondary structure of the 
peptide. 
The study that was carried out, Figure 50, showed no specific interaction between PYY3-36 and 
β-cyclodextrin. β-cyclodextrin showed no secondary structure or ellipticity which is as 
expected as the molecule itself does not self-assemble (no secondary structure) or have any 
specific chirality (R/S). Both the 1 wt% PYY3-36 and the 1:1 mixture (1:3.6 molarity) showed 
similar ellipticity values, clearly showing the α-helical structure of the native peptide is still 
present and at the same intensity in the mixture. This experiment does not fully show that there 
is no interaction as the β-cyclodextrin could still interact with the hydrophilic or hydrogen 
bonding amino acids on the outer edges of the peptide, or even the self-assembled twisted fibres 
PYY3-36 forms. Further studies are needed to confirm or remove this possibility.  
 
Figure 50: Circular Dichroism comparison of PYY3-36, β-cyclodextrin and a 1:1 wt% mixture 
(1:3.6 molarity). Data has been smoothed by Fast Fourier Transform (5 points). All samples 
were prepared in H2O. PYY3-36 and mixture showing the same α-helical content, showing a 
lack of interaction with the α-helix of PYY3-36. 
































6.4 Small Angle X-ray Scattering Study of PYY3-36 with β-cyclodextrin  
A technique that could provide information on the aggregation at the outer edges of the peptide 
is small angle X-ray scattering. As the aggregation occurs the diameter and/or the structure will 
change which, in turn, could give rise to a different SAXS pattern. In this experiment, reduced 
concentrations were used to preserve the amount of sample used and to reduce the possibility 
of affecting the thin capillary used in the high-throughput SAXS experiments (see Chapter 
2.2.2). Other ratios of 1:2 wt% (1:7.2 molarity) and 2:1 wt% (1:1.8 molarity) were used in 
addition to the similar ratio of 1:1 wt% PYY3-36: β-cyclodextrin (1:3.6 molarity) to probe the 
effect of higher concentrations of PYY3-36 or β-cyclodextrin on potential aggregation. 
The results of this experiment can be seen in Figure 51. The first observation to make is that 
diluted samples have made the scattering patterns become more defused, making fitting and 
experimental observations difficult to make. 0.1 wt% PYY3-36 can be seen to have little 
structure as evidenced by the different slope from 0.005 to 0.02A-1 and compared to that of the 
0.2 wt% PYY3-36 pattern (Figure 51, see black vs. dark blue spread). This slope is similar to a 
1 wt% sample of PYY3-36 (see Chapter 3.3) indicating a bilayer formation. This bilayer 
formation has been shown to be a twisted sheet structure in previous chapters using Cryo-TEM 
(Chapter 3.2).  
Figure 51: SAXS patterns comparing PYY3-36, β-cyclodextrin, and 1:1 wt% (1:3.6 molarity), 
1:2 wt% (1:7.2 molarity), and 2:1 wt% (1:1.8 molarity) ratios. All samples were made in water. 
These scattering curves are relatively the same, with PYY3-36 showing the same patterns seen 





The β-cyclodextrin pattern can be seen to have a monomeric pattern as suggested by the 
increased randomness and the shape of the curve of the data (see Figure 51). This result is not 
unexpected as the hydroxyl covered polysaccharide would only be hydrophilic and, as such, 
would not self-assemble. The two other main observations are that 0.1 wt% PYY3-36: 0.1 wt% 
β-cyclodextrin (1:3.6 molarity) and 0.1 wt% PYY3-36: 0.2 wt% β-cyclodextrin (1:7.2 molarity) 
have very similar scattering patterns. Secondly, the increased intensity of the 0.2 wt% PYY3-
36: 0.1 wt% β-cyclodextrin (1:1.8 molarity) sample was compared to the other ratios that 
showed that they generated a similar scattering pattern. This increased intensity for the 0.2 wt% 
PYY3-36 sample is not surprising as it suggests the formation of more twisted sheets as seen in 
the Cryo-TEM in the previous Chapter 3.2. Overall, SAXS does show some change in structure 
from monomeric or gaussian coil type due the presence of similar scattering patterns, however, 
as the samples were dilute, not many conclusions can be drawn from this study. Consequently, 
SAXS experiments with higher concentrations are needed to investigate the interactions 
between these two molecules. 
6.5 Cryo-TEM Visualisation of PYY3-36 with β-cyclodextrin 
Small Angle X-ray Scattering did not provide any insight into what was occurring between the 
twisted fibres of PYY3-36 and that of the monomeric β-cyclodextrin. Another method that has 
been used throughout the previous chapters is Cryo-TEM (Chapters 3.2, 4.4, and 5.2). This 
method could be used to visualise any changes to the conformations of the twisted sheets or 
could show the formation of new self-assembled structures that keep the α-helical structure 
seen in circular dichroism. A similar twisted sheet structure of PYY3-36 can be seen again in 
Cryo-TEM (Figure 52). This was expected as these samples were imaged using a higher 
concentration of PYY3-36 (1 wt%) that was used to increase the possibility of seeing any 





Figure 52: Cryo-TEM images showing the β-cyclodextrin aggregation around that of the α-
helical twisted sheets of PYY3-36. A – A comparison image of 1 wt% PYY3-36 in H2O, showing 
the twisted sheets as seen before in Chapter 3. The scale is 100 nm to allow the twisted sheets 
to be better visualised. B – A second comparison cryo-TEM image of β-cyclodextrin in H2O, 
to show that β-cyclodextrin does not form any structures. This was completed at 0.2 µm scale, 
to help visualise any large structure formation, but there was none. C, D – Two images showing 
the aggregation of β-cyclodextrin around that of the clear twisted sheets of PYY3-36 in a 1:1 
mixture of 1 wt% PYY3-36 and 1 wt% β-cyclodextrin (1:3.6 molarity), in H2O. Two images are 
shown to show the nonuniformity of the aggregation, at the same scale. 
Using circular dichroism, β-cyclodextrin has previously been shown to have no chirality or 
secondary structure that means that no self-assembled structures were expected to be seen in 
the cryo-TEM investigations (Chapter 6.3 Figure 50).  
Only one mixture of 1 wt% PYY3-36 and 1 wt% β-cyclodextrin (1:3.6 molarity) mixture was 
imaged as this was the key mixture of interest and allowed a comparison of it to the results 
from the Circular Dichroism and SAXS analysis. Taking this approach would therefore give a 





showed large, clouded sections surrounding the self-assembled structure of the twisted tapes 
of PYY3-36, which can be seen in Figure 52. 
The contrast seen in Cryo-TEM (Figure 52) shows the aggregation between the PYY3-36 fibres 
and β-cyclodextrin. The areas of high contrast, in this particular case, are very specific and 
seem to be highly aggregated around the fibres. The fibres still show the same structure as seen 
in the previous pictures and as also seen in the previous Chapters 3.2 and 5.2. This observed 
structure includes twisted as well as the elongated structures with lengths over 1000 nm. 
Aggregation with β-cyclodextrin has not disrupted this structure, as seen from Figure 52 and 
CD, which lends evidence to an interaction between the edges of the fibres and the cyclodextrin 
ring. 
This observation needs other studies to add further evidence to fully conclude that the 
interaction between β-cyclodextrin and PYY3-36 is limited due to the charged or hydrophilic 
amino acid residues on the outside of the fibres.  
6.6 A280 nm Study of β-cyclodextrin aggregation with PYY3-36 
A similar study to the one completed in the previous chapter is to study the aromatic groups on 
the arginine amino acids found within the PYY3-36 peptide. Although this does not cover the 
charged groups interactions it could lend evidence to an aromatic interaction.  
Figure 53: Absorbance values for mixtures of PYY3-36 and β-cyclodextrin. All samples were 
made up in H2O and ratio is in wt%, translated to 1:3.6, 1:7.2: 1:10.8, and 1:14.4 molarity 
respectively. Each absorbance value is an average of 3 separate readings. PYY3-36 and β-
cyclodextrin have also been included to allow for comparison. 
The results from this experiment also confirm the circular dichroism results (Figure 49) of no 





confirms that there is also no conformational change of the peptide with the addition of β-
cyclodextrin as the hydrophobic environment has not changed. Even with increasing the ratio, 
1:1 (1:3.6 molarity) to 1:4 (1:14.4 molarity), there was no change in the absorbance value. 
Further to that, all the solutions containing 1 wt% PYY3-36 showed similar absorbance values 
and β-cyclodextrin showed no absorbance, which was expected as it has no aromatic groups 
(Figure 49). 
Overall, this experiment added evidence to the CD data previously gathered (Figure 50) and 
showed there was no conformational change and no interaction between the CD and the peptide 
chain. This means that the high density, seen selectively around the PYY3-36 fibres (Figure 52), 
is occurring by a hydrophilic charged interaction. It also seems to show that this is more of an 
aggregation to the charged moieties rather than a co-assembly.  
Aggregation has been used before to describe self-assembly or a grouping of monomers, but in 
this study, it refers to a loose proximity, formed by weaker interactions, rather than co-
assembly.  
6.7 Zeta Potentials of PYY3-36 and β-cyclodextrin Ratios.  
To add evidence to the theory of charged aggregation, solutions of different ratios were 
prepared similar to the A280 nm experiment above and were then analysed by a Zetasizer to 
measure the charges of molecules within the solution. As mentioned previously, a charge of 
more than plus or minus 5 indicates a molecule that has a stable structure. Anything between 
these values is deemed to be either unstable or unformed.  
The study was carried out to compare the differences in the aromatic and charged species. It 
should be noted, as stated before in Chapter 2.2.5, zeta potential is a measure of the 
electrokinetic potential of the particles, if present, within the sample. More information on this 
can be found within Chapter 2.2.5. In this study the zeta potential is used to measure the charge 
of the twisted sheets seen in Cryo-TEM. This study, it is hoped, will show a loss of charge as 
the sheets become shielded by β-cyclodextrin. 
As seen in Table 14 the results showed a reduction in zeta potential from the native solution of 
PYY3-36 to a mixture of 1:1 (1:3.6 molarity) with β-cyclodextrin. This reduction is around 5 
mV, but the solution still has a zeta potential of 20 mV that indicates that it is still a stable 





Table 11: Zeta potentials for Various Ratios of PYY3-36 and β-cyclodextrin. All solutions 
were made up in H2O, measured using the same sample cell, and are in wt%. Error values for 
each measurement are ±0.1%. 







PYY3-36: β-cyclodextrin 1:1 (1:3.6 molarity) 20.6000 1.6147 0.0685 
PYY3-36: β-cyclodextrin 1:2 (1:7.2 molarity) 0.2504 0.0196 0.0272 
PYY3-36: β-cyclodextrin 1:3 (1:10.8 molarity) -0.0050 -0.0004 0.0083 
PYY3-36: β-cyclodextrin 1:4 (1:14.4 molarity) -0.0662 -0.0052 0.0046 
PYY3-36 25.1333 1.9707 0.1187 
β-cyclodextrin 0.2253 0.0177 0.0070 
 
When the ratio was increased from 1:1 (1:3.6 molarity) to 1:2 (1:7.2 molarity) and beyond, 
there was a total loss of charge observed that lends evidence to a loss of stability. These ratios 
have not been studied using Cryo-TEM due to time limitations on the thesis, so the stability of 
these structures cannot be determined for certain.  
A small reduction was seen in the mobility and conductivity values at 1:1 addition of β-
cyclodextrin, however, at molarity ratios 1:10.8 and 1:14.4 there was a greater reduction in 
these values. These reductions suggest a loss of stability, as identified by other authors’ Zeta-
Potential experiments,546-548 however the structures seen in cryo-TEM (Figure 52) suggest there 
could be a shielding effect being caused by the β-cyclodextrin surrounding the PYY3-36 fibres.  
Figure 54: Zeta-potential diagram explaining the possible shielding effects of β-cyclodextrin 
on the charged twisted sheet structure of PYY3-36. 
The potential shielding effect has been noted in other zeta potential studies, specifically with 
the use of metal ions.517, 549-551 A simplistic view of the suggested aggregation can be seen in 
Figure 53 with the charge of the fibre dropping significantly as β-cyclodextrin aggregates 





of 1:3.2, it is suggested that further ratios need to be researched to evidence these stable self-
assembled structures and not the destabilised monomers that zeta potential suggests.   
6.8 Conclusions of PYY3-36 with β-cyclodextrin 
This chapter set out to analyse two aspects of the synthesis and inclusion potential for 
polysaccharides with PYY3-36 using β-cyclodextrin. However, only the potential of β-
cyclodextrin and PYY3-36 co-assembly was fully investigated as the proposed synthesis route 
of β-cyclodextrin proved problematic, with the work required being beyond the timeframes of 
this thesis.  The largest and most problematic issue was found to be the acid hydrolysis of the 
β-cyclodextrin that produced unusably small quantities of the required product.  
After this synthesis obstacle was encountered a different experiment was proposed, namely an 
aggregation experiment with β-cyclodextrin and PYY3-36. This experiment was considered of 
interest as other molecules such as SDS, azomethine, and pipemidic acid (HPPA), having 
shown complexation with PYY3-36 could be of use in the field of drug delivery for PYY3-36.
518, 
552-553 
To investigate the potential of the aggregation the secondary structure was probed by using 
circular dichroism techniques. The CD showed that a 1:1 ratio of PYY3-36 and β-cyclodextrin 
complex caused no secondary structural change.  
Small Angle X-Ray Scattering showed structural differences between the 1:1 wt% ratio (1:3.6 
molarity) of PYY3-36 and β-cyclodextrin when compared to that of the separated molecules. 
This effect was seen with the higher ratios as well. In previous chapters, the structure of PYY3-
36 has been shown, through a range of techniques, to be twisted sheets (Chapter 3.3). The 
scattering pattern of the 1:3.2 molarity ratio was found to be of a different type that potentially 
indicates the formation of a different self-assembled structure.  
To confirm if different structures were formed, cryo-TEM was used. This showed the presence 
of the original twisted sheets of PYY3-36 in the 1:3.2 molarity β-cyclodextrin mixture. A high 
density of β-cyclodextrin was also seen specifically around these twisted sheets. This 
observation adds weight to the aggregation theory which suggests the aggregation is driven 
through the charged nature of the twisted sheets. 
This observed effect of aggregation was further investigated by A280 nm and zeta potential 





the PYY3-36 peptide chain. Zeta potential analysis on the other hand, which measures the 
charged double layer of any charged species, showed a significant charge decrease from native 
PYY3-36 to that of the 1:1 wt% (1:3.6 molarity) ratio. Combining the results from these methods 
showed a charged aggregation effect but one that was limited to the outer edge of the PYY3-36 
fibres and one that did not affect the aromatic residues found within the PYY3-36 native structure 
itself. Further experiments using fluorescence would help probe the co-aggregation effect on 
the aromatic amino acids in more detail.  
These experiments show an aggregation between the peptide hormone PYY3-36 and the cyclic 
sugar, β-cyclodextrin. The observed aggregation is of a “weak” double layer effect that is 
formed by the charged residues on the outer edges of the self-assembled fibre of PYY3-36. The 
hydrophobic “pocket” found within β-cyclodextrin was shown to have no interaction with the 
peptide chain itself or, for that matter, with the hydrophobic aromatic residues on the peptide 
chain. Post experimentally, it was noted that, as the samples were not pH tested, the addition 
of β-cyclodextrin could have changed the pH which may in turn have affected the result 
findings.  
These observations will have added new information for future β-cyclodextrin and PYY3-36 
inclusion experiments and related drug formulation research. As larger peptides, such as PYY3-
36, have little inclusion research based on them, further research into the different ratios would 
be of interest as well as potentially looking into to the denaturing of the peptide chain (removing 
the secondary structure) to enable a “threading” type assembly to occur.101, 554-557 Other variants 
of PYY3-36 such as the lipopeptides studied in earlier Chapters, 3 and 4, could also be of interest 
to study in this regard. Further controls using cyclodextrin complexing molecules would be of 
interest to help delve deeper into what is occurring in the aggregation of β-cyclodextrin and 
PYY3-36. Small drug molecules (such as meropenem, or camptothecin), or larger surfactants 
such as SDS or dodecyltrimethylammonium bromide (DTAB) would be suggested for this 






7. Conclusions and Future Work 
7.1 Thesis Conclusions 
The conclusions of the experimental work contained within the four previous chapters will be 
summarised in this section. 
The characterisation of the novel lipidated PYY molecule (17PYY3-36) was completed and 
further investigations were carried out into its potential to form a gel. 17PYY3-36 showed a 
reduction in its α-helical structure compared to that of the native peptide (Chapter 3.4). 
Although experimentation showed a reduction in α-helical content, the lipopeptide itself 
showed a more stable response to pH and temperature changes (Chapter 3.4) than the native 
peptide, except at its pI when it precipitates out of solution. The pH values investigated were 
chosen to align with those found within the human body, from pH 2 in the stomach to pH 7.4 
in the large intestine.344 The observations demonstrated that if 17PYY3-36 were given as a drug 
it would undergo less secondary structure changes, if kept away from its pI, which would 
potentially give it valuable increased stability. 
Further experiments showed that the addition of the lipid causes a different self-assembly 
process, namely from twisted sheets to thin fibre structures (Chapter 3). The concentration at 
which 17PYY3-36 molecule assembled was investigated, with greater acidic pH values (pH 2) 
leading to an increased critical aggregation concentration (Chapter 3.5). This observation 
showed that the charges of the surrounding solution affects the assembly process, giving weight 
to the hypothesis that the pH within the body will affect the assembly process as well. 
Investigation into the secondary structure of the fibres showed them to be α-helical in nature at 
lower temperatures (Chapter 3.4). This changed at 45 °C with the internal structure changing 
to a β-sheet structure (Chapter 3.4, Fig. 27 B). Although this temperature is slightly above the 
normal temperature for the human body, 37 °C, it does add information to the need for any 
17PYY3-36 related drug to be stored and transported under careful conditions. The α-helical 
structure of the native peptide has been shown to be important for Y receptor recognition, so 
any change in the secondary structure could limit, if not inhibit, the drug’s potency.271, 273, 333  
Studies into the gels formed from these lipopeptides; 11, 17 and 23PYY3-36, showed that the 





Table 5). Further studies showed the gels were formed because of the lipidation, as native 
PYY3-36 did not form gels at the same pH values for lipidated versions. 
The average gel concentration was found to be 1.7 wt% with circular dichroism spectroscopy 
showing them to have a secondary structure of β-sheet (Chapter 4.5). This was similar in 
structure to that seen in the previous studies of the lipopeptides above 45 °C. The α-helical 
structure to β-sheet structural change was also shown to be extremely important for the 
formation of the gel (Chapter 4.6). Further studies, using TEM, allowed the visualisation of the 
entangled network of fibres which formed up the gel material (Chapter 4.4). These gels showed 
a loss of structure when heated after being formed, and this loss was also shown to be 
irreversible after cooling (Chapter 4.4, Fig. 35). So, again, this lends further importance to the 
need to control temperature when manufacturing or handling these gels. 
This study has shown the potential for lipidation to create a gel from a peptide hormone, which 
could be extremely important from a drug delivery perspective. This process could allow for 
the reduction in additives and reduce research into formulation, ending up with simpler and 
safer delivery systems. 
Other studies in this thesis investigated the lipidated 17PYY3-36 and its interactions with another 
short self-assembled bio-important molecule, LPS. Another anti-bacterial short peptide A9R 
was used as a comparison peptide. Visual and cryo-TEM experiments showed the presence of 
aggregations, between 17PYY3-36 and LPS, which consequently prompted further investigation 
(Chapter 5.2). A9R showed separate formation of structures with little cross-assembly (Chapter 
5.6). Within this study it was shown that these LPS-17PYY3-36 aggregates had a reduced α-
helical secondary structure compared to that of the native peptide (Chapter 5.4, Fig. 39). This 
change in structure was also confirmed by SAXS analysis, with a shift from fibre to bilayer 
formation being seen (Chapter 5.3, Fig. 38). 
Due to organisation budgetary constraints only 120 mg of each lipopeptide were made available 
for this study. To overcome this problem and ensure that progress could be made experiments 
were completed with the cheaper non-lipidated native peptide PYY3-36. Studies using zeta 
potentials, LPS specific dyes and fluorescence showed that PYY3-36 interacted heavily with 
LPS, whereas A9R did not (Chapter 5.11). This work did provide an insight into the importance 
and need to continue investigating how a peptide hormone like PYY3-36 interacts with a 





A different drug delivery method for PYY3-36 was also suggested within this thesis, namely 
that of using the molecule β-cyclodextrin. β-cyclodextrin has been extensively studied for its 
ability to encapsulate smaller drug molecules and has also been shown to have the ability in 
complexation to form potentially useful self-assembled structures. 558-565 
Various ratios of PYY3-36 and β-cyclodextrin, were investigated using a variety of 
spectroscopic techniques. Many of these experiments showed little to no co-self-assembly 
(Chapter 6). The most notable observation was that during SAXS analysis the complex showed 
a change in structure for the 1:1 wt% ratio (1:3.6 molarity ratio) complex as well as for higher 
ratios of β-cyclodextrin (Chapter 6.4). This effect was then further investigated and was shown 
to be an aggregation of the β-cyclodextrin molecules to the highly charged outer edge of the 
PYY3-36 twisted tape like structure (Chapter 6.5, Fig. 53). 
Further investigations, which used the aromatic residues of the peptide chain as indicators, 
showed no change in their environments when PYY3-36 was mixed with β-cyclodextrin 
(Chapter 6.6). Measuring the overall charge of the molecules in solutions also produced similar 
results (Chapter 6.7). Both experiments lend even further evidence to there being no co-
assembly of PYY3-36 and β-cyclodextrin, but that there is solely aggregation between the 
charged aspects of both molecules. 
In summary, 17PYY3-36 was characterised in conditions close to biological pH values (2-8)
344 
and within a wide range of temperatures (20-70 °C). The potential for the lipopeptides to form 
gels was investigated. Gels of 11, 17 and 23PYY3-36 were then characterised, with their fibre 
parameters defined. Further studies investigating the interactions of 17PYY3-36, or native 
PYY3-36 with LPS and β-cyclodextrin were completed. These studies have shown aggregation 
of LPS and β-cyclodextrin by observing the charge effects between the structures. Many of 
these results advance the study of large lipopeptides, from the characterisation of a novel 
bioactive peptide (17PYY3-36) to co-assembly studies with different excipients (LPS and β-
cyclodextrin).  
7.2 Future Work 
High cost of the lipidated peptides (11, 17 and 23PYY3-36) meant that further syntheses of these 
lipopeptides limited the scope of these studies. With additional supplies of these lipopeptides, 
bacterial cell tests and biological receptor experiments would prove to be the most impactful 





peptides. The other aspect of this biological based research would give further insights into the 
effect of self-assembly on the efficacy of a self-assembling drug molecule. 
Further experiments into the effect of different solutions on the self-assembly of these 
lipopeptides would also determine if changing the solution medium (hydrophilic to 
hydrophobic) affects the secondary structure or overall macro-structures formed. Some drug 
formulations can rely on excipients, for example through the addition of ions or small 
molecules, and as such, further studies that investigate these excipients and their impact on 
macro-structures and the nature of their bonding would be beneficial to carry out. The kinetics 
of aggregation would also be useful to investigate, as these are important for drug formulation 
and delivery. Repeating the experiments with the use of buffer systems, such as a phosphate 
buffer that can be tailored to pH 5.8 to 8, or a Tris buffer that can pH 7.1 to 8.9, would provide 
further confidence in the results as this approach would help keep a consistent pH throughout 
the different experimental methods used. 
With additional lipopeptide 11, 17 and 23PYY3-36 further studies into the release profile of the 
gels would be of interest. In addition, these studies would add to the characterisation of the 
lipopeptide and the gels. Although this affect has been seen before for other gels it would be 
important to study this gelation effect and its property on drug delivery. Another important 
aspect of gels is their rheology profile or flow characteristics. This is important to investigate 
as certain viscous gels cannot be injected. The issue with this type of experiment is that it needs 
large quantities of sample and with the limited sample provided for this thesis, this area of 
investigation was not pursued. The fibrils formed by the gels are also closely related to the 
structure of the harmful amyloid fibrils, further experiments using a fibril specific dye, such as 
conga red, can probe this potential structural similarity.  
Further studies relating to the complexation of LPS with 17PYY3-36 and the effects on 
biological cells would also be of particular interest as this complexation potentially reduces the 
toxic effects of LPS on cells. Secondly, one could investigate the difference in complexation 
between the three lipidated PYY3-36 and LPS. The previous experiments were only specific to 
that of 17PYY3-36 (Chapter 5). It would be useful to see, if the lipidation position changes the 
LPS complexation affect, as was similarly seen in their characterisation analysis (Chapter 3 
and 4). There are also further SAXS analytical methods that would help to probe the 
complexation of LPS and 17PYY3-36, such as using the absolute intensity method that would 





would work extremely well with mixed samples and would enable individual shapes and 
volume fractions to be separated for each component of the mixture. With additional 
lipopeptide samples, future studies could be completed to enable a more detailed comparison 
of the separate samples of LPS and 17PYY3-36 to the mixture of the two. 
Another study that would be useful to complete, would be to investigate fragments of PYY3-36 
with LPS. This could show which segment, peptide (hydrophobic or hydrophilic) or lipid, is 
complexed to LPS, could have implications for other drug interactions. Adding other drugs, 
like that of A9R, in a complexation study could reveal other valuable observations with regards 
to interactions with LPS. The TAT peptide, or beta-amyloid, with well over 220,000 
publications each (as of 2019) would appear to be a strong candidate for this comparison. 
As mentioned within the conclusion of Chapter 6 the study of β-cyclodextrin and PYY3-36 
showed no co-aggregation. Other studies have shown β-cyclodextrin to have a “threading” 
affect with many other molecules, so this should still be followed up. The main area that should 
be investigated is, if the denatured peptide could thread within β-cyclodextrin, and once 
threaded, potentially co-assemble, locking β-cyclodextrin to the native peptide. As stated 
earlier, the pH of the mixed β-cyclodextrin and PYY3-36 samples was not recorded, therefore 
repeating the experiments, whilst recording the pH value, would be of use to improve 
knowledge in this area, particularly as it is known that pH can be instrumental in self-assembly 
process. 
Finally, a set of co-assembly experiments, using the lipidated forms 11, 17 and 23PYY3-36, with 
β-cyclodextrin, are also suggested as the results could yield valuable information on whether 
the co-assembly could limit, or even stop, self-assembly of the fibre-like structures through the 
“shielding” of the lipid from the other hydrophobic lipid environments. This proposed study 
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